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 Village grown large 
I return to the womb. 
Smell of fish and sweat of ages 
Stored in a bundle 
Of palm leaves. 
Where bark canoes used to dry 
With salt on their spines 
Fisherman patching nets 
At edge of sea. 
Shark spread on table 
Under a mango tree– 
Nearby heaps of cassava. 
Maize and banana was market. 
Sand and mosquitoes. 
 
From: “Mombasa” by Amin Kassam 
For Kenya, a country that became my second home
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1. Introduction 
1.1 The burden of malaria and (the burden of) its treatment 
Despite already made great achievements, malaria, and especially the infection 
with Plasmodium falciparum, still remains one of the major causes of morbidity 
and mortality worldwide (World Health Organization (WHO), World Malaria 
Report 2016; Snow, R. W. et al. 2005). The World Health Organization 
estimated 200 million malaria episodes in the year of 2015, causing the death of 
450.000 people. 90 % of all malaria deaths occur in Africa. The main age group 
affected are children under five years of age with 300.000 deaths. An estimated 
3.3 billion (3.3 x 109) people worldwide are living at risk of malaria infections, 
which is about half the world´s population (WHO, World Malaria Report 2016).
  
Though a reduction in malaria transmission was achieved between 2000 and 
2015 (Fig. 1), measures need to be taken in order to maintain and further 
improve the situation with regard to reports concerning drug resistant parasites.
 
Fig. 1: Countries endemic for malaria in 2000 and 2015.
1
 
                                                 
1
 World Malaria Report 2016, World Health Organization 
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The economic costs of malaria are estimated to be US$ 12 billion per year for 
Africa alone, counting only direct losses such as illness, treatment and 
premature death.2  
The funding for malaria control programs reached a sum of US$ 2.9 billion in 
2015– still leaving a gap of US$ 2.2 billion to the yearly needed amount of  
US$ 5.1 billion (WHO, World Malaria Report 2016). 
Up to now malaria vaccinations have proven to be only of modest protection 
(The RTS, S. Clinical Trial Partnership 2012) or are still undergoing trials 
(Seder, R. A. et al. 2013). Just recently the RTS, S / AS01 malaria vaccine 
phase III trial was completed showing a moderate statistically significant 
reduction in malaria cases after vaccination (RTS, S Clinical Trial Partnership 
2015). Based on these modest results,  
RTS, S (Mosquirix©) has recently been approved by the European Medicine 
Agency. Up to now the highest impact still lies with control strategies consisting 
of 
 prevention methods (e.g. insecticide treated nets) and vector control 
through (e.g. indoor spraying) and  
 prompt and effective treatment. 
WHO estimated that between 2001 and 2015 almost 7 million lives have been 
saved due to, inter alia, malaria control efforts (WHO, World Malaria Report 
2016). 
Out of Kenya’s 34 million people population there are 25 million still living at risk 
of contracting malaria– with geographically varying predictions of the risks 
(Noor, A. M. et al. 2009). 
To sustain and further improve the significant, if modest, achievements it is 
pivotal to evaluate the effectiveness of antimalarial drugs in order to prevent the 
emergence and spread of drug resistance in malaria parasites. 
                                                 
2
 http://www.rollbackmalaria.org/keyfacts.html (July 08th, 2015) 
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Presently artemisinin derivatives are the most efficient weapon against 
P. falciparum. Treatment guidelines promote the combined use, ideally in co-
formulation, with other drugs to sustain this effectiveness as long as possible. 
Alarmingly, studies from South-East Asia report about multiple foci of 
emergence of parasite tolerance against artemisinins. Drug surveillance has to 
provide timely information on which drug combination should be used in each 
endemic region to delay the emergence of artemisinin-tolerant parasites as long 
as possible.  
The combination of artemether-lumefantrine (AL) is the first-line-treatment of 
uncomplicated P. falciparum malaria in Kenya since 2006. This decision, and 
the finding of the paediatric formula, was mainly based on data collected in Kilifi 
(Falade, C. et al. 2005, Abdulla, S. et al. 2008), where also the Confirmation of 
Tolerance in Malaria Parasites trial (CATMAP) study was conducted. 
1.2 Aims of the work presented 
The aims of this work are, therefore,  
 to present an overview and evaluation of the current artemisinin drug 
susceptibility in Kenyan children infected with P. falciparum in vivo, using 
parameters such as parasite clearance estimation (PCE), parasite 
clearance time (PCT), parasite reduction ratio (PRR) and rate of 
recurrent parasitaemia by day 28 and 
 to establish currrent P. falciparum ex vivo drug responses using the 
histidine-rich protein 2 (HRP2) enzyme-linked immunosorbent assay 
(ELISA) towards artemisinins and artemisinin partner drugs in order to 
discuss susceptibility phenotypes in Coastal Kenya.  
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2. Background 
In order to understand the public health impact of malaria and the high 
importance of continuous drug surveillance first the evolution of the pathogen 
will be presented and its life cycle will be shown. Afterwards the clinical features 
of malaria as well as its prevention and treatment possibilities will be explained. 
That will lead to the main focus of this work, antimalarial drug resistance and 
surveillance of P. falciparum. 
2.1 Evolution and development of Plasmodium into a human pathogen 
and the origin and spread of malaria 
Human malaria is caused by the protozoon Plasmodium, a parasite that is 
transmitted by the female Anopheles mosquito. Known for being pathogenic in 
humans are P. ovale, P. vivax, P. malariae and P. falciparum. Recently there 
have been reports of a fifth species, P. knowlesi, which is mainly found in Old 
World monkeys and, therefore, considered a zoonotic pathogen  
(Knowles, R. M. and Das Gupta, B. 1932, Singh, B. et al. 2004; Cox-Singh, J. et 
al. 2008; Lee, K.-S. et al. 2009; Galinski, M. R. and Barnwell, J. W. 2009). 
Plasmodium parasites are unicellular eukaryotes with a complex life cycle. 
According to Wilson and Williamson (1997) the ancestor was a free-living 
protozoon that developed into a plastid-containing organism through 
endosymbiosis of red algae. Before evolving into a vertebrae parasite, 
Plasmodium supposedly inhabited the gut of aquatic insect larvae, multiplying 
by sexual replication (Wilson, R. J. M. and Williamson, D. H. 1997). These 
aquatic insects were ancestors to the Anopheles mosquito. Since the first 
appearance of the fly species 150 to 200 million years ago, Plasmodium has 
broadened its host range and started to infest multiple different hosts such as 
reptiles and birds. Mosquitoes are still essential in the life cycle of Plasmodium: 
The Anopheles mosquito functions as the site for sexual replication and as the 
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vector, while humans are infected only by haploid asexual stages, including the 
newly formed gametocytes (refer to 2.2). 
Numerous studies looked into the evolution of some Plasmodium species into 
human pathogens. Waters et al. (Waters, A. P. et al. 1991) performed molecular 
experiments with small subunit RNA (ssRNA), finding only remote relatedness 
between the different species of human Plasmodium. They concluded that, 
rather than one incidence giving way to all four human parasites, multiple 
different transfers must have taken place.  
Following this assumption, P. falciparum could also have evolved by lateral 
transfer from birds. The next hypothesis was in accordance with the formerly 
proposed distant relationships between the human pathogens, while also 
suggesting a co-evolution of the chimpanzee parasite P. reichenowi and  
P. falciparum 6 – 10 million years ago (Escalante, A. A. and Ayala, F. J 1994). 
The reliability of these early works was questioned due to limitations in their 
experimental methods such as the length in analysed gen loci or the under-
representation of certain taxa (Prugnolle, F. et al. 2011).  
Many groups have focused on overcoming these limitations since then. In 2008 
Martinsen, E. S. et al. published a full phylogram of the five genera of 
haemosporidian parasites. One year later Rich, S. M. et al. (2009) proposed a 
fairly recent transfer of P. falciparum from chimpanzees instead of a co-
evolution like Waters et al. had suggested. Then Krief, S. et al. (2010) published 
data pointing to the origin of P. falciparum being Bonobos and work by Liu, W. et 
al. (2010) claimed gorillas were the source of P. falciparum malaria.  
Focusing on P. falciparum, work on mitochondrial desoxyribonucleic acid (DNA) 
proposed an origin of human malaria within Africa from where it was able to 
spread (Conway, D. J. et al. 2000). The authors place the first “big wave” of 
human malaria between 4000 and 5000 years ago, the time of agricultural 
revolution in Africa. The shift from a nomadic lifestyle towards the formation of 
villages with plenty resources of water to function as mosquito breeding sites as 
well as humans providing a constant blood supply for nourishment provided 
optimal conditions for the reproduction of the mosquitoes.   
  
14 
 
Further development in agriculture is proposed to have had an immense 
influence on the distribution of Plasmodium (Hume, J. C. C. et al. 2003). With 
trade thriving and a developing travel culture the parasite was able to spread 
easily – now affecting billions of people around the world. 
2.2 Plasmodium and its life cycle 
In 1880 the French military physician Alphonse Laveran discovered 
Plasmodium as the parasite causing malaria. Plasmodium is a unicellular 
parasite that belongs to the phylum Apicomplexa, which is characterized by an 
apical organelle (or, “apical complex“, hence the name) essential for host cell 
invasion (Werk, R. 1985; Mitchell, G. H. and Bannister, L. H. 1988; Joiner, K. A. 
and Dubremetz, J. F. 1993; Sam-Yellowe, T. Y. 1996). 
There are more than one hundred Plasmodium species3, but only four are 
considered pathogenic to humans (refer to 2.1). Plasmodium falciparum is by 
far the most malignant and will be the focus for this work.  
The parasite undergoes a complex life cycle which partly takes place in the 
mosquito and partly in the human host. 
2.2.1 The life cycle of Plasmodium falciparum 
Through the bite of an infected female Anopheles mosquito P. falciparum 
sporozoites are transferred into the tissues of a human host.4  
These sporozoites move actively towards nearby blood vessels and enter the 
blood stream (Boyd, M. F. and Kitchen, S. F. 1939; Matsuoka, H. et al. 2002; 
Aly, A. S. I. et al. 2009). Within minutes sporozoites that have penetrated into 
the blood stream are transported to the liver, where they invade hepatocytes 
                                                 
3
 http://malaria.wellcome.ac.uk/doc_WTD023864.html (August 10th, 2015) 
4
 A visualisation of the lifecycle can for example be found in Portugal, S. et al. 2011. 
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and develop into liver schizonts5. After a single round of asexual replication liver 
schizonts then release the invasive blood stage forms, termed merozoites, into 
the blood stream (Frederich, M. et al 2002; Schlitzer, M. 2007). It has been 
shown that when leaving the hepatocyte, merozoites remain wrapped in a 
remnant of the hepatocyte host membrane (this vesicle is called merosome), 
possibly to escape the immune system until the infection of red blood cells 
(Sturm, A. et al. 2006). The apical organelle is considered essential for both 
quick and specific invasion of erythrocytes (Cowman, A. F. and Crabb, B. S 
2006). Inside the red blood cell, the parasite enlarges and increases its 
metabolism. Due to its characteristic morphology seen by light microscopy in 
Giemsa stained blood smears, this early trophozoite form is also referred to as 
“ring stage”. The parasite now undergoes DNA replication and develops into a 
schizont. After completing this intraerythrocytic stage (duration approximately 48 
hours), 16 – 32 new merozoites are released into the bloodstream for invasion 
of further red blood cells (Schlitzer, M. 2007). This asexual part of the life cycle 
causes the typical clinical symptoms of malaria.  
Instead of forming merozoites, a varying proportion of asexual blood stage 
parasites develop into gametocytes, the sexual haploid form of the organism. 
When a mosquito takes in gametocytes with its next blood meal, certain factors 
in the gut of the fly (drop in temperature, pH changes and mosquito metabolites) 
in addition to a mosquito-derived molecule, xanthurenic acid, induce what is 
called gametogenesis (Billker, O. et al. 1997; Billker, O. et al. 1998; Aly, A. S. I. 
et al. 2009): the gametocyte escapes the red blood cell and becomes either a 
macrogamete (female gamete) or microgamete (male gamete). Upon 
fertilisation of the female gamete by a male gamete, a diploid zygote is formed. 
Then, after meiotic cell division motile ookinetes emerge. Ookinetes penetrate 
the epithelial wall of the gut, where they differentiate and replicate as so called 
oozysts.  
                                                 
5
 Schizgony is a form of asaexual reproduction typical for apicomplexa wherby DNA, organelles 
etc. are multiplied for up to 10.000 daughter cells within the mother cell. Cell fission occurs 
only at the end of schizogony. 
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When an oozyst ruptures it releases sporozoites into the body of the mosquito. 
These sporozoites now will find their way into the salivary glands of the 
mosquito, from where they will be injected into the new host when the mosquito 
takes its next blood meal. 
2.3 Clinical features of malaria 
An infection with Plasmodium falciparum can result in severe or uncomplicated 
malaria or even in an asymptomatic infection. This reflects increasing levels of 
acquired immunity to the parasite in patients in high transmission areas; 
therefore, severe malaria mainly occurs in young children. The symptoms 
become milder and eventually disappear as a function of repeated re-infections 
during childhood. Most adults in such areas are asymptomatically infected. The 
onset of clinical signs after sporozoite inoculation usually takes between 12 to 
15 days (Verhage, D. F. et al. 2005; Roestenberg, M. et al. 2009). Symptoms 
result exclusively from the asexual erythrocytic stages of Plasmodium. Early 
symptoms before the typical fever episodes are unspecific and can be 
described as flu-like with headaches, nausea and fatigue. Other symptoms can 
include coughing, slight jaundice, myalgia, abdominal pain and / or diarrhoea 
and loss of appetite as well as prostration. With increasing parasitaemia the 
patient develops irregularly recurring high fever attacks (White, N. J. 2003,  
pp. 1226 – 1229).  
Uncomplicated malaria can develop into severe malaria within hours presenting 
with altered consciousness, respiratory distress, convulsions, pulmonary 
oedema, disseminated intravascular coagulopathy, severe anaemia and 
hypoglycemia. Despite optimal treatment with intravenous artesunate, the 
mortality rate of patients with severe malaria remains between 8.5 – 15%. If 
parenteral artesunate is not available and treatment is conducted with quinine, 
this mortality rate ranges from 10.9 – 22 % (Dondorp, A. M. 2010; Dondorp, A. 
et al. 2005). 
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2.4 Malaria control strategies 
In May 1955 the World Health Assembly initiated a malaria eradication 
campaign to eliminate the disease worldwide. By 1967 the use of 
Dichlordiphenyltrichlorethan (DDT) against mosquitoes and the treatment of 
patients with antimalarial drugs had lead to the eradication of malaria in all 
developed countries and in some areas of Asia as well as Latin America. 
Unfortunately, due to limited practicability in some countries, emergence of 
resistance against the insecticide and the development of drug-resistant 
parasites imposed problems that prevented worldwide eradication. 
A close to 100 % effective vaccine has been a long-term goal of malaria 
research. Recently, a recombinant vaccine, RTS, S, has been approved as the 
first malaria vaccine. However, it has shown only modest protection for a limited 
period of time (The RTS, S Clinical Trials Partnership 2012 and 2015). 
Therefore, current control strategies remain focused on prevention and fast and 
effective treatment. 
Insecticide treated nets and indoor spraying have been implemented for many 
years now. Free distribution has led to a wide coverage of nets. For the most 
vulnerable groups the WHO recommends chemoprophylaxis, called the 
intermittent preventive treatment. This reaches out to infants and pregnant 
women. It is carried out with sulfadoxine-pyrimethamine given in the absence of 
the disease to suppress infections and prevent malaria. 
Efficient treatment of P. falciparum malaria relies on artemisinin-based-
combination therapies (ACT) in all endemic countries (WHO, Guidelines for the 
treatment of malaria, 2015). 
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2.5 Antimalarial drugs 
The complex life cycle (refer to 2.2) offers different targets for 
chemotherapeutics. Antimalarials can be used for treatment and prevention of 
infection. Most drugs inhibit asexual blood stage replication (blood 
schizontocides); the preerythrocytic (liver stage) effect of medication remains 
mainly uncharacterized. The first known (herbal) medicine against malaria was 
powdered bark of the cinchona tree, containing the quinoline alkaloids quinine 
and quinidine. Sparking off synthetic drug manufacturing in 1891, methylene 
blue went through only a short period of usage as antimalarial drug but gave 
way to numerous synthetic drugs. Regiments such as plasmochin, 
primaquine and mepacrine were replaced by chloroquine (CQ), which 
became the major antimalarial drug after the Second World War and sustained 
its importance for almost two decades. CQ is thought to interfere with the ability 
of the parasite to form haemozoin and, thus, to lead to accumulation of toxic 
haeme, a product from the parasite’s haemoglobin metabolism (Chou, A. A. and 
Fitch, C. D. 1992; Sullivan, D. J. et al. 1996 b). 
In the 1960s the first CQ-resistant strains were reported and by 2005 it was 
estimated that around 80 % of the wild Plasmodium falciparum strains are 
resistant to this highly sufficient drug regimen (Ginsburg, H. 2005). Much effort 
has been put into finding other drugs and synthesising CQ derivatives by 
modifying its chemical structure, leading to substances such as amodiaquine, 
ferroquine, pyronaridine, and piperaquine (PPQ) to overcome CQ resistance 
(Edgcomb, J. H. et al. 1950; Grewal, R. S. 1981; Geary, T. G. and Jensen, J. B. 
1983; Ridley, R. G. et al. 1996; Foley, M. and Tilley, L. 1998). Other antimalarial 
drugs developed, like mefloquine (MFQ), lumefantrine (LUM) and 
halofantrine are analogues of the active antimalarial metabolite quinine and 
quinidine from the above mentioned cinchona tree. The artemisinins like 
artemether and artesunate (AS) derive from the herb known as sweet 
wormwood. 
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Available compounds nowadays are grouped into the following classes: 
 aryl-aminoalcohols (quinoline-related) such as quinine, quinidine, 
chloroquine, amodiaquine, mefloquine, halofantrine, lumefantrine, 
piperaquine, primaquine, tafenoquine, ferroquine, pyronaridine 
 antifolates such as pyrimethamine, proguanil, chlorproguanil, 
trimethoprim 
 artemisinins such as artemisinin, dihydroartemisinin (DHA), artemether, 
artesunate (AS) 
Since P. falciparum treatment guidelines in Kenya are mainly based on 
artemisinins combined with either LUM or PPQ, more detailed information on 
these compounds will be provided in the following subchapters. 
2.5.1 Artemisinins 
Over the past years Artemisinin and its derivatives have proven to be the most 
efficient antimalarial drug since CQ. In traditional Chinese medicine “qinghao” 
was known for its ability to treat fever. In 1971 the antimalarial effects of the 
extract “qinghaosu” from the herb “qinghao” were demonstrated for the first time 
(Qinghaosu Antimalaria CoordinatiTeg Research Group 1979; Editorial The 
Lancet 1992) and its discovery resulted in a Nobel Prize in 2015 (Nobel Media 
AB 2016).  
Artemisinin is extracted from the leaves of sweet wormwood, Artemisia annua. 
To increase its poor bioavailability, artemisinin is structurally modified and semi-
synthetic derivatives in clinical use are artesunate, artemether, arteether, and 
dihydroartemisinin (Fig. 2) (Shen, J. X. 1989; Hien, T. T. and White, N. J. 
1993; Woodrow, C. J. et al. 2005). 
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Artemisinins rapidly clear the patients’ blood from malaria parasites and have 
the broadest time window of antimalarial effect (from ring forms to early 
schizonts) (White, N. J. 2004). In vivo the derivatives are hydrolyzed into the 
main active metabolite DHA. This metabolite has a very short elimination half 
time of about 45 minutes (Teja-Isavadharm, P. et al. 1996; Batty, K. T. et al. 
1998). 
 
Fig. 2: Artemisinin and derivatives chemical structures.
6
  
The exact mechanism of action of artemisinins remains unknown. The key 
structural feature of all artemisinins is an endoperoxide. Artemisinins also act 
against developing, but not mature, sexual blood stages (Kumar, N. and Zheng, 
H. 1990; Meshnick, S. R. 2002; Schlitzer, M. 2007). A reduction in 
gametocytaemia can additionally reduce transmission by decreasing the 
chances of another mosquito taking up gametocytes through a blood meal on a 
malaria patient (Price, R. N. et al. 1996; Okell, L. et al. 2008). 
                                                 
6
 Hien, T. T. and White, N. J. 1993 
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Since 2004 the WHO promotes artemisinin derivatives for the treatment of 
uncomplicated malaria as the main compound of artemisinin-based combination 
therapies (ACT). In ACTs artemisinins account for a rapid onset of parasite 
clearance, the combination with a partner drug with a longer half time and 
different mode of action, e.g. lumefantrine, is thought to delay the emergence of 
resistance (White, N. J. 1999). After the artemisinin is cleared from the body, the 
partner drug eliminates the remaining (few) parasites, including those that 
possibly are still in or are leaving the dormant stage. Additionally, the partner 
drug plays a role in prophylaxis of a new infection by maintaining blood levels 
over a longer period of time. 
2.5.2 Lumefantrine 
LUM was developed by Chinese scientists. Today it is only available in fixed 
combination with artemether (Coartem®), which has been the first-line 
treatment in Kenya since 2004 (Ministry of Public Health and Sanitation, 
National Guidelines for the Diagnosis, Treatment and Prevention of Malaria in 
Kenya, 2010). Several studies have been conducted on this combination-
therapy on the study site in Kilifi, including a first safety and efficacy study 
(Falade, C. et al. 2005), trials for paediatric formulations (Abdulla, S. et al. 2008) 
as well as drug surveillance studies (Borrmann, S. et al. 2011). The last 
mentioned study lead to the CATMAP trial in which this work was embedded. 
LUM is lipophilic and, thus, absorption increases with the intake of fatty food 
(Ezzet, F. et al. 1998). The elimination half-life is estimated to be 3 – 4 days 
(Ezzet, F. et al. 2000). 
 
Fig. 3: LUM chemical structure.
7
  
                                                 
7
 http:\\www.sigmaaldrich.com ( August 10
th
, 2015) 
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2.5.3 Piperaquine 
PPQ is a bisquinoline and one of the drugs synthesised to overcome CQ 
resistance. Hypotheses suggest that its activity against CQ-resistant strains 
derives from its steric bulk, causing it to be not a suitable substrate for the 
Plasmodium falciparum chloroquine resistance transporter (PfCRT), a 
transporter involved in chloroquine resistance (Fidock, D. A. et al. 2000). 
Another suggestion is that its four positive charges are trapping it inside the 
acidic digestive vacuole of Plasmodium (Warhurst, D. C. et al. 2007; Kaur, K. et 
al. 2010).  
PPQ has mainly been used in China, leading to resistant strains in the country 
(Chen, L. et al. 1982; Lan, C. X. et al. 1989; Fan, B. et al. 1998). In Africa it is 
still considered highly effective and applied as a combination therapy with DHA. 
This combination has been reported to be safe and effective in numerous 
studies (Myint, H. Y. et al. 2007; Grande, T. et al. 2007; Abdulla, S. et al. 2008; 
Adam, I. et al. 2010), including a multicentre Phase III trial where the Pingilikani 
clinic (the study site of the CATMAP trial) was one of the study sites (Bassat, Q. 
et al. 2009). 
 
Fig. 4: PPQ chemical structure.
8
 
  
                                                 
8
 http:\\www.sigmaaldrich.com (August 10
th
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3. Antimalarial drug tolerance and resistance 
According to the WHO, antimalarial drug resistance is defined as “the ability of a 
parasite strain to survive and / or multiply despite the administration and 
absorption of a medicine in doses equal to or higher than those usually 
recommended but within tolerance of the subject, provided drug exposure at the 
site of infection is adequate” (WHO, Guidelines for the treatment of malaria, 
2015, p. 113). This leads to a shift to the right in the dose-response curve of the 
drug (White, N. J. 2004). 
Increased tolerance to antimalarial drugs has been reported for all classes of 
antimalarials, which imposes a great threat to the control of the disease. 
Often, the onset of parasite resistance is very easily overlooked by medical 
professionals, as most patients seem to improve clinically while undergoing 
treatment. In most cases, even parasitaemia will eventually disappear below the 
microscopic detection threshold. Three to six weeks after completion of 
treatment symptoms may then reoccur. This will commonly be interpreted as a 
newly acquired infection with Plasmodium rather than a recrudescence of the 
same (resistant) strain. The intervals between fever clearance and reoccurrence 
of the clinical symptoms will then become increasingly shorter until the drug 
regimen will fail to clear the patient from symptoms completely (WHO, 
Guidelines for the treatment of malaria, 2015). This clearly indicates the 
importance of constant drug surveillance studies to monitor drug sensitivity 
continuously be able to react fast to declining responsiveness. 
In 2006 the national Kenyan guidelines adapted the WHO recommendations 
and announced AL as the first-line treatment for uncomplicated  
P. falciparum malaria. This combination has been proven effective even in areas 
of multi-drug-resistant parasites (van Vugt, M. et al. 2000; Hutagalung, R. et al. 
2005). Despite its fairly short time in use, there have already been reports about 
reduced artemisinin sensitivity in P. falciparum. In 2009 Dondorp, A. M. et al. 
described delayed in vivo parasite clearance times after treatment in Western 
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Cambodia. However, no evidence for reduced in vitro drug sensitivity was 
found. This was followed by a study which also showed declined 
responsiveness to ACTs in vivo in Kenya (Borrmann, S. et al. 2011) with no 
indication of drug resistance in vitro. 
In the past years much progress has been achieved in understanding 
artemisinin resistance better. As said before, by the time of the first description 
of delayed response after artemisinin treatment there was no correlate in vitro 
when testing drug sensitivity. Cheeseman, I. H. (2012) aimed to identify genome 
regions under selective pressure by artemisinin treatment in Western Thailand 
and found areas of interest on chromosome 13. Also Borrmann, S. et al. (2013) 
studied genes associated with naturally occurring phenotypic variation of 
artemisinin susceptibility in Kenya and reported about associations with 
chromosome 13.  
In 2013 an altered in vitro phenotype of parasites with reduced artemisinin 
susceptibility was reported. Ring stages showed a higher survival rate and 
better ability to recover compared to mature stages when exposing parasites to 
DHA (Witkowski, B. et al. 2013b). Witkowski et al. then performed a so called 
ring stage survival assay (RSA, refer to 3.1.2) on ring stage parasites at 
different ages during the life cycle (refer to 2.2.1), explicitly at hours 0 – 3  
(RSA0 – 3) and 9 – 12 (RSA9-12) post invasion. Additionally, the survival assay 
was done on trophozoites 18 – 21 hours post invasion (then called trophozoite 
survival assay, TSA18-21) and on ex vivo samples (Witkowski, B. et al. 2013a). 
The survival rate of parasites in the in vitro RSA0 – 3 proved to be much higher in 
slow clearing parasites. They were also able to show a correlation between the 
RSA performed on ex vivo samples and the in vivo parasite clearance half life. 
Thus, the RSA0 – 3 provides a tool for further characterization of artemisinin 
resistance, e.g. as the authors mention association between genome studies 
and RSA0 – 3 results. The ex vivo RSA can be performed in drug surveillance 
studies in areas where artemisinin resistance has not yet been established. 
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Using the established RSA0 – 3 as reference, Ariey, F. et al. (2014) were then 
able to identify a molecular marker on chromosome 13, namely K13 propeller9 
polymorphism, for artemisinin resistance in Cambodia. Straimer, J. et al. (2015) 
genetically modified parasites by inserting resistance-associated mutations in 
the K13-propeller domain and were able to demonstrate higher survival rates 
under DHA drug pressure after the insertion compared to the wild type. 
Transcriptome analysis of clinical isolates then revealed an up-regulation of 
proteins involved in reparation and degradation of proteins damaged by 
artemisinins in drug resistant parasites. Additionally, a slowed progression 
through the ring stage was reported (Mok, S. et al. 2015). Hence, artemisinin 
resistance seems to be a result of a decelerated ring stage development 
together with protection against protein damage caused by artemisinin.  
Mbengue, A. et al. (2015) reported inhibition of P. falciparum 
phosphatidylinositol-3-kinase (PfPI3K) by DHA. This kinase is involved in 
phosphorylation of phosphatidylinositol (PI) leading to phosphatidylinositol-3-
phosphate (PI3P) which promotes cell survival. Ergo, the inhibition of PfPI3K by 
DHA leads to parasite death. In artemisinin resistant parasites it is proposed 
that the mutation in the K13-propeller domain may lead to increased levels of 
PfPI3K and therefore PI3P, promoting the survival of the parasite. 
Interestingly, and supportive in favour of above mentioned hypothesis regarding 
artemisinin resistance, Mita, T. et al. (2016) reported that prior to the 
introduction of ACTs there was little polymorphism at the K13-propeller locus 
worldwide. 
In summary, regarding South East Asia, where artemisinin resistance is 
established, the K13-propeller polymorphism seems to be an appropriate tool to 
                                                 
9
 K13 [PF3D7_1343700 (PF13_0238)] is a one exon gene encoding for a putative kelch protein. 
“K13 has a predicted 3-domain structure, with an approx. 225 residue long, Plasmodium-
specific and well conserved N-terminal domain, followed by a BTB / POZ [broad-complex, 
tramtrack and bric-abrac / poxvirus and zinc-finger] domain and a 6-blade C-terminal 
propeller domain formed of canonical kelch motifs 43,48. Little is known about the protein in 
malaria parasites. Proteomics data indicate that it is produced by asexual (trophozoites, 
schizonts, merozoites and rings) and sexual blood stages (gametocytes) of P. falciparum, 
and that it possesses phosphorylated residues in the N-terminal Plasmodium-specific 
domain (www.plasmodb.org). The M476I mutation is located between the first and second 
blade of the propeller domain. “(Ariey, F.et al. 2014) 
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track the spread of the resistance. The importance for the African region 
remains the subject of further studies. K13-polymorphisms have been reported 
in Mali, where parasite clearance under ACT remains fast, but were also 
present before the introduction of ACTs (Outtara, A. et al. 2015). Kamau, E. et 
al. (2015) detected different K13-propeller polymorphisms than the ones found 
in Asia in Sub-Saharan Africa, but so far no study investigated the RSA0 – 3 in 
association with these findings. Thus, it is crucial to further study molecular 
markers and carry out in vivo as well as ex vivo and in vitro drug sensitivity 
testing in Africa in various regions to clarify significance of already found 
markers and detect others. 
3.1 Monitoring drug efficacy  
Drug monitoring consists of two main aspects: the efficacy of the drug in an 
infected patient (in vivo) and the efficacy outside the patient (ex vivo or in vitro). 
Whereas in vitro and ex vivo data are important tools in research and can give 
additional information, it is always the result of an artificial set-up. In vivo data 
on the other hand provides the actual clinical outcome of treatment that also 
depends on various host-related factors and, therefore, cannot be replaced by 
in vitro tests. At first sight inter-individual differences of patients in clinical trials 
such as e.g. drug metabolism, immunity etc. might seem like an obstacle to get 
comparable results. This data is taken under “real life” conditions though and 
absolutely necessary for the development of clinical guidelines, the 
development of new drugs and much more. This shows a necessity in drug 
surveillance for both clinicians and researchers to be aware of and responsive 
to changes. 
3.1.1 Drug susceptibility in vivo  
Besides measuring clinical outcomes such as body temperature and 
haematological variables (e.g. haemoglobin), the level of parasitaemia is 
documented over time and used as a parameter for the efficacy of the drug(s) 
applied. According to WHO standards the duration of required follow-up-time 
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depends on the half-life of the drug(s) applied (at least 28 days,  
for combinations with MFQ or PPQ at least 42 days) (WHO, Guidelines for the 
treatment of malaria, 2015, pp.112 – 113). 
During an infection with Plasmodium, the parasite multiplication rate is used to 
describe the rate of multiplication of the parasite. In the absence of any 
antimalarial drug activity in non-immune adults this multiplication rate is 
estimated to exceed the rate of 10 per asexual cycle (Simpson, J. A. et al. 
2002). 
The ratio between parasitaemia at onset and at a point of interest after initiation 
of treatment (commonly hour 6, 12, 24 and 48) is called parasite reduction ratio 
(White, N. J. 1997). The PRR varies depending on the drug applied. 
Artemisinins are currently known as the fastest acting antimalarials in vivo 
(White, N. J. 2004). 
Until recently the PCT, i.e. the time from first drug exposure to the recording of 
multiple consecutive negative slides, was the most commonly used parameter 
to describe drug efficacy in vivo. The PCT was found to be dependent on 
numerous factors such as baseline parasitaemia and the frequency of sampling. 
Thus, it proved to be an inaccurate parameter that does not allow comparisons 
between individuals or across cohorts of patients (White, N. J. 2011). 
A recently proposed method is the PCE. This method requires frequent 
sampling and uses a logarithmic transformation of the parasite density data 
over time. It starts by identifying different segments of the parasite clearance 
curve in the patient (Flegg, J. A. et al. 2011). Clearance times are then 
estimated using only the robust, linear segment of the clearance curve over 
time. The segments excluded from this estimation are the lag-phase, the tail 
and outliers. The lag-phase is caused by effects on mainly sequestered 
parasites instead of parasites in the peripheral blood. The tail is the part in the 
clearance curve where parasitaemia approaches the detection limit and 
counting errors are likely to occur. The slope in the fall of parasitaemia in the 
clearance curve after exclusion of lag and tail is proposed to be much less 
vulnerable to influences and, consequently, better for comparison of real drug 
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efficacy than the parasite clearance time. The slope half life, thus, indicates the 
time needed for the parasitaemia to be reduced by half after excluding lag and 
tail. Parasite clearance 50 and 99 are also adapted to the linear part of the 
curve and refer to the time it takes for the parasitaemia to be reduced to 50 and 
99 % of the admission parasitaemia. The clearance rate constant shows the 
fractional reduction of parasites per unit in time. To be able to compare obtained  
results to numerous other studies which used either PCT or PCE, including data 
from the same study area (Borrmann, S. et al. 2011), both parameters will be 
shown and discussed here. 
The rate of occurrence of recurrent parasitaemia is another parameter used for 
the determination of drug efficiency. Recurrent parasitaemia can occur due to 
reinfection with a new parasite or recrudescence of the same parasite. The 
second scenario indicates treatment failure. To distinguish between reinfection 
and recrudescence, genotyping of highly diverse parasite loci, such as 
merozoite surface protein 1(msp1), merozoite surface protein 2 (msp2) and / or 
glutatmate-rich protein (glurp), is done. 
Blood concentrations of the drug of interest can be measured in order to 
distinguish between real treatment failure and failure to achieve effective blood 
concentrations, e.g. due to non-adherence of the patient or variable 
bioavailability of the drug. 
3.1.2 Drug susceptibility ex vivo / in vitro 
When measuring drug sensitivity outside the patient, it is crucial to distinguish 
between ex vivo and in vitro methods. Also genetic methods can be performed 
for specific forms of drug resistance that are confirmed to be associated with 
molecular markers (e.g., certain mutations in the pfcrt or Dihydrofolate 
reductase (dhfr) and Dihydroptearate synthase (dhps) genes in case of 
chloroquine or antifolate resistance, respectively). The drug sensitivity testing is 
in general performed by exposing parasites to different drug concentration 
levels for a specific of time. Afterwards inhibition will be determined by the effect 
of the drug on growth and multiplication.  
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In vitro applies to methods that are carried out on parasites that have been 
adapted to parasite culture. Ex vivo methods on the other hand are performed 
directly on the patients´ sample. Various different methods have been 
developed and established, each with its advantages and disadvantages 
(Noedl, H. et al. 2003). Below, a few examples of the many methods are 
mentioned. 
The simplest method of drug sensitivity testing is the WHO schizont 
maturation test that is based on microscopic assessment of schizonts 
development following drug exposure in a 24-hour culture. This method can 
easily be used in the field but is very work-intensive and is susceptible to inter-
individual variability of assessment. 
Isotopic methods, such as the widely used radio-labelled [3H]-hypoxanthine 
assay (Desjardins, R. E. et al. 1979), are based on the uptake of the labelled 
hypoxanthine by the parasite and the measurement of radioactivity in a liquid 
scintillation counter. Reproducible results for high quantities of isolates are the 
advantages of this assay, but costly equipment (e.g. liquid scintillation counter) 
and the exposure of laboratory staff to and the disposal of radioactive materials 
are limiting the use of this assay. The main problem though is the fairly high 
parasite density of 0.5 % needed in order to obtain reliable results. 
Another method is the detection of parasite specific lactate dehydrogenase 
(pLDH) (Piper, R. et al. 1999), which measures the activity of pLDH (an enzyme 
actively produced by the parasite during growth and differing from the human 
LDH) and allows for quantification of parasites. 
Widely used is the SYBR-Green assay. A fluorescent dye, the SYBR-Green, 
with affinity to double-stranded DNA, is added to the drug exposed isolate and 
fluorescence is measured. This assay produces reliable results from a fairly 
high parasitaemia of 0.75 % on. Also samples need to be purified from white 
blood cells in order to avoid unspecific DNA staining. This makes it fairly cost-
intensive and unreliable for usage in the field (Vossen, M. G. et al. 2010). 
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One method which can be performed ex vivo as well as in vitro and which was 
performed in this study is the Histidine Rich Protein 2 (HRP2) Enzyme-linked 
immunosorbent assay (ELISA) (Noedl, H. et al. 2002a). P. falciparum HRP2 has 
been identified as a protein associated with Plasmodium falciparum infected 
erythrocytes. HRP2 is localized in several cell compartments, including the 
parasite cytoplasm. It is known to be histidine-and alanine-rich and synthesised 
in each P. falciparum parasite, regardless of its knob-phenotype10 (Rock, E. P. 
et al. 1987). HRP2 is found in concentrated packages in the host-erythrocytes 
as well as in the host plasma (or culture supernatant) due to secretion by the 
parasite (Howard, R. J. et al. 1986). The exact role of HRP2 remains unknown 
but it has been suggested to function in the haemoglobin metabolism of  
P. falciparum (Sullivan, D. J. et al. 1996a). There is only a slight inhibition in the 
production of HRP2 under drug pressure; therefore, it remains a good tool for 
drug sensitivity testing (Noedl, H. et al. 2002b). Besides sensitivity testing, rapid 
diagnostic tests are also based on the detection of HRP2.  
The HRP2 ELISA as an assay for drug sensitivity testing in P. falciparum was 
first described in 2002 (Noedl, H. et al. 2002a). Compared to other assays it 
does not only require little equipment but also produces reliable results in low 
parasitaemia samples, which occur frequently. The assay can be performed ex 
vivo, directly on the isolates taken from the patient without prior parasite culture, 
leukocyte depletion or usage of radioactive markers. Compared to the WHO 
schizont maturation assay it is not subject to individual variability, is far less 
labour intensive and provides more accurate results concerning inhibitory 
concentrations. 
After drug exposure an enzyme-linked immunosorbent assay is performed, 
measuring the concentration of HRP2, a protein that is produced by the parasite 
throughout its life cycle. This assay needs only fairly low parasitaemia starting 
from 0.01 % on and only little equipment. It is easy to reproduce and can quickly 
be performed on a great number of isolates at the same time.  
                                                 
10
 Erythrocytes infected with P. falciparum show an alteration of the cytoskeleton in the form of 
protrusions called knobs. These knobs are induced by the parasite (Deitsch, K. W. and 
Wellems, T. E. 1996) and play a role in cytoadherence (Crabb, B. S. et al. 1997). 
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On ex vivo samples (especially without prior depletion of leukocytes and 
samples with low parasitaemia) it has been shown to be superior to the SYBR-
Green method (Chaorattanakawee, S. et al. 2013) and the radio-labelled-
hypoxanthine-reuptake assay (Tritten, L. et al. 2009). 
Very recently, as described above, a novel sensitivity assessment test gained 
importance with regards to artemisinin drug testing (Witkowski, B. 2013a). The 
Survival Assay is performed on ring stage parasites (ring survival assay) and 
mature stage parasites (mature survival assay, MSA). Parasites are 
synchronized to the stage of interest and at a parasitaemia 1 – 2 % exposed to 
six hours of high DHA levels (700 nM). The short exposure to high doses of the 
drug is assumed to imitate the drug exposure in vivo better than continuous 
exposure to lower doses as it is being done in other sensitivity tests. Depending 
of the parasite age post invasion the assay is called RSA0 – 3, referring to 
parasites 0 – 3 hours post invasion etc. Then viable second generation rings or 
trophozoites will be determined by microscopy after e.g. another 66 hours 
(RSA) or 42 hours (MSA) (specific time depends on the age of parasites when 
performing drug exposure) of incubation. 
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4. Material and Methods 
4.1 Material  
Sample processing 
Albumax II Gibco Invitrogen, New Zealand 
Gentamicin (stock 10 mg / ml) Sigma Aldrich, USA 
Giemsa Sigma Aldrich, USA 
Glucose 10 % Sigma Aldrich, USA 
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) 
Gibco, USA 
Human European AB serum 
Universitätsklinikum Heidelberg, 
Germany 
Hypoxanthine 10 mM ccpro, Germany 
L-Glutamine 200 mM Sigma Aldrich, USA 
Methanol Scharlab SL, Spain 
NaOH 12 % Sigma Aldrich, USA 
Roswell Park Memorial Institute medium 
(RPMI) 1640 without L-Glutamine 
Sigma Aldrich, USA 
Solutions 
Complete culture medium (CCM): RPMI 1640 without glutamine 
plus  5 ml L- glutamine 
plus  3 ml NaHCO3 
plus  5 ml hypoxanthine 
plus  18.5 ml HEPES 
plus  1.25 ml gentamicin 
plus  50 ml 5 % albumin II 
plus  10 ml glucose 
plus  10 ml human AB serum 
The CCM was stored at 4 °C and used for a maximum of one week. 
Blocking solution: BSA diluted at 2 % in PBS 
Washing solution: Tween 20 diluted at 0.05 % in phosphate buffered saline 
(PBS) 
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Stop solution: 1 M sulphuric acid (10 ml sulphuric acid added to 90 ml water) 
Diluent for second antibody: 2 % BSA + 1 % Tween 20 in 97 ml PBS (10 ml 
per plate)  
Antibody dilutions: Following the standard operating procedure (SOP) for the 
HRP2 ELISA11 the first antibody was diluted to 1.0 µg / ml in PBS. The second 
antibody was transferred into the diluent for the second antibody (see above) to 
0.2 µg / ml. Depending on the activity of the conjugate this was adjusted, if 
required. 
Drug sensitivity assay 
AS Sigma Aldrich, USA 
Bovine Serum Albumin (BSA) Sigma Aldrich, USA 
CQ Sigma Aldrich, USA 
DHA Sigma Aldrich, USA 
LUM Novartis, Switzerland 
MFQ Sigma Aldrich, USA 
MPFG-55G (second antibody) Immunology Consultants Inc, USA 
MPFM-55A (first antibody) Immunology Consultants Inc, USA 
PBS tablets (Dulbecco A) Thermo Scientific, Oxoid limited, UK 
PPQ SigmaTau, Italy 
Tetramethylbenzidine (TMB) substrate Sigma Aldrich, Germany 
Tween 20 Sigma Aldrich, USA 
Software 
HN-NonLin V1.1 Available at www.malaria.farch.net 
Microsoft Office 2011  
Prism 6  GraphPad Software Inc 
  
                                                 
11
 Available at www.meduniwien.ac.at/user/harald.noedl/malaria/hrp2sop.html (August 10th, 
2015) 
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Equipment 
Cell culture plates Greiner bio one 
EDTA tubes BD Vacutainer, bd USA 
ELISA plates Greiner bio one 
ELISA plate washer Biotek 
ELISA plate reader Synergy 4, Gen 5 
Heparin tubes BD Vacutainer, BD USA 
Incubator Jencons, Nuaire 
Microscope Nikon Eclipse E200, China 
Multi-channel pipette Accu Jet Pro, Steinbrenner 
Pipette tips Neptunes, USA 
4.2 Methods 
4.2.1 Study site 
The Pingilikani Dispensary (Fig. 5) is located on the Coast Province of Kenya in 
the Kilifi District, about 20 km south of Kilifi town. It is operated by the Ministry of 
Health and the Kenya Medical Research Institute (KEMRI) / Centre for 
Geographic Medicine Research-Coast. 
 
Fig. 5: The Pingilikani dispensary.
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A ward is located next to the dispensary where patients were admitted for three 
days after enrolment (Fig. 6). 
 
Fig. 6: The Pingilikani ward.
13
 
The clinical team in Pingilikani has been conducting research studies since 
2005 (CATMAP study protocol 2011, v.1.3). Perennial transmission of malaria in 
the area has been reported with typical peaks within two rainy seasons 
throughout the year, one from April to June and the second from October to 
November (O’Meara, W. P. et al. 2008). The transmission rate for P. falciparum 
has been reported to range between 22 to 53 infective bites per person per year 
(Mbogo, C. M. et al. 2003). Bejon, P. et al. (2014) further investigated 
transmission in the Kilifi area and found hotspots which then again contained 
hotspots, sometimes narrowing down to one single high transmission household 
having an impact on the area surrounding it. They conclude that mosquito 
ecology as one determinant of malaria transmission could be influenced at a 
wide range of spatial scales in the area, ranging from macro- to micro-
geographical characteristics. 
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4.2.2 Study design 
Investigations were carried out as part of the “Confirmation of Artemisinin 
Tolerance in Malaria Parasites trial” (Study ID Number KEMRI_CT_2010/0013, 
SSC 1821; NCT Number NCT0119037114). The study was designed as a 
single-arm trial observing parasitological and clinical responses of P. falciparum 
to a 7-day mono-treatment with AS in order to answer the question if 
Plasmodium falciparum infections in Kenya have become less response to 
artemisinin treatment. Children who met the inclusion criteria (Appendix 1) were 
enrolled after obtaining written informed consent from a parent or a legal 
guardian. They were admitted to the paediatric ward in Pingilikani and treated 
orally with 2 mg / kg body weight AS for 7 days. Admission was planned for 3 
days (day 0 – 3); from day 4 – 6 the children were seen and treated as out-
patients. Follow-up was carried out on days 7, 14, 21, 28 and 42 including 
clinical and laboratory check-ups (CATMAP study protocol v1.3 2011,  
refer to 14). 
This work as part of the CATMAP study is about drug surveillance of artemisinin 
and its partner drugs with a more specific focused on the ex vivo data in 
comparison with previous data collected in the area. This will be supported by 
some of the collected in vivo data of the CATMAP trial. 
4.2.3 Determination of parasite density in the field 
Parasite density for the clinical outcomes was determined by an experienced 
laboratory technician according to the applicable Kilifi slide reading SOP. It was 
expressed as the number of asexual parasites per µl of blood by dividing the 
number of asexual parasites by the number of white blood cells counted. This 
number was multiplied by an assumed fixed white blood cell density of  
8,000 / µl. 
                                                 
14
 As registered under clinicaltrials.gov, available under 
https://clinicaltrials.gov/ct2/show/record/NCT01190371?term=CATMAP&rank=1 (June 30th, 
2016) 
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Parasite density (per µl) = 
Number of parasites counted  8,000 
Number of leukocytes counted 
The parasitaemia values calculated by this method were uploaded to the 
Worldwide Antimalarial Resistance Network (WWARN) web-based tool for 
calculation of parasite clearance estimation.15 
4.2.4 Determination of parasite density in the laboratory 
Parasite density was calculated through inspection of 10 microscopic fields. The 
number of infected erythrocytes was divided by the number of total red blood 
cells to calculate the percentage of parasitaemia. This value was used for 
setting up the drug sensitivity assay. 
4.2.5 Preparation of antimalarial drugs 
All the drugs applied during the course of the ex vivo study were obtained 
readily dissolved as so called stock-solutions.  
Prior to the set-up of the culture plate each drug had to be diluted down with 
RPMI 1640 to create a working solution. Those working-solutions were created 
as portrayed in the table below and stored at 4 °C. 
Working solutions  Medium (ml) Drug stock solution (µl) 
CQ 4.991 9.259 
MFQ 4.998 1.543 
DHA 4.998 1.530 
AS 4.998 1.530 
LUM 4.990 10.285 
PPQ 4.997 3.086 
 
                                                 
15
 Available under: http://www.wwarn.org/tools-resources/toolkit/analyse/parasite-clearance-
estimator-pce (June 30th, 2016) 
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4.2.6 Handling of samples in the laboratory 
 
Fig. 7a: Schematic of sample processing in the laboratory.  
 
A The blood sample for ex vivo investigation of the inhibitory concentration 50 % (IC50) 
was collected from the study participants before administering the first dose of AS on day 0 as 
well as on the day of recurrent parasitaemia. 4 ml of venous blood was collected into a heparin 
tube and stored at 4 °C until cooled transport to the KEMRI Immunology laboratory (within 
8 hours after collection). The sample was centrifuged at 2000 rpm for 5 min. The plasma was 
removed and stored separately (not necessary, removal done since further investigations within 
the CATMAP study were planned with it). The buffy coat was removed from the sample with a 
pipette and a thin slide was prepared. The slide was dried, fixed with methanol and stained with 
10 % Giemsa for 15 minutes. Reading 10 microscopic fields under a light microscope (oil-
immersion, 1000-fold magnification), the percentage of parasitaemia was determined. The 
volume of blood needed for the HRP2 assay was determined with regards to parasitaemia and 
an aliquot was made to set up the assay (C-D, see Fig. 7b). The rest of the sample was stored 
at -80 °C for other investigations within CATMAP.  
 
B The blood sample for genotyping investigations was taken before the first treatment and 
on the day of recurrent parasitaemia. 4 ml venous blood was collected into an EDTA tube and 
stored at 4 °C until cooled transport to the KEMRI Immunology laboratory (within 8 hours after 
collection). The sample was immediately transferred into a 15 ml tube and the equal amount 
(1:1) of cold PBS was added before running the sample through a CF11 column for depletion of 
leukocytes and, consequently, human DNA. After centrifugation (2000 rpm for 5 min) an aliquot 
was made out of the pellet of favourably 200 µl for polymerase chain reaction (PCR) / 
genotyping and stored at -80 °C until further processing. 
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Fig.7b: Schematic of HRP2 ELISA.  
  
C The aliquot mentioned under Fig. 7a A was washed with incomplete RPMI and 
centrifuged at 1800 rpm. Then the sample was adjusted to a cell medium mixture (CMM) with a 
parasitaemia at 0.2 % and a haematocrit of 1.5 %. If the parasitaemia in the sample exceeded 
0.2 %, it was diluted down using 0-negative red blood cells. 200 µl of this CMM was now 
transferred onto the pre-dosed drug exposure plate and put into an incubation chamber which 
allowed for daily application of gas consisting of a mixture of 3 % O2, 5 % CO2 and 92 % N2. After 
72 hours of incubation at 37 °C to allow for a full parasite life cycle, the culture was removed 
and frozen at -80 °C until further processing.  
 
D For the ELISA test the incubated culture plates from C were removed from the freezer 
and haemolysed by further freeze-thawing. Then 3 µl of each well was transferred onto the pre-
coated ELISA plate. After one hour of incubation contents were discarded, the plate washed 
three times with 200 µl / well washing solution and bang-dried. 100 µl working solution of the 
second antibody was transferred into each well followed by another hour of incubation. 
Afterwards the contents were discarded, each well was washed three times and the plate was 
bang-dried before adding 100 µl / well of TMB substrate. The plate was incubated in the dark 
and then 50 µl of stopping solution to each well was added. Absorbance was read in the ELISA 
plate reader at 450 nm. For more details of HRP2 ELISA refer to the main text. 
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4.2.7 Drug sensitivity testing ex vivo via HRP2 ELISA 
The HRP2 ELISA (refer to 3.1.2) was carried out on ex vivo samples to test 
drug sensitivity. The drugs chosen for testing were DHA, AS, LUM, MFQ, PPQ 
and CQ according to following rationale: 
Artemisinin derivatives are considered the most efficient drugs for the treatment 
of Plasmodium falciparum malaria. Since monotherapies have been proven to 
encourage drug resistance, the artemisinins are combined with a partner drug. 
A total of six drugs were tested in the CATMAP study and all results will be 
reported here, while the main focus of this work will remain on the artemisinins, 
LUM and PPQ.  
The IC50s for two artemisinins, namely AS and DHA were chosen to monitor 
the efficacy of artemisinins in Kenya. The main active metabolite of all 
artemisinins is DHA (Woerdenbag, H. J. et al. 1994; Morris, C. A. et al. 2011; 
Hall, A. J. 2013). The exposure to AS itself, consequently, is fairly low in 
comparison to DHA (Navaratnam, V. et al. 2000; Olliaro, P. L. et al. 2001; 
Morris, C. A. et al. 2011). Testing two artemisinins in the same assay makes it is 
also possible to use them as internal control. 
LUM belongs to the aryl-amino-alcohol group of antimalarials and is the partner 
drug in the current ACT used as first-line treatment in uncomplicated  
P. falciparum malaria in Kenya. MFQ belongs to the same group as LUM and 
plays an important role in the global treatment and prevention of malaria. MFQ 
is used in combination with AS as ACT. Both compounds are thought to have 
similar mechanisms of action, supposedly due to the same basic chemical 
characteristic, consisting of a hydroxyl group near the ring which is 
hypothesized to be the key feature in antimalarial activity (Chien, P. L. and 
Cheng, C. C. 1976; Karle, J. M. and Karle, I. L. 1991). Therefore, similar IC50 
values can be shown (Basco, L. K. et al. 1998). 
PPQ is a bisquinoline (dimeric 4-aminoquinoline) and has been combined with 
DHA into an ACT as another option in treatment for P. falciparum malaria.  
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PPQ has been synthesised in order to conquer CQ resistance by adding 
structural modifications (Schlitzer, M. 2007). The proposal for the mechanism of 
action in the group of aryl-amino-alcohols as well as in the group of 4-
aminoquinolines has been by interference with the haeme polymerization. In 
China cross-resistance between CQ and PPQ has been reported (Fan, B. et al. 
1998; Yang, H. et al. 1999), but these results could not be reproduced e.g. in 
Cameroon (Basco, L. K. and Ringwald, P. 2003). To gather current data from 
Kenya, CQ as former first-line treatment was tested here as well. 
4.2.7.1 Preparations for HRP2 ELISA 
Drug exposure culture plate preparation and layout  
On the drug exposure culture plate parasites were incubated under drug 
pressure before the ELISA (Fig. 7b, C).  
 
Fig. 8: Drug exposure plate layout for the inhibition assay. Drug sensitivity was measured in 
duplicates. The number in each well (4) displays the drug concentration in ng / ml. 
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When planning the set-up, in order to find the highest drug solution needed for 
full inhibition, the previously reported IC50 values for the area (Borrmann, S. et 
al. 2011) were used as reference, leading to a plate layout as shown in 
Fig. 8, 4. To prepare for drug dilution, each well of a 96-well plate was filled with 
50 µl of CCM (refer to 4.1, solutions) (Fig. 8, 1).   
To each well in row H 25 µl working solution of the drug of interest was added in 
duplicates (Fig. 8, 2). Using a multi-channel pipette starting in row H the 
solution was mixed by pipetting up and down and then 25 µl of the mixture was 
transferred from row H into row G. After mixing, now 25 µl was transferred from 
row G to F. This procedure was repeated for each row going up, resulting in a 3-
fold dilution per row. 25 µl was discarded after row B to allow each row to 
contain the same amount of 50 µl (Fig. 8, 3). Row A was skipped and 
functioned as positive control row without drug exposure. 
Pre-coating of ELISA plates  
For each ELISA plate the primary antibody was diluted to 1 µg / ml in PBS.  
100 µl of this mixture was transferred into each well of the ELISA plate using a 
multi-channel pipette. The plate was then sealed and incubated overnight at  
4 °C. The following day the contents were discarded and the plate bang-dried. 
To each well 200 µl of freshly prepared blocking solution was added. After an 
incubation time of 2 hours at room temperature the contents were discarded 
and the plate bang-dried a second time. Following that the plate was washed 
with 200 µl washing solution per well and bang-dried again before adding the 
sample. 
4.2.7.2 The HRP2 ELISA 
The HRP2 ELISA is a sandwich ELISA, whereas a primary antibody is coated 
onto the ELISA plate (refer to 4.2.7.1, Pre-coating of ELISA plates) Then the 
sample is added and the protein of interest, here HRP2, binds specifically to the 
primary antibody. After incubation and removal of unbound material with 
washing solution the second antibody is added. This second antibody is 
conjugated to an enzyme, called Horseradish peroxidase (HRP). This second 
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antibody now also binds to HRP2 at a different site, thereby “sandwiching” it in 
between the primary and the second antibody. After another washing step a 
substrate is added. This substrate is a chromogen which changes colour due to 
the HRP linked to the second antibody. This colour change depends on the 
quantity of the second antibody, and, thus, also the quantity of HRP2. This 
colour change can then be measured in an ELISA plate reader to quantify 
exactly the presence of HRP2 and, consequently, parasite growth. 
For the ELISA (Fig. 7b, D) the incubated drug exposure culture plates were 
removed from the freezer and haemolysed by further freeze-thawing until all 
wells looked clear. To ensure proper mixing, the content of each well was 
pipetted up and down multiple times before transferring 3 µl of each well onto 
the pre-coated ELISA plate with a multi-channel pipette. The remaining sample 
was frozen again. Allowing for incubation, the plate was left for one hour before 
discarding the contents and washing three times with 200 µl / well washing 
solution. The plate was then bang-dried.  
Now, using a multi-channel pipette, 100 µl working solution of the second 
antibody was transferred into each well. This was followed by another hour of 
incubation. Afterwards the contents were discarded, each well was washed 
three times with 200 µl washing solution and the plate was bang-dried before 
adding 100 µl / well of TMB substrate. For seven minutes the plate was 
incubated in the dark before adding 50 µl of stopping solution (refer to 4.1, 
solutions) to each well. Then absorbance was read in the ELISA plate reader at 
450 nm.  
Optical density (OD) values were stored in an excel sheet and evaluated with 
regard to growth differences between the well with the highest drug exposure 
up to the lowest concentration and control wells. The values had to show at 
least a 2-fold growth in order to be included in the analysis. In some cases this 
limit was not reached, but the values were included in the analysis nevertheless 
because they showed a noticeable growth and a distinct half maximal inhibitory 
concentration.  
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All included samples were then manually transferred onto the HN-NonLin V1.1 
sheet16 provided to calculate IC50 values (ng / ml). The IC50 values were 
transferred into nM by using an excel sheet containing the needed formula for 
each drug (Appendix 2). 
4.2.8 Genotyping of recurrence samples to distinguish between 
recrudescence and reinfection 
DNA was extracted from matched pairs of parasite isolates from baseline and 
recurrence samples (Fig. 7a, B) with a commercial QIAGEN kit. Capillary 
electrophoresis analysis of fluorescence-labelled nested msp2-PCR products 
was done both in Kilifi and in Germany. 
4.2.9 Statistical analysis 
Fever was defined as temperature above 37.5 °C. Mean time to fever clearance 
was determined if the patient had fever within the first 24 hours. Time to fever 
clearance was then calculated from enrolment until two consecutive 
documentations of temperature below or equal to 37.5 °C. The parasite 
reduction ratio was defined as the parasite count at admission divided by the 
parasite count on the hour of interest. This value was then expressed as 
logarithm (log10). When parasitaemia falls below the detection level in the 
clinical settings, the value 0 is stated by the microscopist. When excluding these 
values the PRR is underestimated. Therefore, to accommodate for the ongoing 
decline in parasite reduction, the value 0 at hour 12 was substituted by 1, at 
hour 18, at hour 12 by 0.5, at hour 24 by 0.1 etc.17. The ratios were determined 
by using parasite count at hour 0 as numerator and the hour of interest as 
denominator (parasite reduction ratio within the first 6 hours (PRRH6), within 12 
hours (PRRH12), within 24 hours (PRRH24) and within 48 hours (PRRH48).  
                                                 
16
 Available for download under http:\\www.malaria.farch.net (August 10
th
, 2015) 
17
 Refer to http://www.statssa.gov.za/isi2009/ScientificProgramme/IPMS/0607.pdf (May 11th, 
2014) 
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In order to determine the development of the reduction ratios as well, the 
parasite reduction ratio six hours before was subtracted from the hour of 
interest and divided by 6 to obtain a rate / hour for each six hourly interval. The 
correlation of patient age and initial parasitaemia with clinical treatment 
responses and other independent variables was evaluated by linear regression 
analysis. Ex vivo inhibitory concentrations were obtained by using logarithmic 
transformed drug concentrations in a polynomial non-linear regression model 
(automatically done when copying OD values into the HN-NonLin V.1.1 sheet) 
and expressed as geometric mean with the 95 % Confidence Interval (CI). Hints 
for cross-resistance were looked for using pair-wise correlation of Spearman 
(rho) (non-parametric test), coefficient of correlation of Pearson (r) (parametric 
test) including the coefficient of correlation (r2). Wilcoxon´s paired 
nonparametric test was used to evaluate differences in the ex vivo drug 
responses between baseline and recurrent infections. Linear regression 
analysis was done to examine whether the time of drug storage influenced the 
IC50 values. When a possible influence was recognised, a non-paired, non-
parametric t-test (between DHA and AS values in- and excluding the 
measurements made with the conspicuous drug solutions) was used to check 
whether this influence created a statistically significant difference. Numbers 
were rounded to two digits after the comma. In some cases, were necessary, 
rounding was done to three digits after the comma. Percentages were rounded 
to full numbers. 
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5. Results 
5.1 Study cohort 
One hundred and seventy five patients (n = 175) were recruited between April 
and December 2011 into the CATMAP study. The children were treated with AS 
monotherapy for 7 days (2 mg / kg body weight) and followed up for 42 days. 
Due to consent withdrawal the baseline sample was not taken from six children. 
One patient was withdrawn on day 4 due to persisting parasitaemia under 
treatment with AS and given rescue treatment. There was one consent 
withdrawal on day 14 and one on day 28. One patient was excluded on day 28 
due to taking AL from a different drug dispensary. Three patients were lost in the 
follow- up (one on day 28, two on day 42). Seven patients were enrolled despite 
their parasitaemia exceeded the maximum enrolment parasitaemia of  
300,000 / µl (302,505 – 566,470 / µl). The median patient age was 51 months 
and the median P. falciparum parasitaemia at enrolment was 95,200 / µl.  
Further information on the baseline characteristics is provided in Tab. 1. 
BASELINE CHARACTERISTICS 
Median age (range) in months 51 (7 months – 10 years) 
Median axillary temperature (range) in °C 37.5 (36.4 – 40.3) 
Median asexual P. falciparum density / µl 
(range) 
95,203 (16,579 – 566,470) 
Tab. 1: Baseline characteristics of patients from CATMAP. 
 
5.1.1 Clinical treatment responses and analysis 
The mean overall parasite clearance time (n = 168) was 30.5 hours. The 
median PCT was 30 hours for patients with a parasitaemia below 105 / µl and 36 
hours for patients with a parasitaemia above 105 / µl (p = 0.001). 
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Tab. 2 displays the clinical and parasitological results. 
Tab. 2: Clinical and parasitological results in the study patients. (n = 168, one did not clear 
parasites and six withdrew consent right after enrolment) 
Clinical and Parasitological Results 
Parasite clearance time in 
hours 
Median (range) 30.5 
(12 – 54) 
For patients with 
baseline parasite 
density < 105 / µl 
Number of patients 88 / 168 
(52 %) 
 Median PCT (range) in hours 30 
(12 – 54) 
For patients with 
baseline parasite 
density > 105 / µl 
Number of patients 80 / 168 
(48 %) 
 Median PCT (range) 36 
(12-54) 
Parasite reduction ratio Median (range) log10 parasite 
reduction ratioH6 
0.2 
(-1.14 – 2.11) 
 Median (range) log10 parasite 
reduction ratioH12 
1.07 
(-0.31 – 5.25) 
 Median (range) log10 parasite 
reduction ratioH24 
2.5 
(0.02 – 6.05) 
 Median (range) log10 parasite 
reduction ratio H48 
5.97 
(1.89 – 6.75) 
Patients presenting with 
fever (> 37.5 °C) 
Baseline / Day 0 83 
 Mean time to fever clearance time 
(95 % CI) in hours 
24.42 
(20.37 – 28.48) 
Patients with recurrent 
parasitaemia  
 56 / 168 
(33 %) 
 < Day 28 32 / 168 
(19 %) 
 > Day 28 24 / 168 
(14 %) 
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On day of enrolment elevated body temperature (> 37.5 °C) was recorded in 83 
patients, mean time to fever clearance was 24 hours (95 % CI 20 – 28 hours).
  
On the first day (24 hours) after initiation of treatment there were 117 / 168 
patients (Day 1 Parasite Prevalence Rate PPRD1 70 %) with residual 
parasitaemia. By hour 48, only 3 patients had residual parasitaemia  
(PPRD2 2 %) and by hour 54 all patients were cleared of parasitaemia except of 
one patient, who was later excluded and given rescue treatment for suspected 
clinical treatment failure. 
Most parasites were killed between 6 and 12 hours after the treatment dose. 
The increase in parasite reduction was high between hour 6 and 12 after 
initiation of treatment (reduction rate rose from 0.2 to 1.07, therefore, from  
0.03 / hour to 0.14 / hour). It then decreased until reaching the time of second 
artesunate treatment dose at hour 24. After the second dose it increased rapidly 
within six hours between hour 24 and 30 (0.08 / hour to 0.55 / hour) to then slow 
once again (Fig. 9). 
 
Fig. 9: Median parasite reduction ratios per hour in six hourly intervals for the first 
48 hours after initiation of treatment. 
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Fig. 10 shows the reduction in total mean parasitaemia levels over time. 
 
Fig. 10: Reduction in mean parasitaemia levels over hours. Green dots display mean 
parasitaemia in overall study population over time. Red dots display parasitaemia in one single 
patient not clearing parasites. Bars show 95 % CI of mean parasite counts. 
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The parasite clearance estimation was obtained by entering the data into the 
web based tool as mentioned above (refer to 15). 
An overview of the results is displayed in Tab. 3. 
PCE 
Clearance rate constant ( / hr) Median 0.29 
 Geometric mean 0.30 
Slope half life (hrs) Median 2.37 
 Geometric mean 2.33 
Lag phase (hrs) Median 11.93 
 Geometric mean 11.72 
Parasite clearance 50 (PC50) (hrs) Median 4.67 
 Mean 5.69 
Parasite clearance 90 (PC90) (hrs) Median 10.80 
 Mean 11.18 
Parasite clearance (PC99) (hrs) Median 18.76 
 Mean 19.41 
Tab. 3: Parasite clearance estimation values as calculated by web-based tool provided by 
WWARN (refer to 
15
). 
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As mentioned before (refer to 3.1.1), the PCT has been reported to correlate 
with initial parasitaemia. Baseline parasitaemia counts did show a significant 
positive correlation with the initial parasitaemia at enrolment (p < 0.001)  
(Fig. 11). 
 
Fig. 11: Correlation of PCT and initial parasitaemia. Significant positive correlation; linear 
regression analysis showed a significant deviation from zero for the slope (p < 0.0001); dotted 
line shows 95 % CI. 
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No significant correlation could be found between PCT and the age of the 
patient (Fig. 12). 
 
Fig. 12: Correlation of PCT and patient age. No significant correlation; dotted line shows  
95 % CI. 
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Using the PCE values as obtained from the web-based tool on the other hand, 
no significant correlation could be found between the clearance rate constant 
and initial parasitaemia (Fig. 13). 
 
Fig. 13: Correlation of clearance rate constant and initial parasitaemia. No significant 
correlation; linear regression analysis showed a perfect line for clearance rate constant and 
log10 initial parasitaemia; dotted lines show 95 % CI. 
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Also, the age of the patient did not show a significant correlation with the 
clearance rate constant (Fig. 14). 
 
Fig. 14: Correlation of clearance rate constant and patient age. No significant correlation; 
linear regression analysis stated a non-significant deviation from 0 for the slope; dotted lines 
show 95 % CI. 
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The same applied for the slope half life (Fig. 15). 
 
Fig. 15: Correlation of slope half life and initial parasitaemia. No significant correlation; 
linear regression analysis stated a non-significant deviation from 0 for the slope; dotted lines 
show 95 % CI. 
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No correlation was seen between the slope half life and the patient age  
(Fig. 16). 
 
Fig. 16: Correlation of slope half life and patient age. No significant correlation; linear 
regression analysis stated a non-significant deviation from 0 for the slope; dotted lines show  
95 % CI.  
 
5.1.2 Recurrent parasitaemia 
A total of 56 / 168 patients (33 %) showed recurrent parasitaemia during the 
follow-up. Up to day 28 we recorded 32 / 168 patients (19 %) with recurrent 
parasitaemia. Median parasitaemia at presentation of recurrent parasitaemia 
was 75,800 parasites / µl.  
Analysis of the genotyping data confirmed recrudescence in 8 / 168 patients  
(5 %), whereas 5 / 168 patients (3 %) had recrudescent parasites within 28 
days. 
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5.1.3 Ex vivo drug responses and analysis 
Out of 175 patients that were recruited for the CATMAP study, 6 patients 
withdrew consent before having the baseline blood samples taken. From 145 
successfully set up assays, 111 showed adequate growth and inhibition against 
at least one drug and were included in the final analysis (77 %). The intra-
sample correlation between the duplicates as a measure of reproducibility was 
high (median 0.94, range 0.91 – 0.98). 
Baseline ex vivo IC50 drug responses were determined using the established 
HRP2 ELISA. The median AS IC50 value was 6.6 nM, the geometric mean 5.8 
nM. Median and geometric mean for DHA were 4.5 nM and 4.8 nM. For LUM 
the median and geometric mean IC50 values were 13.7 nM and 12.1 nM; 
median and geometric mean for PPQ were 7.9 nM and 8.0 nM.  
 
Fig. 17: Distribution of baseline IC50 values. Red bars show geometric mean with 95 % CI. 
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All IC50 values calculated are also presented in the above Fig. 17. + Tab. 4. 
Ex vivo susceptibility CQ MFQ DHA AS LUM PPQ 
Number of values 97 99 111 111 99 98 
Minimum 4.93 1.48 0.42 0.30 1.25 1.25 
25 % Percentile 10.22 7.36 2.80 2.82 8.26 5.65 
Median 15.63 12.59 4.52 6.59 13.71 7.88 
75 % Percentile 32.64 21.12 8.99 11.84 19.54 11.85 
Maximum 446.80 76.19 54.17 64.19 206.2 106.50 
Geometric mean 21.15 11.76 4.84 5.82 12.10 8.03 
Lower 95 % CI of geo. mean 16.98 9.86 4.10 4.77 10.31 6.91 
Upper 95 % CI of geo. mean 26.35 14.03 5.70 7.12 14.20 9.34 
Tab. 4: Ex vivo susceptibility in nM of isolates of Plasmodium falciparum to AS, DHA, CQ, 
MFQ, LUM and PPQ. 
Pair-wise correlation analysis was done in order to look for indications of cross-
resistance (Tab. 5 + Fig. 18 - Fig. 32).  
A significant positive correlation was shown between DHA and AS (Rho = 0.77, 
p < 0.0001), but also between DHA and PPQ (Rho = 0.54, p < 0.0001), DHA 
and LUM (Rho = 0.46, p < 0.0001) and DHA and MFQ (Rho = 0.49, p < 0.0001). 
Likewise did AS show a significant positive correlation with PPQ (Rho = 0.41,  
p < 0.0001), with LUM (Rho = 0.42, p < 0.0001) and with MFQ (Rho = 0.44,  
p < 0.0001).  
Susceptibility to PPQ correlated with LUM (Rho = 0.31, p = 0.0018) and MFQ 
(Rho = 0.22, p = 0.0324), and LUM additionally correlated with MFQ in a 
statistically significant way (Rho = 0.62, p < 0.0001).  
A negative correlation was found between LUM and CQ (Rho = -0.24, p = 0.02). 
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Correlations CQ DHA AS PPQ LUM 
DHA      
Rho 0.002     
p-value 0.98     
r2 0.005     
AS      
Rho 0.04 0.77    
p-value 0.70 < 0.0001    
r2 0.008 0.58    
PPQ      
Rho 0.09 0.54 0.41   
p-value 0.40 < 0.0001 < 0.0001   
r2 0.003 0.02 0.03   
LUM      
Rho -0.24 0.46 0.42 0.31  
p-value 0.020 < 0.0001 < 0.0001 0.002  
r2 0.006 0.01 0.03 4.929e-006  
MFQ      
Rho 0.04 0.49 0.44 0.22 0.62 
p-value 0.7 < 0.0001 < 0.0001 0.0324 < 0.0001 
r2 0.002 0.04 0.10 0.006 0.05 
Tab. 5: Spearman (rho) and Pearson (r
2
) correlation of ex vivo responses. Significant 
correlations in bold. 
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Fig. 18: Scatter plot of IC50 values of AS 
and DHA. Rho = 0.77, p < 0.0001. 
Fig. 19: Scatter plot of IC50 values of PPQ 
and DHA. Rho = 0.54, p < 0.0001. 
  
  
Fig. 20: Scatter plot of IC50 values of LUM 
and DHA. Rho = 0.46, p < 0.0001. 
Fig. 21: Scatter plot of IC50 values of MFQ 
and DHA. Rho = 0.49, p < 0.0001. 
  
  
Fig. 22: Scatter plot of IC50 values of PPQ 
and AS. Rho = 0.41, p < 0.0001. 
Fig. 23: Scatter plot of IC50 values of LUM 
and AS. Rho = 0.42, p < 0.0001. 
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Fig. 24: Scatter plot of IC50 values of MFQ 
and AS. Rho = 0.44, p < 0.0001. 
Fig. 25: Scatter plot of IC50 values of LUM 
and PPQ. Rho = 0.31, p = 0.0018. 
  
  
Fig. 26: Scatter plot IC50 values of MFQ 
and PPQ. Rho = 0.22, p = 0.0324. 
Fig. 27: Scatter plot of IC50 values of MFQ 
and LUM. Rho = 0.62, p < 0.0001. 
  
  
Fig. 28: Scatter plot of IC50 values of DHA 
and CQ. 
Fig. 29: Scatter plot of IC50 values of AS 
and CQ. 
  
62 
 
 
 
Fig. 30: Scatter plot of IC50 values of LUM 
and CQ. Rho = -0.24, p = 0.0202. 
 
  
  
Fig. 31: Scatter plot of IC50 values of PPQ 
and CQ. 
Fig. 32: Scatter plot of IC50 values of MFQ 
and CQ. 
Multiple drug solutions were used in the study (refer to 5.2.1) which differed in 
their responses. The correlation analysis was also done for each drug solution 
separately to further look at the ranges and to detect smaller correlations which 
might not be significant in the overall analysis but have been shown in other 
studies before (Appendix 3). 
5.2 Potential confounding variables on the ex vivo analysis 
When appraising the ex vivo drug susceptibility of the isolates, a range of 
potential confounding variables needs to be considered for a correct 
interpretation of results. The assay was set up in a controlled manner and 
experiment conditions did not change over time to reduce possible confounders 
to a minimum.  
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However, there were two factors that need further consideration which could 
have altered the results apart from a change in susceptibility of the parasite 
isolate and need to be taken into account: 
 The drugs were stored as stock solutions. The working solutions used 
during the assay were prepared seven times in total over the course 
of the study. The steps taken and instruments used in the preparation 
were always the same. However, a slight change in concentration due 
to pipetting mistakes can never be completely ruled out. 
 Over the course of the study 175 patients were recruited within a time 
frame of 9 months (April – December 2011). The patients were 
distributed over these 9 months due to multiple reasons (no malaria 
cases, refusals of enrolment as well as amendments in the study 
protocol resulting in a break in enrolment for about 6 weeks). Hence, 
some working solutions of the drugs were stored only for a short time 
when recruitment was proceeding quickly; others were stored over a 
longer period. Since storage conditions remained unaltered, the time 
of storage of drugs was plotted against the IC50 value to check for 
dependence. 
5.2.1 Drug working solutions 
The ex vivo drug susceptibility assays were performed with seven working 
solutions of the different drugs. This might account for different results among 
different solutions. Therefore, each working solution was also looked at 
individually concerning the distributions of IC50 (AS Fig. 33 + Tab. 6,  
DHA Fig. 34 + Tab. 7, LUM Fig. 35 + Tab. 8, MFQ Fig. 36 + Tab. 9,  
CQ Fig. 37 + Tab. 10, PPQ Fig. 38 + Tab. 11). 
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5.2.1.1 Artesunate solution I – VII 
 
Fig. 33: Distribution of AS IC50 values among prepared drug solutions. Red lines show 
geometric mean with 95 % CI. 
AS I II III IV V VI VII 
Number of values 11 16 18 21 9 21 15 
Minimum 2.68 1.78 3.33 1.65 1.26 6.53 0.30 
25 % Percentile 4.60 4.72 5.45 2.80 2.08 13.76 0.50 
Median 7.10 8.46 8.06 3.75 4.14 19.02 1.06 
75 % Percentile 8.52 11.88 9.67 9.05 7.54 32.06 1.54 
Maximum 23.79 21.32 16.66 15.14 11.27 64.19 2.30 
Geometric mean 7.14 7.04 7.36 4.62 3.84 20.23 0.96 
Lower 95 % CI of  
geometric mean 
4.62 4.93 5.89 3.40 2.17 15.53 0.68 
Upper 95 % CI of  
geometric mean 
11.05 10.05 9.2 6.28 6.77 26.35 1.35 
Tab. 6: AS IC50 values in nM among prepared drug solutions. 
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5.2.1.2 Dihydroartemisinin solution I – VII 
 
Fig. 34: Distribution of DHA IC50 values among prepared drug solutions. Red lines show 
geometric mean with 95 % CI. 
DHA I II III IV V VI VII 
Number of values 11 16 18 21 9 21 15 
Minimum 2.55 0.97 3.04 1.16 0.42 2.56 0.98 
25 % Percentile 2.80 1.66 4.01 3.28 1.16 8.19 1.76 
Median 4.80 3.44 5.68 4.72 1.69 12.20 2.97 
75 % Percentile 5.72 4.46 7.15 9.98 3.62 21.44 5.47 
Maximum 22.59 10.18 14.02 13.93 5.87 54.17 8.03 
Geometric mean 5.32 2.93 5.30 4.94 1.83 12.98 3.01 
Lower 95 % CI of 
geometric mean 
3.37 2.05 4.30 3.58 0.99 9.10 2.10 
Upper 95 % CI of 
geometric mean 
8.40 4.21 6.52 6.83 3.39 18.51 4.31 
Tab. 7: DHA IC50 values in nM among prepared drug solutions. 
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5.2.1.3 Lumefantrine solution I – VII 
 
Fig. 35: Distribution of LUM IC50 values among prepared drug solutions. Red lines show 
geometric mean with 95 % CI. 
LUM I II III IV V VI VII 
Number of values 9 15 17 21 7 17 13 
Minimum 3.31 2.50 6.99 4.15 1.28 3.93 1.25 
25 % Percentile 5.25 5.45 10.29 7.47 2.27 10.57 3.74 
Median 10.19 13.28 13.68 15.75 8.26 16.61 10.68 
75 % Percentile 17.25 26.10 16.83 25.71 16.72 23.13 20.40 
Maximum 36.08 206.20 24.90 43.90 23.66 47.51 21.71 
Geometric mean 9.88 13.45 13.49 13.60 7.13 15.66 8.40 
Lower 95 % CI of  
geometric mean 
5.53 7.37 11.37 9.87 2.60 11.18 4.80 
Upper 95 % CI of  
geometric mean 
17.65 24.54 16.00 18.76 19.53 21.93 14.72 
Tab. 8: LUM IC50 values in nM among prepared drug solutions. 
  
67 
 
5.2.1.4 Mefloquine solution I – VII 
 
Fig. 36: Distribution of MFQ IC50 values among prepared drug solutions. Red lines show 
geometric mean with 95 % CI. 
MFQ I II III IV V VI VII 
Number of values 9 15 16 21 7 11 14 
Minimum 2.09 1.53 9.04 1.95 1.69 3.87 1.47 
25 % Percentile 4.18 4.29 16.22 7.14 4.61 7.36 3.96 
Median 14.68 10.09 23.56 13.10 11.92 11.26 8.66 
75 % Percentile 34.10 18.44 30.81 27.38 14.25 21.05 16.92 
Maximum 76.19 24.10 54.79 69.95 16.54 37.37 23.05 
Geometric mean 12.83 8.510 22.58 13.33 8.24 11.79 7.38 
Lower 95 % CI of  
geometric mean 
5.06 5.14 17.74 8.76 3.88 7.61 4.45 
Upper 95 % CI of  
geometric mean 
32.52 14.08 28.76 20.29 17.46 18.27 12.22 
Tab. 9: MFQ IC50 values in nM among prepared drug solutions. 
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5.2.1.5 Chloroquine solution I – VII 
 
Fig. 37: Distribution of CQ IC50 values among prepared drug solutions. Red lines show 
geometric mean with 95 % CI. 
CQ I II III IV V VI VII 
Number of 
values 
8 15 16 21 7 17 13 
Minimum 4.92 4.92 9.00 9.06 4.92 4.92 6.13 
25 % Percentile 6.60 10.18 15.17 11.71 4.92 10.13 7.75 
Median 11.62 11.87 21.19 23.29 9.81 13.48 18.12 
75 % Percentile 20.96 14.67 66.12 36.39 285.9 28.41 38.71 
Maximum 29.87 124.30 421.70 446.80 346.70 121.90 287.20 
Geometric mean 11.70 14.49 29.71 30.09 30.13 15.68 21.47 
Lower 95 % CI of  
geometric mean 
6.93 9.53 16.88 17.47 5.21 10.29 11.34 
Upper 95 % CI of  
geometric mean 
19.74 22.04 52.29 51.82 174.30 23.90 40.65 
Tab. 10: CQ IC50 values in nM among prepared drug solutions. 
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5.2.1.6 Piperaquine solution I – VII 
 
Fig. 38: Distribution of PPQ IC50 values among prepared drug solutions. Red lines show 
geometric mean with 95 % CI. 
PPQ I II III IV V VI VII 
Number of values 9 15 17 21 7 17 12 
Minimum 1.63 1.34 4.91 4.58 1.25 4.71 2.12 
25 % Percentile 10.88 3.67 6.64 6.52 1.64 8.23 3.44 
Median 28.87 5.74 7.87 8.56 3.60 11.02 6.11 
75 % Percentile 55.40 7.20 9.49 13.39 7.02 13.45 10.64 
Maximum 106.50 12.04 13.73 16.23 10.67 16.43 19.00 
Geometric mean 19.95 5.21 8.04 9.11 3.73 10.21 6.22 
Lower 95 % CI of  
geometric mean 
6.39 3.67 7.02 7.62 1.81 8.48 4.04 
Upper 95 % CI of  
geometric mean 
62.29 7.39 9.21 10.90 7.71 12.30 9.57 
Tab. 11: PPQ IC50 values in nM among prepared drug solutions. 
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5.2.2 Drug sensitivity over time of drug storage 
Due to the fluctuation of patients recruited within a time span, some of the drug 
solutions were stored longer than others. To check if and how the storage time 
of the drug might influence the IC50 value, the measured inhibitory 
concentrations were plotted against the time of drug storage and analysed by 
linear regression. The time of drug storage did show a significant positive 
correlation with the IC50 values determined of AS (p < 0.0001) (Fig. 39) and 
DHA (p < 0.0001) (Fig. 40). 
  
  
Fig. 39: Correlation between days of drug 
storage and AS IC50 values. p < 0.0001. 
Fig. 40: Correlation between days of drug 
storage and DHA IC50 values. p < 0.0001. 
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All the other drugs did not show an indication for a decrease in efficacy over 
time of drug storage (Fig. 41 – Fig. 44). 
  
  
Fig. 41: Correlation between days of drug 
storage and IC50 values of LUM. 
Fig. 42: Correlation between days of drug 
storage and IC50 values of MFQ. 
  
  
  
Fig. 43: Correlation between days of drug 
storage and IC50 values of CQ. 
Fig. 44: Correlation between days of drug 
storage and IC50 values of PPQ. 
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Highlighting the plots of the IC50 values in different colours according to their 
drug solutions, measurements from the longest stored drug solution (AS VI) 
produced almost exclusively values of high mean inhibitory concentrations  
(Fig. 45, encircled). 
 
Fig. 45: Scatter plot of AS IC50 values dependent on time of drug storage and drug 
working solution. 
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Also the coloured plot of DHA according to drug solution and time of storage 
(Fig. 46, encircled) showed the same as above mentioned for AS. 
 
Fig. 46: Scatter plot of DHA IC50 values dependent on time of drug storage and drug 
working solution. 
This one drug solution was stored over a long period of time. That indicates that 
ex vivo IC50 values of the artemisinins are highly influenced by the time of drug 
storage. The efficacy decreases with time and in order to produce reliable 
results drug storage time has to be strictly observed and controlled. 
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Already the analysis of individual drug solutions of the artemisinins (refer to 
5.2.1.1 and 5.2.1.2) did show that the distribution of IC50 values in drug solution 
VII differed between AS and DHA. To re-evaluate this finding, the ratio between 
DHA and AS IC50 was calculated as quotient (IC50 DHA / IC50 AS) and plotted 
with regards to drug solution and time of drug storage (Fig. 47). It was seen that 
the ratio was not influenced by time of drug storage, indicating that both drugs 
degrade at similar rates over time. But, as suspected, did drug solution VII show 
a high variety of ratios differing significantly from the rest (p < 0.0001). Since 
this was suspicious only in that one set of drug solution it is likely that another 
confounder, e.g. pipetting inaccuracy etc. influenced the results. 
 
Fig. 47: Scatter plot of ratio between DHA and AS IC50 values dependent on time of drug 
storage and drug working solution. 
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5.2.3 Corrected analysis by accounting for the effect of drug batches 
To account for the confounder time of drug storage as well as an unknown one 
(solution VII) the analysis was repeated excluding the sixth and seventh drug 
solution. Tab. 12 shows IC50 values for DHA and AS in- (DHA, AS) and 
excluding (DHA*, AS*) those drug solutions in comparison. 
Ex vivo susceptibility DHA*  DHA AS* AS 
Number of values 75 111 75 111 
Minimum 0.42 0.42 1.26 0.30 
25 % Percentile 2.66 2.80 3.50 2.82 
Median 4.17 4.52 6.26 6.59 
75 % Percentile 6.02 8.99 9.72 11.84 
Maximum 22.59 54.17 23.79 64.19 
Geometric mean 4.04 4.84 5.89 5.82 
Lower 95 % CI of geometric mean 3.41 4.10 5.06 4.76 
Upper 95 % CI of geometric mean 4.71 5.70 6.86 7.12 
Tab. 12: Ex vivo susceptibility (in nM) of AS and DHA when excluding (AS*, DHA*) the 
working solutions that were potentially confounded. 
The correlation analysis to check for cross-resistance was repeated as well for 
the concerned pairs (Tab. 13). The IC50 values for DHA and AS were tested 
using unpaired nonparametric t-test to check for differences when excluding the 
values from the potentially degraded drug solution VI and the other suspicious 
drug solution VII. The overall analysis was not significantly influenced by the 
discussed confounders (AS vs. AS* p = 0.72, DHA vs. DHA* p = 0.23). 
Interestingly, the corrected correlation analysis did show a main difference for 
the correlation between the artemisinins and MFQ. Before the correction the 
correlation between DHA and AS and MFQ was significant but with only a 
coefficient of determination of r2 = 0.04 and 0.10, respectively. After the 
correction this coefficient of determination increased to 0.41 and 0.36, 
respectively. 
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The corrected analysis does now indicate cross resistance between MFQ and 
the artemisinins. Other correlations did not change significantly. 
Correlations CQ DHA* AS* PPQ LUM 
DHA*      
Rho 
0.15 
    
p-value 0.23     
r2 0.003     
AS*      
Rho 0.04 0.74    
p-value 0.79 < 0.0001    
r2 0.02 0.61    
PPQ      
Rho 0.09 0.46 0.35   
p-value 0.40 < 0.0001 0.004   
r2 0.003 0.08 0.08   
LUM      
Rho -0.24 0.45 0.46 0.31  
p-value 0.02 < 0.0001 < 0.0001 0.002  
r2 0.006 0.001 0.03 4.929e-006  
MFQ      
Rho 0.04 0.63 0.63 0.22 0.62 
p-value 0.70 < 0.0001 < 0.0001 0.0324 < 0.0001 
r2 0.002 0.41 0.36 0.006 0.05 
Tab. 13: Pair-wise Spearman (Rho) and Pearson (r
2
) correlation matrix of ex vivo 
responses to different compounds after exclusion of potentially confounded working 
solutions VI and VII. Significant correlations in bold. 
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5.3 Drug sensitivity in recurrent parasitaemia samples 
Recurrent parasitaemia was recorded in 56 / 168 patients over the course of the 
follow-up (33 %). Before or on day 28 after enrolment, 32 patients (19 %) had 
recurrences and 24 (14 %) after day 28. From 39 (70 %) of these 56 total 
recurrent parasitaemia patients another sample for drug sensitivity testing was 
obtained before giving treatment.   
The drug-sensitivity assay was successful in 35 of these samples (90 %). The 
distributions of the IC50 values among all the recurrence samples are shown 
below (Fig. 48). 
 
Fig. 48: Distribution of IC50 values determined in isolates obtained from recurrent 
infections. 
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Results are displayed without regards to the used drug solution. IC50 
distributions in recurrent parasitaemia isolates (as shown in 5.2.1 for baseline 
samples) can be found as additional information in the Appendix (Appendix 4). 
Tab. 14 shows the IC50 values of recurrent samples in detail. 
IC50 of isolates from 
recurrent infections 
CQ MFQ DHA AS LUM PPQ 
Number of values 35 35 35 35 35 34 
Minimum 4.93 1.19 1.29 0.47 1.07 0.67 
25 % Percentile 8.41 5.38 1.86 1.86 7.49 3.57 
Median 14.35 14.57 3.03 3.70 13.66 5.08 
75 % Percentile 23.45 27.48 4.91 6.83 17.11 7.56 
Maximum 301.60 47.99 15.14 36.83 89.92 26.81 
Geometric mean 16.62 11.95 3.37 3.62 11.76 5.17 
Lower 95 % CI of geo. mean 11.89 8.47 2.66 2.52 8.61 4.04 
Upper 95 % CI of geo. mean 23.23 16.86 4.27 5.199 16.07 6.61 
Tab. 14: Ex vivo susceptibility of isolates obtained from recurrent infections. 
A total of 18 matched pairs of samples obtained from baseline and recurrent 
infections for ex vivo drug susceptibility testing were collected. 
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Comparing these 18 pairs using Wilcoxon´s paired nonparametric test, the IC50 
values between the baseline sample and recurrence sample did not differ 
significantly besides a slightly significant lower value of DHA in the isolates from 
recurrent infections. (p = 0.02) (Fig. 49). This may be difficult to explain but 
importantly, drug selection did not lead to elevated values. 
 
Fig. 49: Whisker plots showing ex vivo drug responses of matched baseline-recurrence 
isolates. No significant differences in responses between baseline and recurrence samples 
except a significant lower value in the isolates of recurrent infections towards DHA (p = 0.02). 
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6. Discussion 
The continued and uncontrolled use of monotherapies against malaria parasites 
has led to widespread reduced susceptibility of almost all known antimalarials. 
The introduction of combination therapies was hoped to prevent or at least 
delay the emergence of reduced susceptibility to the fastest acting antimalarial 
drugs these days, artemisinin derivatives. Drug surveillance studies monitor 
drug efficacy and effectiveness to be able to detect and react to declining 
responsiveness of malaria parasites as fast as possible. 
This chapter will first discuss the in vivo parameters and their limitations before 
comparing results obtained here with previous data. Afterwards ex vivo drug 
susceptibility testing and its general limitations will be debated. The results 
gathered here will be also compared to previous findings. While completing this 
work an important study was published reporting a correlation between in vivo 
parasite clearance and in vitro artemisinin susceptibility using an assay called 
RSA0 – 3 (Witkowski, B. et al. 2013a). The HRP2 ELISA is accordingly not the 
correct tool to identify artemisinin resistance. Nevertheless does, considering 
the results from Borrmann, S. et al. (2013), the approach via the HRP2 assay 
allow identification of artemisinin drug susceptibility phenotypes. In 
consideration of the recent developments regarding artemisinin drug tolerance 
the role of the results and the concluded need for further surveillance will be 
underlined. 
6.1 Artemisinin drug susceptibility in vivo  
Parameters such as parasite clearance time, parasite reduction ratio and 
parasite prevalence rate can indicate the effectiveness of a drug applied in 
vivo by providing values to compare how fast parasites fall under the 
microscopic threshold after initiation of treatment. 
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In 2009, the first artemisinin-resistant malaria episodes were reported in 
Cambodia (Dondorp, A. M. et al. 2009) with a prolonged mean parasite 
clearance time of 84 hours in Pailin, Cambodia and of 50 hours in Wang Pha, 
Thailand. Following that the longitudinal study by Borrmann, S. et al. (2011) in 
the coast of Kenya showed a rise in mean PCT from 37.8 (2005 – 2006) to 46.0 
(2007 – 2008) hours after treatment with DHA-PPQ and from 45.0  
(2005 – 2006) to 49.8 (2007 – 2008) hours after treatment with ART-LUM. Here, 
after treatment with the single drug AS at a dose of 2 mg / kg body weight, the 
mean PCT was 30.5 hours at the same study site. 
The PCT is mostly determined by microscopic evaluations of blood smears and 
therefore, limited by the microscopically detectable parasite biomass,  
(≤ 108 parasites). A patient might be declared parasite-free when actually 
parasitaemia was just reduced below that threshold. In this case the efficacy of 
the drug would be overestimated, leading to wrong implications for further drug 
usage. The determination of parasitaemia in the field using an average 
leukocyte count of 8,000 / µl (refer to 4.2.3) leads to inaccuracy. Especially in 
children the leukocyte counts can vary within a wide range, often depending on 
the age. Here the white blood cell count had a median of about 8,600 / µl (range 
2,900 – 21,700 / µl). The average leukocyte count of 8,000 / µl as an overall 
value was, thus, close to the median, but an underestimation of parasitaemia in 
patients with higher leukocytes and overestimation in the ones with lower white 
blood cell count have to be considered and the possibility of inaccurate 
clearance and reduction ratios kept in mind. Besides microscopic threshold and 
counting errors, the PCT has been shown to be influenced by factors such as 
initial parasitaemia, the stage of development of the parasite, the frequency of 
sampling and host defence (immunity and, therefore, also the age of the patient 
in high transmission areas) (White, N. J. 2011). Also do different drugs act at 
different stages during the parasite life cycle (refer to 2.5). A drug that is not 
exactly administered at the point of highest vulnerability of the parasite might 
suggest a PCT and PRR that are prolonged or reduced. This might also lead to 
falsely drawn conclusions regarding drug efficacy.  
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Parasite clearance is regarded as a first-order-process; higher initial 
parasitaemia, consequently, lead to longer clearance times. The PCT did show 
a correlation with the initial parasitaemia (Fig. 11, p < 0.0001). About half of the 
patients (52 %) had a parasitaemia at enrolment below 105 parasites / µl, the 
other half (48 %) above. For the first group the PCT was 30 hours, for the 
second 36 hours (p = 0.001). Comparing the results of this study with the 
previous study by Borrmann, S. et al. (2011) CATMAP enrolled patients with 
initial asexual parasitaemia between 10,000 – 300,000 / µl; the previous study 
included patients with lower parasitaemia (2,000 – 200,000 / µl). 
Median asexual P. falciparum density was lower in the last study  
(34,600 – 57,600 parasites / µl); here the median parasitaemia was  
95,200 parasites / µl. Therefore, in comparison to PCTs of 38 and 50 hours in  
2005 – 2008, for now no further indication for a decline of responsiveness in 
vivo to artemisinin could be found. 
Another confounder often mentioned is the immunity of the patient against 
malaria acquired in high transmission areas. The age group most at risk for 
severe infections are children up to 5 years of age. After that, they are 
considered to have built up a level of immunity. Hence, age can be used as an 
indicator for immunity. However, no correlation was seen between the patients’ 
age and the PCT in this study. It is possible that due to a general decline in 
malaria transmission in the area (O´Meara, W. P. et al. 2008) the level of 
immunity has decreased, thus, not showing a correlation here. 
The parasite prevalence rate on the first day after initiation of treatment (PPRD1) 
with an ACT is mainly determined by the artemisinin partner (White, N.J. 2004). 
From 2005 – 2006 to 2007 – 2008, an increase in the PPRD1 from 55 % to 87 % 
in patients receiving treatment with DHA-PPQ and from 81 % to 95 % in the AL 
group was noted, meaning that after initiation of treatment with an ACT the 
number of patients with remaining parasitaemia 24 hours later rose in both 
study arms. The hypothesis drawn from this drop in early treatment response 
was a declined sensitivity to the artemisinin-derivate as the fast acting 
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component of the ACT. Comparison of the PPRD1 of 70 % (117 / 168) as 
observed after monotherapy with AS in CATMAP shows a faster clinical 
response than to ART-LUM. The PPRD1 here also places itself in between the 
2005 – 2006 and 2007 – 2008 recorded values for DHA-PPQ. This again did 
not raise further concerns of overall reduced drug susceptibility to artemisinins 
at the time CATMAP was carried out. Moreover, when comparing the parameter 
for patients that still had detectable parasitaemia on the second day after 
initiation of treatment (PPRD2), it was much lower (2 %) than the  
4 % (DHA-PPQ) / 7 % (ART-LUM) in 2005 / 2006 and the  
5 % (DHA-PPQ) / 13 % (ART-LUM) in 2007 / 2008 in the same study area. 
Another parameter, the parasite reduction ratio is defined as the factor by which 
parasitaemia declines over time and is, therefore, describing how fast the 
antimalarial agent reduces parasite burden. Median parasite reduction ratio on 
the first day (PRRH24) for DHA-PPQ fell from 2.5 to 1.8 and for AM-LUM from 
1.9 to 1.4 in the previous study in Kenya- thus, resembling the observed incline 
in detectable parasitaemia on Day 1. Here the median PRRH24 was fairly high 
with 2.5. Parasite reduction rates increased quickly within 6 – 12 hours after 
each treatment dose, whereas the parasite reduction rate rose from 0.03 / hour 
to 0.14 / hour between hour 6 and 12. After the second treatment dose this 
reduction rate increased even further within the same time span  
(from 0.08 / hour to 0.55 / hour). Also this clinical parameter still indicates a high 
susceptibility to Artemisinins with rapid onset of parasite reduction. 
Due to multiple potential confounders of the PCT, a new method, the PCE, was 
proposed (Flegg, J. A. et al. 2011). In summary, there is only one segment in the 
parasite clearance curve which is robust against the above mentioned 
confounder. The PCE excludes the two segments that are easily influenced, the 
lag phase and the tail, and also identifies outliers. From the robust segment the 
parasite clearance values are calculated. Here, for wider comparison with the 
results from different studies from regions in artemisinin resistant areas as well 
as the study by Borrmann, S. et al. (2011) which used different methods, PCE 
and PCT values were shown. 
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As stated before, the PCT did indeed show a significant correlation with the 
initial parasitaemia, but not with the age of the patient. The PCE values 
however, specifically the clearance rate constant and the slope half life showed 
no significant correlation with these variables, suggesting them to be indeed 
more independent values for discussing drug sensitivity. 
The mean slope half life of 2.37 hours indicated no overall reduced 
susceptibility compared to other studies where AS-monotherapy was given at 
the same dose– mean of half life in Pursat (artemisinin resistant area)  
5.85 hours, in Wang Pha (artemisinin responsive area) 2.16 hours 
(Amaratunga, C. et al. 2012), mean half life in western Thailand 3.7 hours 
(Phyo, A. P. et al. 2012)– or with even higher doses (4 mg / kg body weight)– in 
Mali mean half life 1.9 hours (Lopera-Mesa, T. M. et al. 2013). PC90 in the 
artemisinin resistant parasites in Pailin (Dondorp, A. M. et al. 2009) was as high 
as 23 hours, in Wang Pha on the other hand 12 hours.   
In Coastal Kenya an estimated PC90 of 11.18 hours, therefore, also does not 
indicate slowed parasite clearance. The median time of the lag phase was 11.93 
hours which confirms above mentioned drastic rise in PRR between hour 6 and 
12. Fig. 10 visualizes this lag phase by the first linear part of the clearance 
curve (green dots) between hour 0 and 6 before parasite biomass reduces.
  
As one last clinical aspect, fever clearance happened within about 24 hours, 
which is slightly faster than in the previous study in Kilifi (27 – 30 hours). 
Borrmann, S. et al. (2011) already suggested that the drop reported in clinical 
response might not be due to less sensitivity to the artemisinins, but due to a 
change in transmission (O´Meara, W. P. et al. 2008). Less transmission results 
in lower immunity of the children, leading to higher parasitaemia at admission 
and in conclusion to prolonged clinical clearance times. The initial parasitaemia 
in this study was raised compared to initial parasitaemia from the last study in 
the same study area, hinting towards a further decline in immunity against  
P. falciparum infections. Parasite clearance and reduction ratios though showed 
high susceptibility. Describing in vivo observations there are variables within the 
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patient that might have an impact on clinical outcomes (Amaratunga, C. et al. 
2012). Consequently, changes in values as PCT and PPR cannot singularly be 
assumed to be a result of changes in drug response. Nevertheless, the larger 
impact comes from the genetics of the parasite (Anderson, T. J. C. et al. 2010), 
still making the description of these parameters a useful tool to monitor drug 
efficacy in vivo. The PCE provides a robust tool to uniform in vivo surveillance, 
which cannot be replaced by ex vivo and in vitro tests but should complement 
each other. 
Altogether high susceptibility to artemisinins in vivo in the coast of Kenya can 
still be assumed. Looking at individual patients though, there was one patient in 
particular to point out: This patient still had parasitaemia on the fourth day after 
initiation of treatment Pharmacokinetic analysis revealed a lower level of drug 
exposure in the patient’s blood (personal communication with Prof. Dr. S. 
Borrmann). This could have been the main reason for not responding 
adequately to the treatment and, thus, not meeting the WHO criteria for drug 
resistance (refer to 3). 
Recurrent parasitaemia can occur due to recrudescence of the same parasite 
or reinfection with a different strain. To distinguish between these two cases, 
PCR-based techniques and genotyping of baseline and recurrence samples are 
undertaken. For instance, high polymorphism has been shown for msp1, msp2 
and glurp genes (Babiker, H. A. et al. 1997; Felger, I. et al. 1999; Snounou, G. 
et al. 1999; Magesa, S. M. et al. 2001; Aubouy, A. et al. 2003) which, therefore, 
have been proposed as means by which one could distinguish between 
recrudescence and newly acquired infection (Kain, K. C. et al. 1996).  
Even with optimal experimental conditions there are sources for mistakes 
though. First, the allele diversity of genes in a parasite population is high, but 
not indefinite. 
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Second, in patients with multiplicity of infection, the PCR-bias18 might lead to 
non-detection of a recrudescence. The possibility of being reinfected with a 
strain possessing an identical genotype has been reported as low, but not 
impossible (Snounou, G. and Beck, H. P. 1998)– thus, imposing a bias in the 
conclusions drawn. 
Here a total of 56 patients presented with recurrent parasitaemia during the 
follow-up. Out of these eight patients (5 %) had PCR confirmed recrudescence, 
five (3 %) within 28 days. The null-hypothesis stated for the CATMAP study was 
a reinfection adjusted failure rate of ≤ 5 % within 28 days after artesunate 
monotherapy. With 3 % recrudescences within 28 days the null hypothesis 
cannot be proven false, but undermines importance of further surveillance. 
Pharmacokinetic tests carried out in the CATMAP study are unpublished to this 
date but will reveal further information on whether sufficient drug levels were 
reached in all these patients with recrudescent parasitaemia. 
6.2 Drug susceptibility testing ex vivo 
In support of monitoring in vivo parameters, drug sensitivity testing is also 
carried out ex vivo or in vitro. Ex vivo tests are performed on parasites which 
were freshly obtained from the patient. Any preservation in the laboratory might 
lead to an alteration in the genome expression of the parasite, as shown for 
genes related to virulence (Peters, J. M. et al. 2007; Zhang, Q. et al. 2011; 
Fowler, E. V. et al. 2006) and possibly also to alteration in drug responses or to 
selection of certain parasites (Brockelman, C. R. et al. 1981; Le Bras, J. et al. 
1983, Chaorattanakawee, S. et al. 2015). 
                                                 
18
 Alleles might be different in length. The time that the enzymes need to amplify the shorter 
allele is consequently reduced compared to a longer allele. While the reaction is running, 
there is more time to amplify the short allele and that one will overrun the longer one in 
quantity. 
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Here, to determine ex vivo drug susceptibility the established HRP2 ELISA was 
chosen. It determines growth via measurement of HRP2, a stable protein that is 
produced throughout all stages in the life cycle of P. falciparum, making it a 
reliable marker for multiplication. The culture conditions were controlled and all 
the samples were tested ex vivo. That means only ring-stage parasites were 
used without prior culturing or manipulation by sorbitol treatment for 
synchronization. The increase of HRP2 was determined per single column 
between concentration in the well with the highest drug concentration  
(full inhibition, in this case wells in row H) and the control, which was calculated 
automatically as the geometric mean in the well without drug and the well with 
the lowest drug concentration (full growth, in this case row A and B). Therefore, 
each parasite strain was functioning as its own control. Parasite growth was 
given out in ranges. All the drugs were run in duplicates for verification of a 
measured inhibition (intra-sample correlation as a measure for reproducibility). 
Results were checked for adequate parasite growth on each culture plate and 
excluded if not fitting the needed criteria. 
Considering limitations of the assay, it is first of all possible that a patient can be 
infected with more than one parasite strain. Without genotyping one cannot 
exclude that a patient had multiplicities of infection at the time the sample was 
taken. An example of the effect on the performed assay would be a sample with 
one isolate with reduced and a second isolate with high drug susceptibility. If 
drug resistance is accompanied by a loss of fitness, it is possible that the 
resistant strain does not grow under the culture conditions as effortlessly as the 
sensitive one. If this is the case, the inhibitory assay would mainly show the 
IC50 of the sensitive strain and the resistant one could possibly not be detected. 
Consequently, the conclusion would be a good susceptibility to the drug leading 
to wrong implications in treatment policies.  
Another limitation is the stage-specific action of antimalarial drugs. All drugs 
used here are acting against the asexual blood-stages of Plasmodium. There 
are differences in the sensitivity of the parasite to the drug applied in the course 
of its life cycle (Geary, T. G. et al. 1989; Wilson, D. W. et al. 2013) and, 
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therefore, the timing of the onset of drug exposure can lead to alterations in the 
outcome of the assay. The samples were collected and stored cool until 
transport to the laboratory. Nevertheless, the time until exposure to the drug 
could have varied. A sample that was processed quicker and where the set-up 
of the drug exposure plate happened during the early ring-stage might, thus, 
possibly show different drug responses than one of which processing took 
longer and was set up in the late ring stage. 
Regarding the performance of the assay an important limitation was the 
absence of a reference. In the set-up and the performances of the sensitivity 
tests there might be inter-individual variances. Additionally, the preparation and 
dilution of the drugs could include pipetting errors– leading to a slightly 
divergent drug concentration than proposed does exist. A culture adapted 
reference strain (for example 3D7 or W2) which is known to be sensitive to all 
monitored drugs should be tested in each run to standardize the drugs and 
function as a reference for sensitivity. That way results will be easier and more 
reliable to interpret rather than just determining the absolute value 
(Rutsivisuttinunt, W. et al. 2012). 
Despite these general limitations a high quality of assays could be achieved 
here. A median intra-sample correlation between the duplicates of the tested 
drugs of 0.94 (range 0.91 – 0.98) indicated high reproducibility of the results. 
The scatter plot of the two artemisinins DHA and AS (Fig. 18) and the 
correlation matrix (Tab. 5) show how well the results for the two artemisinin 
compounds correlate (p < 0.0001). In a well performed assay, a parasite that is 
less susceptive against AS should show a higher tolerance to exposure to DHA 
just as it was seen here. The coefficient of determination of r2 = 0.58 even rose 
up to 0.61 after excluding the two drug solutions with suspicious results. 58 % 
(61 %) of the differences in the response to DHA can, therefore, be related to 
differences in the response to AS. This result is comparable to a report by 
Pascual, A. et al. (with r2 = 0.68) and similar to correlations found by Borrmann, 
S. et al. (2013). All together this supports the overall quality of the ex vivo 
results displayed here. 
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Specific potential confounders in the analysis concern the use of seven different 
working solutions. Due to known decreasing efficacy of some drugs over time 
and the fluctuation in enrolment of patients it was not possible to prepare one 
dilution of each drug and use it for all samples. Differences in values 
determined can be due to multiple reasons such as unequal distribution of 
sensitive and less sensitive strains between drug solutions, time of drug 
storage, inter-individual differences in sample processing etc. The artemisinins 
specifically showed a correlation between the IC50 values with the time of drug 
storage. When marking the plot of IC50 values for each drug solution against 
time (Fig. 45 + Fig. 46) in different colours it became obvious that most of the 
higher IC50 values were obtained from one drug solution that was stored over a 
longer period of time (up to 7.5 times longer, 141 % – 750 % of the average 
storage time), making it very possible that the age of the solution lead to a 
decrease in the efficacy of the drug. Statistically this correlation between IC50 
value obtained and the time of drug storage was highly significant (p < 0.0001). 
The ratio between IC50 values for DHA and AS (Fig. 47) indicated similar 
degradation of the two drugs over time.  
Accordingly it is correct to question the reproducibility of the results obtained 
when using freshly prepared drug solutions. This assay was set up from ex vivo 
samples, therefore, the only way to test these isolates again is by culturing and 
repeating the drug sensitivity testing in vitro. This, on the other hand, would be 
accompanied by culture adaptation and a restriction in comparison with the 
other values. Additionally, the display of results from each drug solution (refer to 
5.2.1) did show a deviation in the distribution of values for AS and DHA in the 
seventh drug solution (Fig. 33 and Fig. 34). This is not in accordance with the 
high correlation between the IC50´s for artemisinins in general and gave rise to 
analyse also drug solution VII further in order to include all possible 
confounders. In this case the ratio between the measured IC50 for AS and DHA 
(Fig. 47) confirmed the deviation between AS and DHA for solution VII (almost 
all values far above the upper level of the 95 % CI of the median). Due to the 
wide distribution of ratios it can be assumed that the cause of this was not in the 
drug solution itself but rather in the set-up of the individual assays. 
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An analysis excluding these suspicious results (refer to 5.2.3) however did not 
reveal a significant influence of these confounders on the overall results. The 
median IC50 of DHA did change from 4.52 nM (geometric mean 4.84 nM,  
95 % CI 4.10 – 5.70 nM) to 4.17 nM (geometric mean 4.04 nM,  
95 % CI 3.41 – 4.71 nM) (p = 0.23) and for AS from 6.59 nM (geometric mean 
5.82 nM, 95 % CI 4.77 – 7.12 nM) to 6.26 nM (geometric mean 5.89 nM,  
95 % CI 5.06 – 6.86 nM) (p = 0.72) when excluding both drug solutions. When 
only excluding the sixth solution with a definite reason for degradation, AS 
differed slightly significant (p = 0.04) and DHA showed the trend to significance 
(p = 0.08). All together this does imply a trend of higher IC50 values over time of 
drug storage and the high importance of controlling for this confounder. 
An overall slightly higher value for AS could possibly be explained by 
hydrolyzation of AS into DHA, the active metabolite, and succinic acid in 
aqueous solutions (Rutvisuttinunt, W. et al. 2012), whereas DHA already is an 
active metabolite.  
When testing isolates from patients with recurrent parasitaemia, drug selection 
did not lead to elevated IC50 values (Fig. 49). 
In comparison with previous studies in the same study population (Borrmann, S. 
et al. 2011 and 2013), the IC50 for DHA now is statistically significantly higher  
(p < 0.001) but remains on a low level. Another study by Borrmann, S. et al. 
(2013) showed a median IC50 of 2 nM (range 0.5 – 4 nM) for DHA. In these 
studies the 3H-hypoxanthine uptake assay (Desjardins, R. E. et al. 1979) was 
used to test drug susceptibility. Thus, it can be argued, that the difference is 
caused by inter-test variability. The HRP2 ELISA though has been shown to 
produce similar results when compared directly to other assays, including the 
isotopic method (Noedl, H. 2002a).  
New developments in the research field of artemisinin resistance also have to 
be taken into account. Though, considering recent reports as Witkowski, B.  
et al. (2013a), the results obtained here are not qualified to detect artemisinin 
resistance, they do show the various phenotypes of artemisinin drug responses 
in P. falciparum in Coastal Kenya. Fig. 17 displays the variety in artemisinin 
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susceptibility in all isolates. Different phenotypes like these have been 
connected to SNPs by Borrmann et al. 2013, including SNPs on chromosome 
13. This is of particular interest since chromosome 13 has been discussed 
before in the context of artemisinin susceptibility (Cheeseman, I. H. et al. 2012) 
and remains a candidate of high attentiveness (Ariey, F. et al. 2014; Mbengue, 
A. et al. 2015, Straimer, J. et al. 2015, Mita, T. et al. 2016). Since artemisinin 
susceptibility phenotypes have been correlated in Kenya with chromosome 13 
despite no reports of artemisinin resistance in this area it is crucial to carry out 
further drug surveillance and to investigate the importance of already existing 
molecular markers and possibly even identify others. Borrmann, S. et al. (2013) 
argued, that the molecular markers might not show signatures of recent positive 
selection since by that time artemisinins were only introduced 2 – 3 years 
before the sampling started. The development of this finding has to be followed 
over time of artemisinin usage and connected with clinical treatment responses. 
Equally important is the RSA testing in the area to investigate a correlation with 
parasite clearance in this area and identify its importance in further surveillance 
in Kenya. 
Apart from artemisinin susceptibility it is of interest, since treatment guidelines 
nowadays abandon the use of monotherapies in P. falciparum malaria, to take a 
closer look at the drug susceptibility to the ACT partner drugs. The combination 
of AL is the first line-treatment for malaria in Kenya, DHA-PPQ the second line-
treatment (Ministry of Public Health and Sanitation, National Guidelines for the 
Diagnosis, Treatment and Prevention of Malaria in Kenya, 2010). Median IC50 
values for LUM were 13.71 nM (geometric mean 12.10 nM, 95 % CI 10.31 – 
14.20 nM) and for PPQ 7.88 nM (geometric mean 8.03 nM, 95 % CI 6.91 – 9.34 
nM). Both did not show any indication for a decrease in efficacy ex vivo since 
the last studies (Borrmann, S. et al. 2011 and 2013– where LUM IC 50 median 
was 42.04 nM and 69.67 nM (2011) as well as 17 nM (2013), PPQ 27.83 nM 
and 19.67 nM (2011) as well as 49 nM (2013)). Both drugs can, consequently, 
as far as ex vivo data is concerned, be considered a safe choice as partner in 
artemisinin combination therapy. 
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A correlation matrix was calculated in order to check for hints of cross-
resistances between drugs. The observed patterns were consistent with 
previously reported findings (Wrongsrichanalai, C. et al. 2002; Sidhu, A. B. et al. 
2006; Borrmann, S. et al. 2013).  
The artemisinins did show significant correlations with LUM, PPQ and MFQ  
(p < 0.0001). For PPQ and LUM, the coefficients of determinations were small, 
ranging from r2 = 0.01 to 0.03. In vitro responses between PPQ and artemisinin 
drugs have been reported indifferent or antagonistic (Davis, T. M. E. et al. 2006; 
Fivelman, Q. L. et al. 2007), but proven safe and efficient for the treatment of 
malaria in Africa (Bassat, Q. et al. 2009; Nambozi, M. et al. 2011; Adam, I. et al. 
2010), South America (Grande, T. et al. 2007) and Asia (Valecha, N. et al. 
2010). Looking at this analysis in more detail (see Appendix 3), PPQ actually 
did show higher r2 (up to 0.5) with DHA. Since this is an effect produced ex vivo, 
with very few isolates as well, and clinically the drug combination has been 
proven safe and efficient the relevance for this effect is unclear. Additionally, one 
of these solutions was the solution shown to be influenced by time of drug 
storage. The result should, therefore, be verified.  
Also LUM did show such a high coefficient of determination with the 
artemisinins (up to 0.69, refer to Appendix 3) in single drug solutions, making 
PPQ not inferior to LUM.  
One highly interesting finding related to the corrected analysis was the 
correlation between the artemisinins and MFQ. Before these drugs did correlate 
(rho = 0.49 and 0.44 for MFQ and DHA and AS, respectively) but with fairly low 
coefficients of determination (r2 = 0.04 and 0.10 for MFQ and DHA and AS, 
respectively). In the corrected analysis the correlation became more obvious by 
rho = 0.63 for each drug. Coefficients of determination rose up to r2 = 0.41 and 
0.36 for MFQ and DHA and AS, respectively. This correlation was also reported 
by Borrmann, S. et al. (2013). Considering the fact that earlier reports 
investigated in vitro drug responses in association with pfmdr1 gene 
amplification (Sidhu, A. B. et al. 2006) and found that not only MFQ drug 
susceptibility was correlated inversely with pfmdr1 copy numbers but also other 
drug responses– including the drug response to artemisinin–  
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this finding is alarming. Price, R. N. et al. (2004) had before presented pfmdr1 
amplification as the cause for MFQ resistance in vitro and in vivo. This was also 
correlated with decreased artemisinin susceptibility. These findings all indicate 
that the found in vitro and ex vivo correlation of MFQ and artemisinins could be 
of clinical importance (Noedl, H et al. 2001).  
Though pfmdr1 has an importance in South East Asia, it used to be rare in the 
African region. But lately a rise in pfmdr1 copy numbers has been reported after 
the introduction of ACTs in Kenya (Gadalla, N. B. et al. 2012; Duah, N. et al. 
2013; Ngalah, B. S. et al. 2015) underlining how rapidly and suddenly changes 
in the genome of P. falciparum occur. This, together with the findings of SNPs 
on chromosome 13 by Borrmann et al. (2013) is significant despite– or maybe 
especially because of– the absence of reports of artemisinin resistance in 
Kenya so far since molecular markers for the track of resistance are the most 
useful when established before the onset of resistance. Only then it can be 
detected as fast as possible and its spread actually be prevented. 
Looking at possible cross-resistances between the partner drugs LUM and PPQ 
and other drugs, especially CQ with worldwide resistance, neither PPQ nor 
LUM showed alarming results. Former reports of cross-resistance between CQ 
and PPQ from China (Fan, B. et al. 1998; Yang, H. et al. 1999) could not be 
reproduced in African isolates from Cameroon (Basco, L. K. and Ringwald, P. 
2003). It has been proposed by Mwai, L. et al. (2009) that sensitivity to CQ has 
increased again since its withdrawal in Kenya, proposing a cut-off point for CQ-
resistance at 25 nM. Here an overall median inhibitory concentration of  
15.63 nM, geometric mean 21.15 nM can be reported. Inhibitory tests from  
2005 – 2008 showed a median of 36.8 nM and mean 33.64 nM towards CQ. 
This supports the findings by Mwai, L. et al (2009). In accordance with the 
results from Cameroon, also in this analysis here does PPQ not show 
decreased sensitivity in isolates resistant to CQ in Kenya. For example, highly 
CQ-resistant strains IC50 values of 124.29 nM, 186.49 nM, 421.74 nM, 422.05 
nM did show high sensitivity to PPQ with IC50s of 12.04 nM, 9.14 nM, 11.21 nM 
and 11.41 nM, respectively.  
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Interestingly, LUM even showed a negative correlation with CQ– indicating that 
isolates resistant to CQ might be even more susceptible to LUM. MFQ was 
included in the drug testing due to its continued role in treatment and prevention 
of malaria. Median and mean values of these two drugs were very similar here 
(median LUM 13.71 nM, mean 12.10 nM; median MFQ 12.59 nM, mean  
11.76 nM). MFQ and LUM are both aryl-amino-alcohols and share the same 
basic characteristic– a hydroxyl group near the ring in their structure that has 
been hypothesized to be the key structure in the antimalarial activity of synthetic 
amino-alcohols (Chien, P. L. and Cheng, C. C 1976; Karle, J. M. and Karle, I. L 
1991; Basco, L. K. and Le Bras, J. 1993). The similar structure might explain 
the highly positive correlation (rho = 0.62, p < 0.0001) and the similar IC50 
values. 
6.3 Clinical implications and the need for further drug surveillance 
In 2005 the WHO published an implementation guide for changing malaria 
treatment to artemisinin-based combinations (Rational Pharmaceutical 
Management Plus 2005, Center for Pharmaceutical Management 2005). To 
prevent or delay the emergence of resistance against artemisinin derivatives 
they have been combined with partner drugs with different mechanisms of 
action and a longer half-life.  
Regarding clinical aspects, malaria treatment needs to be prompt and effective. 
One practical aspect regarding the complexity of this is access to treatment. 
Since AL was adapted as first-line treatment of uncomplicated  
Plasmodium falciparum malaria in Kenya there have been reports of stock-outs 
and inaccessibility (Sudoi, R. K. et al. 2012). This is often leads to the use of 
monotherapies in malaria, which should be avoided in order to prevent drug-
resistance. Another study in two districts in Kenya showed, from a perspective 
of wanting to prevent drug resistance, disastrous findings. Just about 60 % of 
the patients were adherent to the AL. Besides knowledge of the dosing regimen 
the amount of tablets was criticized (Lawford, H. et al. 2011). AL has to be taken 
twice a day for 3 days in a row under a strict dosing-regimen  
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(at hours 0, 8, 24, 36, 48 and 60). Depending on the age and weight of the 
patient these doses can consist of a total of 6 – 24 tablets (Ministry of Public 
Health and Sanitation, National Guidelines for the Diagnosis, Treatment and 
Prevention of Malaria, 2010). This amount of tablets and the strict regimen for 
dosing can easily lead to non-adherence and in the long run imposes a threat 
on drug-susceptibility in malaria parasites. The rationale for combining two 
drugs with different modes of actions and accordingly different mechanisms of 
drug resistance was explained in detail by Nosten and White (Nosten, F. and 
White, N. J. 2007). In combination therapy the artemisinin-derivative is 
eliminated quickly from the patient, always being protected by the partner drug 
against possible resistant parasites. But when the artemisinin derivative is not 
present anymore, the partner drug with a longer half-life is slowly reduced in the 
concentration in the blood of the patient. First this might work as prevention 
against reinfection, but when the drug concentration falls below a certain 
threshold there is a time-span in which the drug is concentrated too low to kill 
parasites due to a new infection. This would lead to parasites being exposed to 
low concentrations of the drugan a raise in possibility of creating resistant 
parasites. That is a disadvantage of drugs with longer elimination half-time. 
Therefore, not only drug susceptibility to the fast-acting drug artemisinin need to 
be under surveillance, but also the partner drugs. 
The main partner drugs of ACT-regimens used in Kenya, LUM and PPQ, both 
showed high ex vivo efficacy. Until new antimalarials are discovered, working 
with what we have at the most efficient level is crucial, which includes 
avoidance of monotherapies. Since no inferiority of DHA-PPQ to AL was shown 
in other studies and data from 2005 - 2008 did even show better clearance data 
after treatment with DHA-PPQ, the question arises if DHA-PPQ should possibly 
gain more clinical importance in Kenya (so far it is only second-line treatment). 
A Cochrane review from 2009 comparing the ACTs stated the overall well 
performance of DHA-PPQ when looking at (PCR adjusted) cure rates, serious 
adverse events, gametocyte-development, anaemia and vomiting (Sinclair, D. et 
al. 2009). The treatment with DHA-PPQ even showed a significantly lower rate 
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of new infections over the 42-day follow up period, which demonstrates the 
good post-treatment prophylactic effect of PPQ due to its long elimination half 
time (Bassat, Q. et al. 2009). Several clinical studies have reported non-
inferiority of DHA-PPQ compared to AL in multiple African countries such as 
Zambia (Nambozi, M. et al. 2011), Uganda (Yeka, A. et al. 2008) in a 
multicentre-trial carried out in Cameroon, Côte d´Ivoire and Senegal (Yavo, W. 
et al. 2011) and in Kenya (Bassat, Q. et al. 2009). 
This study has presented data which overall did not confirm a decreased in vivo 
responsiveness towards artemisinins in the area as reported before. Ex vivo 
drug responses identified different artemisinin susceptibility phenotypes and 
indicated cross-resistances with so far mainly unclear clinical importance. 
Especially MFQ could possibly impact artemisinin susceptibility in high 
transmission areas (Noedl, H. et al. 2001), and the shown correlation in this 
analysis together with previous works underlines the necessity for surveillance 
of drug usage and susceptibility. Recent studies showed much progress 
regarding drug susceptibility surveillance via the RSA (Witkowski, B. et al. 
2013a and b). This assay also needs to be implemented for surveillance in 
Africa. Molecular markers for resistance like the K13-propeller polymorphism 
and pfmdr1 have to be under observation and / or other markers for the African 
region have to be established. 
Apart from these treatment considerations, the main and most important 
conclusion drawn from this work though has to be the need for further 
continuous drug surveillance. Both aspects, in vivo as well as ex vivo / in vitro 
susceptibility have to be monitored to detect any changes in parasite drug 
susceptibility in appropriate time. At the beginning of this work it was stated that 
the first onset of upcoming resistance is often overlooked by clinicians since 
patients first appear to improve clinically. Fever clearance remains quick and 
patients are considered to be cured. In the case of detection of recurrent 
parasitaemia within 28 days after a malaria treatment though, clinicians have to 
be alarmed. Also during the initial treatment parameters such as parasite 
reduction ratios can easily be calculated in order to check whether parasites 
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clear the patients´ blood as expected or if treatment response is inadequate 
(e.g. no adequate parasite reduction after 12 hours, since PRR here increased 
highly per hour between hour 6 and 12). Besides the attention of each clinician 
treating malaria patients, there is a high need for sentinel sites across Africa in 
order to monitor drug susceptibility continuously. The major public health 
importance of malaria explained in the beginning of this work in addition to the 
history of previous emergence of antimalarial resistance justifies and requires 
continuous supervision of antimalarial treatment. The responsibility lies with 
national as well as international facilities. Sentinel sites are usually able to 
obtain data of higher quality and in more detail, but each health facility should 
feel responsible to monitor drug susceptibility, inform patients on the importance 
of therapy adherence and report suspicious events. Drug efficiency has to be 
transparent, for example through an open database. In addition to selected 
sentinel sites at areas of high transmission and with many malaria cases, 
studies like CATMAP with preferably a standard protocol at different study sites 
can function as additional support to the continuous drug surveillance. They can 
however not replace it since changes might be detected too late and resistance 
spreads fast once established. 
All together it can be said that artemisinins for now remain highly effective 
against P. falciparum malaria in Coastal Kenya. In vivo data suggested fast 
overall parasite clearance after treatment with artesunate. Ex vivo drug 
susceptibility tests identified different phenotypes but need to be investigated 
further, e.g. correlation with molecular markers and RSA testing. A high need for 
continuous drug surveillance in Kenya as well as the whole African region is 
given due to the enormous public health importance of malaria, the 
spontaneous occurrence of drug resistance and its fast spread. 
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7. Summary 
7.1 English 
Background: Malaria remains one of the major causes of morbidity and 
mortality worldwide. Artemisinin-based combination therapies are used as first-
line treatment in all endemic countries for uncomplicated P. falciparum malaria. 
artemether-lumefantrine was introduced as first-line treatment in Kenya in 2006. 
Since the first report of artemisinin-resistant P. falciparum malaria in 2009 on 
the Thai-Cambodian border, concerns about declining responsiveness to 
artemisinins have also been expressed in Kenya, stressing the need for 
continued drug-surveillance studies. 
Methods: In a single-armed trial children between the ages of 6 months and  
10 years with microscopically detected P. falciparum malaria were treated with a  
7-day artesunate monotherapy regimen (2 mg / kg per body weight per day as a 
single dose) and followed up for 42 days. Data on parasite clearance 
parameters was used in order to either substantiate or refute the previously 
reported decline in artemisinin responses. Additionally, susceptibility to 
lumefantrine and piperaquine, the two most commonly prescribed artemisinin-
based combination therapy partner drugs in Kenya, was tested ex vivo via 
Histidine-rich protein 2 Enzyme-linked-immunosorbent-assay. To distinguish 
between reinfection and recrudescence, Merozoite-surface-protein 2 -
genotyping was carried out. 
Results: 175 patients were recruited between April and December 2011. Mean 
overall parasite clearance times were 30.5 hours and median slope half life was 
2.4 hours, with a median clearance rate constant of 0.29 / hour. The highest 
reduction in parasites took place between hour 6 and hour 12 after initiation of 
treatment (parasite reduction ratio increased from 0.03 / hour to 0.15 / hour).  
Ex vivo drug susceptibility showed geometric means of 3.8 nM and 4.2 nM for 
dihydroartemisinin and artesunate, respectively.  
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Geometric mean IC50 for lumefantrine and piperaquine were 12.1 nM and  
8.0 nM, respectively. An indication for cross-resistance between artemisinins 
and mefloquine was found (r2 = 0.41 and 0.38 p < 0.0001 for each value). Out of 
a total of 56 (33 %) total recurrent parasitaemia cases, 32 (19 %) happened 
within 28 days after initiation of treatment. Eight patients had PCR-confirmed 
recrudescence (5 %), 5 of those (3 %) within 28 days. Tested recurrence 
samples did almost exceptionally not differ significantly from baseline values 
regarding their IC50 (0.02 ≤ p ≥ 0.96). 
Conclusion: For now overall artemisinin susceptibility in Kenya remains high, 
clinically as well as when testing ex vivo. In order to prevent resistance and to 
respond adequately in the case of it, new drugs and combinations have to be 
studied. PPQ proved to be highly efficient ex vivo. This suggests a high 
importance as alternative to the first-line combination therapy in Kenya. All 
together it is inevitable to further continue close drug surveillance. High drug 
pressure is present due to the frequent use of artemether-lumefantrine in Kenya 
and mutations that could affect drug susceptibility arise spontaneously. By 
closely monitoring drug effectiveness, a decline in response of P. falciparum 
towards artemisinins can be detected and contained early. 
 
 
 
 
 
 
Maria Rebekka Marschallek    Prof. Dr. med. Steffen Borrmann 
  
  
100 
 
7.2 German 
Hintergrund: Malaria stellt weltweit noch immer eine wesentliche Ursache für 
Morbidität und Mortalität dar. Kombinationstherapien mit Artemisinin-Derivaten 
sind seit einigen Jahren in allen endemischen Gebieten als Goldstandard 
etabliert. Artemether-Lumefantrin bildet in Kenia seit 2006 den Grundstein der 
Therapie. Seit dem ersten Report über Artemisinin-resistente P. falciparum 
Malaria an der thailändisch-kambodschanischen Grenze im Jahr 2009 wird 
auch aus Kenia über abnehmende Sensibilität gegenüber Artemisinin berichtet. 
Daraus resultiert die Dringlichkeit weiterer Studien zur Medikamentensensitvität 
von P. falciparum in diesem Land. 
Methoden: In einer einarmigen Studie wurden im Kinder zwischen 6 Monaten 
und 10 Jahren mit mikroskopisch verifizierter P. falciparum Malaria mit einer  
7-tägigen Artesunat Monotherapie (2 mg / kg Körpergewicht) behandelt und 
über einen 42-tägigen Zeitraum beobachtet. Parasiten Eliminations-Parameter 
und ex vivo Medikamentensensitivität dienten als Indikatoren um eine zuvor 
publizierte abnehmende Wirksamkeit von Artemisinin in Kenia zu verifizieren 
oder zu widerlegen. Die ex vivo Medikamentensensitivität wurde anhand eines 
antikörperbasierten Nachweisverfahrens von Histidin-reichem-Protein 2 
bestimmt. Zusätzlich wurden die ex vivo Sensitivitäten von Lumefantrin und 
Piperaquin, den beiden am häufgsten genutzten Kombinationspartnern der 
Artemisinine, getestet. Um zwischen einer Rekrudeszenz und einer Reinfektion 
zu unterscheiden, wurde eine Genotypisierung anhand des Merozoiten-
Oberflächen-Proteins 2 durchgeführt. 
Resultate: 175 Patienten wurden zwischen April und Dezember 2011 rekrutiert. 
Die mittlere Parasiten Eliminations-Zeit betrug 30,5 Stunden, mediane 
Steigungs-Halbzeit 2,37 Stunden. Die höchste Parasitenreduktion fand 
zwischen 6 und 12 Stunden nach der ersten Medikamenteneinnahme statt 
(Anstieg der Rate von 0.03 / Stunde auf 0.15 / Stunde). Die ex vivo- 
Inhibitionskonzentration betrug im geometrischen Mittel 3,8 nM gegenüber 
Dihydroartemisinin und 4,2 nM gegenüber Artesunat. Gegenüber Lumefantrin 
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und Piperaquin wurden Werte von 12,1 nM und 8,0 nM bestimmt. Statistisch 
gab es durch Errechnung des Determinationskoeffizienten r2 Hinweise auf 
Kreuzresistenz zwischen den Artemisinen und Mefloquin (r2 = 0.41 und 0.38,  
p jeweils < 0.0001). Von insgesamt 56 (33 %) wiederkehrenden Parasitämie- 
Fällen traten 32 (19 %) innerhalb von 28 Tagen nach Beginn der Therapie mit 
Artesunat auf. 8 Patienten hatten PCR- bestätigte Rekrudeszenz (5 %), 5 davon 
(3 %) innerhalb von 28 Tagen nach Therapiebeginn. Die 
Inhibitionskonzentrationen bei wiederkehrender Parasitämie unterschieden sich 
nahezu ausschließlich nicht signifikant von denen vor Behandlungsbeginn  
(0.02 ≤ p ≥ 0.96). 
Schlussfolgerung: Die Artemisinin-Wirksamkeit gegenüber P. falciparum in 
Kenia erweist sich klinisch und auch ex vivo als noch immer hoch. Um 
Resistenzen zu verhindern und gegebenenfalls rasch und adäquat handeln zu 
können, sind Untersuchungen neuer Medikamente und Kombinationen 
unabdingbar. PPQ zeigt eine hohe Effektivität ex vivo und könnte daher eine 
Alterative zum Goldstandard in Kenia darstellen. Trotzdem ist es unerlässlich 
weiterhin kontinuierlich Medikamentenwirksamkeitsstudien durchzuführen. Die 
häufige Verwendung von Artemether-Lumefantrin bedingt einen hohen 
Selektionsdruck der Parasiten. Zudem treten Mutationen, welche die 
Medikamentensensitivität beeinflussen können, sehr spontan auf. Durch 
engmaschige Kontrollen der Medikamentenwirksamkeit lässt sich deren 
Abnahme früh detektieren und ihre weitere Ausbreitung eindämmen. 
 
 
 
Maria Rebekka Marschallek    Prof. Dr. med. Steffen Borrmann 
 
  
  
102 
 
8. References 
1. Abdulla, S.; Sagara, I., Borrmann, S.; Allesandro, U., González, 
R.; Hamel, M., Ogutu, B.; Mårtensson, A.; Lyimo, J.; Maiga, H.; Sasi, P.; 
Nahum, A.; Bassat, Q.; Juma, E., Otieno, L.; Björkman, A.; Beck, H. P.; 
Andriano, K.; Cousin, M., Lefèvre, G.; Ubben, D.; Prmji, Z. (2008): 
Efficacy and safety of artemether-lumefantrine dispersible tablets 
compared with crushed commercial tablets in African infants and children 
with uncomplicated malaria: a randomised, single-blind, multicentre-trial. 
In: Lancet 372 (9652), pp. 1819 – 1827. 
2. Adam, I.; Salah, M. T.; Eltahir, H. G.;Elhassan, A. H.; Elmardi, K. 
A., Malik, E. M. (2010): Dihydroartemisinin-piperaquine versus 
artemether-lumefantrine, in the treatment of uncomplicated Plasmodium 
falciparum malaria in central Sudan. In: Ann. Trop. Med. Parasitol. 104 
(4), pp. 319 – 326. 
3. Aly, A. S. I.; Vaughan, A. M; Kappe, S. H. I (2009): Malaria parasite 
Development in the Mosquito and Infection of the Mammalian Host. In: 
Microbiol. Mol. Biol. Rev. 63, pp. 195 – 221. 
4. Amaratunga, C.; Sreng, S.; Suon, S.; Phelps, E. S:, Stepniewska, 
K.; Lim, P.; Zhou, C.; Mao, S.; Anderson, J. M.; Lindegardh, N.; Jiang, H.; 
Song, J.; Su, X. Z.; White, N. J.; Dondorp, A. M.; Anderson, T. J.; Fay, M. 
P.; Mu, J.; Duong, S.; Fairhurst, R. M. (2012): Artemisinin-resistant 
Plasmodium falciparum in Pursat province, western Cambodia: a 
parasite clearance rate study. In: Lancet Infect. Dis. 12 (11), pp. 851 – 
858. 
5. Anderson, T. J. C.; Nair, S.; Nkhoma, S.; Williams, J. T.; Imwong, 
M.; Yi, P.; Socheat, D.; Das, D.; Chotivanich, K.; Day, N. P.; White, N. J.; 
Dondorp, A. M.  (2010): High heritability of malaria parasite clearance 
rate indicates a genetic basis for artemisinin resistance in western 
Cambodia. In: J. Infect. Dis. 201 (9), pp. 1326 – 1330. 
6. Ariey, F.; Witkowski, B.; Amaratunga, C.; Beghain, J.; Langlois, A.-
C.; Khim, N.; Kim, S.; Duru, V.; Bouchier, C.; Ma, L.; Lim, P.; Leang, R.; 
Duong, S.; Sreng, S.; Suon, S.; Chuor, C. M.; Bout, D.M.; Ménard, S.; 
Rogers, W. O.; Genton, B.; Fandeur, T.; Miotto, O.; Ringwald, P.; Le Bras, 
J.; Berry A.; Barale, J.-C.; Fairhurst, R. M.; Benoit-Vical, F.; Mercereau-
Puijalon, O., Ménard, D. (2014): A molecular marker of artemisinin-
resistant Plasmodium falciparum malaria. In: Nature, 505, pp. 50 – 55. 
7. Aubouy, A.; Migot-Nabias, F.; Deloron, P. (2003): Polymorphism in 
two merozoite surface proteins of Plasmodium falciparum isolates from 
Gabon. In: Malar. J. 2:12. 
  
103 
 
8. Babiker, H. A.; Lines, J.; Hill, W. G.; Walliker, D. (1997): Population 
structure of Plasmodium falciparum in villages with different malaria 
endemicity in east Africa. In: Am. J. Trop. Med. Hyg. 56 (2), pp. 141 – 
147. 
9. Basco L. K.; Le Bras J. (1993): In vitro activity of artemisinin 
derivatives against African isolates and clones of Plasmodium 
falciparum. In: Am. J. Trop. Med. Hyg. 49 (3), pp. 301 – 307. 
10. Basco, L. K.; Bickii, J.; Ringwald, P. (1998): In vitro activity of 
lumefantrine (benflumetol) against clinical isolates of Plasmodium 
falciparum in Yaoundé, Cameroon. In: Antimicrob. Agents Chemother. 42 
(9), pp. 2347 – 2351. 
11. Basco, L. K.; Ringwald, P. (2003): In vitro activities of piperaquine 
and other 4-aminoquinolines against clinical isolates of Plasmodium 
falciparum in Cameroon. In: Antimicrob. Agents Chemother. 47 (4), pp. 
1391 –  1394. 
12. Bassat, Q.; Mulenga, M.; Tinto, H.; Piola, P.; Borrmann, S.; 
Menéndez, C.; Nambozi, M.; Nabasuma, C.; Sasi, P.; Bacchieri, A.; 
Corsi, M.; Ubben, D.; Talisuna, A.; D’Allesandro, U. (2009): 
Dihydroartemisinin-Piperaquine and Artemether-Lumefantrine for 
Treating Uncomplicated Malaria in African Children: A Randomised, Non-
Inferiority Trial. In: PLoS ONE 4 (11), e7871. 
13. Batty, K. T.; Thu L. T.; Davis T. M.; Ilett, K. F.; Mai, T. X.; Hung, N. 
C.; Tien, N. P.; Powell, S. M., Thien, H. V.; Binh, T. Q.; Kim, N. V. (1998): 
A pharmacokinetic and pharmacodynamic study of intravenous vs oral 
artesunate in uncomplicated falciparum malaria. In: Br. J. Clin. 
Pharmacol.  45 (2), pp. 123 – 129. 
14. Bejon, P.; William, T. N.; Nyundo, C.; Hay, S. I.; Benz, D.; Gething, 
P. W.; Otiende, M.; Peshu, J.; Bashraeil, M.; Greenhouse, B.; Bousema, 
T.; Bauni, E.; Marsh, K:; Smith, D. L.; Borrmann, S. (2014): A micro-
epidemiological analysis of febrile malaria in Coastal Kenya showing 
hotspots within hotspots. In: eLife, 3, e02130. 
15. Billker, O.; Lindo, V.; Panico, M.; Etienne, A. E.; Paxton, T.; Dell, 
A.; Rogers, M.; Sinden, R. E.; Morris, H. R. (1998): Identification of 
xanthurenic acid as the putative inducer of malaria development in the 
mosquito. In: Nature 392 (6673), pp. 289 – 292. 
16. Billker, O.; Shaw, M. K.; Margos, G.; Sinden, R. E. (1997): The 
roles of temperature, pH and mosquito factors as triggers of male and 
female gametogenesis of Plasmodium berghei in vitro. In: Parasitology 
115 (Pt 1), pp. 1 – 7. 
  
104 
 
17. Borrmann, S.; Sasi P.; Mwai, L.; Bashraheil, M.; Abdallah, A.; 
Muriithi, S.; Frühauf, H.; Schaub, B.; Pfeil, J.; Peshu, J.; Hanpithakpong, 
W.; Rippert, A.; Juma, E.; Tsofa, B.; Mosobo, M.; Lowe, B.; Osier, F.; 
Fegan, G.; Lindegårdh, N.; Nzila, A.; Peshu, N.; Mackinnon, M.; Marsh, 
K. (2011): Declining Responsiveness of Plasmodium falciparum 
Infections to Artemisinin-Based Combination Treatments on the Kenyan 
Coast. In: PLoS ONE 6 (11), e26005. 
18. Borrmann, S.; Straimer, J.; Mwai, L.; Abdi, A.; Rippert, A.; 
Okombo, J.; Muriithi, S.; Sasi, P.; Kortok, M.M.; Lowe, B.; Campino, S.; 
Assefa, S.; Manske, M.; Maslen, G.; Peshu, N.; Kwiatkowski, D.P.; 
Marsh, K.; Nzila, A.; Clark, T.G. (2013): Genome-wide screen identifies 
new candidate genes associated with artemisinin susceptibility in 
Plasmodium falciparum in Kenya. In: Nature Sci. Rep. 3:3318. 
19. Boyd, M. F.; Kitchen S. F. (1939): The Demonstration of 
Sporozoites in Human Tissues. In: Am. J. Trop. Med. Hyg. 19, pp. 27 – 
31. 
20. Brockelman, C. R.; Monkolkeha, S.; Tanariya, P. (1981): Decrease 
in susceptibility of Plasmodium falciparum to mefloquine in continuous 
culture. In: Bull. World Health Organ. 59 (2), pp. 249 – 252. 
21. Chaorattanakawee, S.; Tyner, S. D.; Lon, C.; Yingyuen, K.; 
Ruttvisutinunt, W.; Sundrakes, S.; Sai-gnam, P.; Johnson, J. D.; Walsh, 
D. S.; Saunders, D. L.; Lanteri, C.A. (2013): Direct comparison of the 
histidine-rich protein-2 enzyme-linked immunosorbent assay (HRP-2 
ELISA) and malaria SYBR green I fluorescence (MSF) drug sensitivity 
tests in Plasmodium falciparum reference clones and fresh ex vivo field 
isolates from Cambodia. In: Malar. J. 12:239. 
22. Chaorattanakawee, S.; Lanteri, C. A.; Sundrakes, S.; Yingyuen,K.;  
Gosi, P.; Chanarat, N.; Wongarunkochakorn, S.; Buathong, N.; Chann, 
S.; Kuntawunginn, W.; Arsanok, M.; Lin, J. Z.; , Juliano, J. J.; Tyner, S.D.; 
Char, M.;  Lon, C.; Saunders, D. L. (2015): Attentuation of Plasmodium 
falciparum in vitro drug resistance phenotype following culture adaptation 
compared to fresh clinical isolates in Combodia. In: Malar. J. 14:486. 
23. Cheeseman, I. H.; Miller, B. A.; Nair, S.; Nkhome, S.; Tan, A.; Tan, 
J.C.; Saai, S. A.; Phyo, A. P.; Moo, C. L.; Lwin, K.M.; McGready, R.; 
Ashley, E.; Imwong, M.; Stepniewska, K.; Yi, P.; Dondorp, A. M.; 
Mayxay, M.; Newton, P. N.; White, N. J.; Nosten, F.; Ferdig, M. T.; 
Anderson, T. J. C. (2012): A major genome region underlying artemisinin 
resistance in malaria. In: Science 336 (6077), pp. 79 – 82. 
24. Chen L.; Qu F. Y.; Zhou Y. C. (1982): Field observations on the 
antimalarial piperaquine. In: Chin. Med. J. 95 (4), pp. 281 – 286. 
  
105 
 
25. Chien P. L.; Cheng C. C (1976): Difference in antimalarial activity 
between certain amino alcohol diastereomers. In: J. Med. Chem. 19 (1), 
pp. 170 – 172. 
26. Chou A. A.; Fitch C. D. (1992): Heme Polymerase Modulation by 
Chloroquine Treatment of a Rodent Malaria. In: Life Sci. 51, pp. 2073 – 
2078. 
27. Conway D.J.; Fanello C.; Lloyd J. M.; Al-Joubori, B. M.; Baloch, A. 
H.; Somanath, S. D.; Roper, C.; Oduola, A. M.; Mulder, B.; Povoa, M. M., 
Singh, B.; Thoma, A. W. (2000): Origin of Plasmodium falciparum malaria 
is traced by mitochondrial DNA. In: Mol. Biochem. Parasitol. (111), pp. 
163 – 171. 
28. Cowman, A. F.; Crabb, B. S (2006): Invasion of Red Blood Cells by 
Malaria Parasites. In: Cell 124 (4), pp. 755 – 766. 
29. Cox-Singh, J.; Davis, T. M. E.; Lee, K.-S.; Shamsul, S. S. G.; 
Matusop, A.; Ratnam, S.; Rahman, H. A.; Conway, D. J.; Singh, B. 
(2008): Plasmodium knowlesi malaria in humans is widely distributed and 
potentially life- threatening. In: Clin. Infect. Dis. 46 (2), pp. 165 – 171. 
30. Crabb, B. S.; Cooke, B. M.; Reeder, J. C.; Waller, R. F.; Caruana, 
S. R.; Davern, K. M.; Wickham, M.E.; Brown, G. V.; Coppel, R. L.; 
Cowman, A. F. (1997): Targeted gene disruption shows that knobs 
enable malaria-infected red cells to cytoadhere under physiological shear 
stress. In: Cell 89 (2), pp.287 – 296. 
31. Davis, T. M. E.; Hamzah, J.; Ilett, K. F.; Karunajeewa, H. A.; 
Reeder, J. C.; Batty, K. T.; Hackett, S; Barrett, P. H. R. (2006): In vitro 
interactions between piperaquine, dihydroartemisinin, and other 
conventional and novel antimalarial drugs. In: Antimicrob. Agents 
Chemother. 50 (8), pp. 2883 – 2885. 
32. Deitsch, K. W.; Wellems, T. E. (1996): Membrane modifications in 
erythrocytes parasitized by Plasmodium falciparum. In: Mol. Biochem. 
Parasitol. 76 (1-2), pp. 1 – 10. 
33. Desjardins, R. E.; Canfield, C. J.; Haynes, J. D.; Chulay, J. D. 
(1979): Quantitative assessment of antimalarial activity in vitro by a 
semiautomated microdilution technique. In: Antimicrob. Agents 
Chemother. 16 (6), pp. 710 – 718. 
  
  
106 
 
34. Dondorp, A. M.; Fanello, C. I.;  Hendriksen, I. C. E.; Gomes, E.; 
Seni, A.; Chhaganlal, K. D.; Bojang, K.; Olaosebikan, R.; Anunobi, N.; 
Maitland, K.;  Kivaya, E.; Agbenyega, T.; Nguah, S. B.; Evans, J.; 
Gesase, S.; Kahabuka, C.; Mtove, G.; Nadjm, B.; Deen, J.; Mwanga-
Amumpaire, J.; Nansumba J.; Karema, C.; Umulisa, N.; Uwimana, A.; 
Mokuolu, O. A.; Adedoyin, O. T.; Johnson, W. B. R.;  Tshefu, A. K.;  
Onyamboko, M. A.; Sakulthaew, T.; Ngum, W. P.; Silamut, K.; 
Stepniewska, K.; Woodrow, C. J.; Bethell, D.; Wills, B.; Oneko, M.; Peto, 
T. E.; von Seidlein, L.; Day, N. P. J.; White, N. J. for the AQUAMAT group 
(2010): Artesunate versus quinine in the treatment of severe falciparum 
malaria in African children (AQUAMAT): an open-label, randomised trial. 
In: Lancet, 376, pp.1647 – 1657. 
35. Dondorp, A.; Nosten, F.; Stepniewska, K.; Day, N.; White, N.; 
South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group 
(2005): Artesunate versus quinine for the treatment of severe falciarum 
malaria: randomised trial. In: Lancet 376 (9487), pp. 717 – 725. 
36. Dondorp, A. M.; Nosten, F.; Yi, P.; Das, D.; Phyo, A. P.; Tarning, J.; 
Lwin, K. M.; Ariey, F.; Hanpthakpong, W.; Lee, S. J.; Ringwald, P.; 
Silamut, K.; Imwong, M.; Choivanich, K.; Lim, P.; Herdman, T.; An, S. S.; 
Yeung, S.; Singhasivanon, P.; Day, N. P.; Lindegardh, N.; Socheat, D.; 
White, N. J. (2009): Artemisinin Resistance in Plasmodium falciparum 
Malaria. In: N. Engl. J. Med. 361 (5), pp. 455 – 467. 
37. Duah, N. O.; Matrevi, S. A.; de Souza, D. K.; Binnah, D. D.; 
Tamakloe, M. M.; Opoku, V. S.; Onwona, C. O.; Narh, C. A.; Quashie, N. 
B.; Abuaka, B.; Duplessis, C.; Kronmann, K. C.; Koram, K. A. (2013): 
Increased pfmdr1 gene copy number and the decline in pfcrt and pfmdr1 
resistance alleles in Ghanian Plasmodium falciparum isolates after the 
change of anti-malarial treatment policy. In: Malar. J. 12:377. 
38. Edgcomb, J. H.; Arnold, J; Yount, E. H. jr.; Alving, A. S.; 
Eichelberger, L.; Jeffery, G. M.; Eyles, D.; Young, M. D. (1950): 
Primaquine, SN13272, a new curative agent in vivax malaria, a 
preliminary report. In: J. Natl. Malar. Soc. 9 (4), pp. 285 – 292. 
39. Editorial (1992): Rediscovering wormwood: qinghaosu for malaria. 
In: Lancet 339 (8794), pp. 649 – 651. 
40. Escalante, A. A.; Ayala, F. J (1994): Phylogeny of the malarial 
genus Plasmodium, derived from rRNA gene sequences. In: Proc. Natl. 
Acad. Sci. 91, pp. 11373 – 11377. 
41. Ezzet, F.; Mull, R.; Karbwang, J. (1998): Population 
pharmacokinetics and therapeutic response of CGP 56697 (artemether + 
benflumetol) in malaria patients. In: Brit. J. Clin. Pharmacol. 46 (6), pp. 
553 – 561. 
  
107 
 
42. Ezzet, F.; van Vugt, M.; Nosten, F.; Looareesuwan, S.; White, N. J. 
(2000): Pharmacokinetics and pharmacodynamics of lumefantrine 
(benflumetol) in acute falciparum malaria. In: Antimicrob. Agents 
Chemother. 44 (3), pp. 697 – 704. 
43. Falade C.; Makanga, M.; Premji, Z.; Ortmann, C. E.; Stockmeyer, 
M.; de Palacios, P. I. (2005): Efficacy and safety of artemether-
lumefantrine (Coartem®) tablets (six-dose-regimen) in African infants and 
children with acute, uncomplicated malaria. In: Trans. R. Soc. Trop. Med. 
Hyg. 99, pp. 459 – 467. 
44. Fan, B.; Zhao, W.; Ma, X; Huang, Z.; Wen, Y.; Yang, J.; Yang, Z.  
(1998): In vitro sensitivity of Plasmodium falciparum to chloroquine, 
piperaquine, pyronaridine and artesunate in Yuxi prefecture of Yunnan 
province. In: Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za 
Zhi 16 (6), pp. 460 – 462. 
45. Felger, I.; Smith, T.; Edoh, D.; Kitua, A.; Alonso, P.; Tanner, M.; 
Beck, H. P. (1999): Multiple Plasmodium falciparum infections in 
Tanzanian infants. In: Trans. R. Soc. Trop. Med. Hyg. 93 Suppl 1, pp. 29 
– 34. 
46. Fidock D. A.; Nomura T.; Talley A. K.; Cooper, R. A.; Dzekunov, S. 
M.; Ferdig, M..; Ursos, L. M.; Sidhu, A. B.; Naudé, B.; Deitsch, K. W.; Su, 
X. Z.; Wootton, J. C., Roepe, P. D.; Wellems, T. E. (2000): Mutations in 
the P.falciparum Digestive Vacuole Transmembrane Protein PfCRT and 
Evidence for Their Role in Chloroquine Resistance. In: Mol. Cell 6 (4), 
pp. 861 – 871. 
47. Fivelman, Q. L.; Adagu, I. S.; Warhurst, D. C. (2007): Effects of 
piperaquine, chloroquine, and amodiaquine on drug uptake and of these 
in combination with dihydroartemisinin against drug-sensitive and -
resistant Plasmodium falciparum strains. In: Antimicrob. Agents 
Chemother. 51 (6), pp. 2265 – 2267. 
48. Flegg, J. A.; Guerin, P. J.; White, N. J.; Stepniewska, K. (2011): 
Standardizing the measurement of parasite clearance in falciparum 
malaria: the parasite clearance estimator. In: Malar. J. 10:339. 
49. Foley, M.; Tilley, L. (1998): Quinoline antimalarials: mechanisms of 
action and resistance and prospects for new agents // Quinoline 
antimalarials: mechanisms of action and resistance and prospects for 
new agents. In: Pharmacol. Ther. 79 (1), pp. 55 – 87. 
50. Fowler, E. V.; Chavchich, M.; Chen, N.; Peters, J. M.; Kyle, D. E.; 
Gatton, M. L.; Cheng, Q. (2006): Physical linkage to drug resistance 
genes results in conservation of var genes among West Pacific 
Plasmodium falciparum isolates. In: J. Infect. Dis. 194 (7), pp. 939 – 948. 
  
108 
 
51. Frederich, M.; Dogne, J.-M.; Angenot, L.; De Mol, P. (2002): New 
Trends in Anti- Malarial Agents. In: Curr. Med. Chem. 9 (15), pp. 1435 – 
1456. 
52. Gadalla, N. B.; Adam, I.; Elzaki, S. E.; Bashir, S.; Mukhtar, I.; 
Oquike, M.; Gadall, A.; Mansour, F.; Warhurst, D.; El-Sayed, B. B.; 
Sutherland, C. J. (2011): Increased pfmdr1 copy number and sequence 
polymorphisms in Plasmodium falciparum isolates from Sudanese 
malaria patients treated with artemether-lumefantrine. Antimicrob Agents 
Chemother 55, pp. 5408 – 5411. 
53. Galinski, M. R.; Barnwell, J. W (2009): Monkey malaria kills four 
humans. In: Trends Parasitol. 25 (5), pp. 200 – 204. 
54. Geary, T. G; Divo, A. A.; Jensen, J. B. (1989): Stage specific 
actions of antimalarial drugs on falciparum in culture. In: Am. J. Trop. 
Med. Hyg. 40 (3), pp. 240 – 244. 
55. Geary, T. G.; Jensen, J. B. (1983): Lack of cross- resistance to 4- 
aminoquinolines in chloroquine- resistant Plasmodium falciparum in vitro. 
In: J. Parasitol. 69 (1), pp. 97 – 105. 
56. Ginsburg, H. (2005): Should chloroquine be laid to rest? In: Acta 
Tropica 96 (1), pp. 16 – 23. 
57. Grande, T.; Bernasconi, A.; Erhart, A.; Gamboa, D.; Casapia, M.; 
Delgado, C.; Torres, K.; Fanello, C.; Llanos-Cuentas, A.; D’Alessandro, 
U. (2007): A randomised controlled trial to assess the efficacy of 
dihydroartemisinin-piperaquine for the treatment of uncomplicated 
falciparum malaria in Peru. In: PLoS ONE 2 (10), e1101. 
58. Grewal, R. S. (1981): Pharmacology of 8- aminoquinolines. In: 
Bull. World Health Organ. 59 (3), pp. 397 – 406. 
59. Hall, A. J.; Chappell, M. J.; Aston, J. A. D.; Ward, S. A. (2013): 
Pharmacokinetic modelling of the anti-malarial drug artesunate and ist 
active metabolite dihydroartemisinin. In: Comput. Meth. Prog. Bio. 112 
(1), pp. 1 – 15. 
60. Hien, T. T.; White, N. J. (1993): Qinghaosu. In: Lancet 341, pp. 603 
– 608. 
61. Howard, R. J.; Uni, S.; Aikawa, M.; Aley, S. B.; Leech, J. H.; Lew, 
A. M.; Wellems, T. E.; Rener, J.; Taylor, D. W. (1986): Secretion of a 
malarial histidine-rich protein (Pf HRP II) from Plasmodium falciparum-
infected erythrocytes. In: J. Cell Biol. 103 (4), pp. 1269 – 1277. 
  
109 
 
62. Hume, J. C. C.; Lyons, E. J.; Day, K. P (2003): Human migration, 
mosquitoes and the evolution of Plasmodium falciparum. In: Trends 
Parasitol. 19 (3), pp. 144 – 149. 
63. Hutagalung, R.; Paiphun, L.; Ashley, E. A.; McGready, R.; 
Brockman, A.; Thwai, K.L.; Singhasivanon, P.; Jelinek, T.; White, N. J.; 
Nosten, F. H. (2005): A randomized trial of artemether-lumefantrine 
versus mefloquine-artesunate for the treatment of uncomplicated multi-
drug resistant Plasmodium falciparum on the western border of Thailand. 
In: Malar. J. 4:46. 
64. Joiner, K. A.; Dubremetz, J. F. (1993): Toxoplasma gondii: a 
protozoan for the nineties. In: Infect Immun. 61 (4), pp. 1169 – 1172. 
65. Kain, K. C.; Craig, A. A.; Ohrt, C. (1996): Single-strand 
conformational polymorphism analysis differentiates Plasmodium 
falciparum treatment failures from re-infections. In: Mol. Biochem. 
Parasitol. 79 (2), pp. 167 – 175. 
66. Kamau, E.; Campino, S.; Amenga-Etego, L.; Drury, E.; Ishengoma, 
D.; Johnson, K.; Mumba, D.; Kekre, M.; Yavo, W.; Mead, D.; Bouyou-
Akotet, M.; Apinjoh, T.; Golassa, L.; Randrianarivelojosia, M.; Andagalu, 
B.; Maiga-Ascafare, O.; Amambbua-Ngwa, A.; Tindana, P.; Ghansa, A.; 
McInnis, B.; wiatkowski, D.; Djimde, A. A. (2015): K13-Propeller 
Polymorphisms in Plasmodium falciparum Parasites From Sub-Saharan 
Africa. In: J. Infect. Dis., 211 (8), pp.1352 – 1355. 
67. Karle, J. M.; Karle, I. L. (1991): Crystal structure and molecular 
structure of mefloquine methylsulfonate monohydrate: implications for a 
malaria receptor. In: Antimicrob. Agents Chemother. 35 (11), pp. 2238 – 
2245. 
68. Kaur, K.; Jain, M.; Reddy, R. P.; Jain, R. (2010): Quinolines and 
structurally related heterocycles as antimalarials. In: Eur. J. Med. Chem. 
45 (8), pp. 3245 – 3264. 
69. Knowles, R. M.; Das Gupta, B. (1932): A study of monkey–malaria 
and its experimental transmission to man. In: Ind. Med. Gaz. 67, pp. 301 
– 320. 
70. Krief, S.; Escalante, A.A.; Pacheco, M. A.; Mugish, L.; André, C.; 
Halbwax, M.; Fischer, A.; Krief, J. A.; Kasenene, J. M.; Crandfield, M.; 
Cornejo, O. E.; Chavatte, J.-M.; Lin, C.; Letourneur, F.; Grüner, A. C.; 
McCutchan, T. F.; Rénia, L.; Snounou, G. (2010): On the Diversity of 
Malaria Parasites in African Apes and the Origin of Plasmodium 
falciparum from Bonobos. In: PLoS Pathog. 6 (2), e1000765. 
  
110 
 
71. Kumar, N.; Zheng, H. (1990): Stage-specific gametocytocidal 
effect in vitro of the antimalarial drug qinghaosu on Plasmodium 
falciparum. In: Parasitol. Res.76 (3), pp. 214 – 218. 
72. Lan, C. X.; Lin, X.; Huang, Z. S.; Chen, Y. S.; Guo, R. N (1989): In 
vivo sensitivity of Plasmodium falciparum to piperaquine phosphate 
assayed in Linshui and Baisha counties, Hainan Province. In: Zhongguo 
Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 7 (3), pp. 163 – 
165. 
73. Lawford, H.; Zurovac, D.; O´Reilly, L.; Hoibak, S.; Cowley, A.; 
Munga, S.; Vulule, J.; Juma, E.; Snow, R. W.; Allan, R. (2011): Adherence 
to prescribed artemisinin-based combination therapy in Garissa and 
Bunyala districts, Kenya. In: Malar. J. 10:281. 
74. Le Bras, J.; Deloron, P.; Ricour, A.; Andriueu, B.; Savel, J.; Coulad, 
J. P. (1983): Plasmodium falciparum: drug sensitivity in vitro of isolates 
before and after adaptation to continuous culture. In: Exp. Parasitol. 56 
(1), pp. 9 – 14. 
75. Lee, K.-S.; Cox-Singh, J.; Brooke, G.; Matusop, A.; Singh, B. 
(2009): Plasmodium knowlesi from archival blood films: Further evidence 
that human infections are widely distributed and not newly emergent in 
Malaysian Borneo. In: Int. J. Parasitol. 39 (10), pp. 1125 – 1128. 
76. Liu, W.; Li, Y.; Learn, G.; Rudicell, R. S.; Robertson, J. D.; Keele, 
B. F.; Ndjango, J.-B. N., Sanz, C. M.; Morgan, D. B.; Locatelli, S.; 
Gonder, M. L.; Kranzusch, P. J.; Walsh, P. D.; Delaporte, E.; Mpoudi-
Ngole, E.; Georgiev, A. V.; Muller, M. N.; Shaw, G. M.; Peeters, M.; 
Sharp, P. M.; Rayner, J. C.; Hahn, B. H. (2010): Origin of the human 
malaria parasite Plasmodium falciparum in gorillas. In: Nature 467 
(7314), pp. 420 – 425. 
77. Lopera-Mesa, T. M.; Doumbia, S.; Chiang, S.; Zeituni, A. E.; 
Konate, D. S.; Doumbouya, M.; Keita, A. S.; Stepniewska, K.; Traore, K.; 
Diakite, S. A.; Ndiaye, D.; Sa, J. M.; Fay, M. P.; Long, C. A.; Diakite, M.; 
Fairhurst, R. M. (2013): Plasmodium falciparum clearance rates in 
response to artesunate in Malian children with malaria: effect of acquired 
immunity. In: J. Infect. Dis. 207 (11), pp. 1655 – 1663. 
78. Magesa, S. M.; Mdira, K. Y.; Farnert, A.; Simonsen, P. E.; 
Bygbjerg, I. C.; Jakobsen, P. H. (2001): Distinguishing Plasmodium 
falciparum treatment failures from re-infections by using polymerase 
chain reaction genotyping in a holoendemic area in northeastern 
Tanzania. In: Am. J. Trop. Med. Hyg. 65 (5), pp. 477 – 483. 
  
  
111 
 
79. Martinsen, E. S.; Perkins, S. L.; Schall, J. J. (2008): A three-
genome phylogeny of malaria parasites (Plasmodium and closely related 
genera): Evolution of life-history traits and host switches. In: Mol 
Phylogenet. Evol. 47 (1), pp. 261 – 273. 
80. Matsuoka, H.; Yoshida, S.; Hirai, M.; Ishii, A. (2002): A rodent 
malaria, Plasmodium berghei, is experimentally transmitted to mice by 
merely probing of infective mosquito, Anopheles stephensi. In: Parasitol. 
Int. 51 (1), pp. 17 – 23. 
81. Mbengue, A.; Bhattacharjee, S.; Pandharkar, T.; Liu, H.; Estiu, G.; 
Stahelin, R. V.; Rizk, S.; Njimoh, D. L.; Ryan, Y.; Chotivanich, K.; Nguon, 
C.; Ghorbal, M.; Lopez-Rubio, J.-J.; Pfrender, M.; Emrich, S.; Mohandas, 
N.; Dondorp, A. M.; Wiest, O.; Haldar, K. (2015): A molecular machanism 
off artemisinin resistance in Plasmodium falciparum malaria. In: Nature, 
520 (7549), pp. 683 – 687. 
82. Mbogo C. M.; Mwangangi J. M.; Nzovu J.; Gu, W.; Yan, G.; 
Gunter, J. T.; Swalm, C.; Keating, J.; Regens, J. L.; Shililu, J. I.; Beier, J. 
C. (2003): Spatial and Temporal Heterogeneity of Anopheles Mosquitoes 
and Plasmodium Falciparum Transmission along the Kenyan Coast. In: 
Am. J. Trop. Med. Hyg. 68 (6), pp. 734 – 742. 
83. Meshnick, S. R. (2002): Artemisinin: mechanisms of action, 
resistance and toxicity. In: Int. J. Parasitol. 32 (13), pp. 1655 – 1660. 
84. Ministry of Public Health and Sanitation (2010): National 
Guidelines for the Diagnosis, Treatment and Prevention of Malaria in 
Kenya. Third Edition. 
85. Mita, T.; Culleton, R.; Takahashi, N.; Nakamura, M.; Tsukahara, T.; 
Hunja, C. W.; Win, Z. Z.; Htike, W. W.; Marma, A. A.; Dysoley, L.; 
Ndounga, M.; Dzodzomenyo, M.; Akhwale, W. S.; Kobayashi, J.; 
Uemura, H.; Kaneko, A.; Hombinhanje, F.; Ferreira, M. U.; Björkman, A.; 
Endo, H.; Ohashi, J. (2016): Little Polymorphism at the K13 propeller 
Locus in Worldwide Plasmodium falciparum Populations Prior to the 
Introduction of Artemisinin Combination Therapies. In: Antimicrob. Agents 
Chemother., 60 (6), pp. 3340 – 3347. 
86. Mitchell, G. H.; Bannister, L. H. (1988): Malaria parasite invasion: 
interactions with the red cell membrane. In: Crit. Rev. Oncol. Hematol. 8 
(4), pp. 225 – 310. 
  
  
112 
 
87. Mok, S.; Ashley, E. A.; Fereira, P. E.; Zhu, L.; Lin, Z.; Yeo, T.; 
Chotivanich, K.; Imwong, M.; Pukrittayakamee, S.; Dhorda, M.; Nguon, 
C.; Lim, P.; Amaratunga, C.; Suon, S.; Hien, T. T.; Faiz, M. A.; 
Onyamboko, M. A.; Mayxay, M.; Newton, P. N.; Tripura, R.; Woodrow, C. 
J.; Miotto, O.; Kwiatkowski, D. P.; Nosten, F.; Day, N. P. J.; Preiser, P. R.; 
White, N. J.; Dondorp, A. M.; Fairhurst, R. M.; Bozdech, Z. (2015): 
Population transcriptomics of human malaria parasites reveals the 
mechanism of artemisinin resistance. In: Science, 347 (6220), pp.431 – 
435. 
88. Morris, C. A.; Duparc, S.; Borghini-Fuhrer, I.; Jung, D.; Shin, C. S.; 
Fleckenstein, L. (2011): Review of the clinical pharmacokinetics of 
artesunate and its active metabolite dihydroartemisinin following 
intravenous, intramuscular, oral or rectal administration. In: Malar. J. 
10:263. 
89. Mwai, L.; Ochong, E.; Abdirahman, A.; Kiara, S.M.; Ward, S.; 
Kokwaro, G.; Sasi, P.; Marsh, K.; Borrmann, S.; MacKinnon, M.; Nzila, A.  
(2009): Chloroquine resistance before and after its withdrawal in Kenya. 
In: Malar. J. 8:106. 
90. Myint, H. Y; Ashley E. A.; Day N. P. J.; Nosten F.; White N. J 
(2007): Efficacy and safety of dihydroartemisinin-piperaquine. In: Trans. 
R. Soc. Trop. Med. Hyg. 101 (9), pp. 858 – 866. 
91. Ngalah, B. S.; Ingasia, L. A.; Cheruiyot, A. C.; Chebon, L. J.; 
Juma, D. W.; Muiruri, P.; Onyango, I.; Ogony, J.; Yeda, R. A.; Cheruiyot, 
J.; Mbuba, E.; Mwangoka, G.; Achieng, A. O.; Ng’ang’a, Z.; Andagalu, B.; 
Akala, H. M.; Kamau, E. (2015): Analysis of Major Genome Loci 
Underlying Artemisinin Resistance and pfmdr1 Copy Number in pre- and 
post- ACTs in Western Kenya. In: Sci. Rep. 5:8308. 
92. Nambozi, M.; Geertruyden, J.-P.; Hachizovu, S.; Chaponda, M.; 
Mukwamataba, D.; Mulenga, M.; Ubben, D.; D’Alessandro, U. (2011): 
Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-
lumefantrine in the treatment of uncomplicated Plasmodium falciparum 
malaria in Zambian children. In: Malar. J. 10:50. 
93. Navaratnam, V.; Mansor, S. M.; Sit, N. W.; Grace, J.; Li, Q.; 
Olliaro, P. (2000): Pharmacokinetics of artemisinin-type compounds. In: 
Clin. Pharmacokinet. 39 (4), pp. 255 – 270. 
94. Noedl, H.; Wernsdorfer, W. H.; Krudsood, S.; Wilairatana, P.; 
Kollaritsch, H.; Wiedermann, G.; Looareesun, S. (2001): In Vivo–In Vitro 
Model For The Assessment Of Clinically Relevant Antimalarial Cross 
Resistance. In: Am. J. Trop. Med. Hyg. 65 (6), pp. 696 – 699. 
  
  
113 
 
95. Noedl, H.; Wernsdorfer, W. H.; Miller, R. S.; Wongsrichanalai, C. 
(2002): Histidine-Rich Protein II: a Novel Approach to Malaria Drug 
Sensitivity Testing. In: Antimicrob. Agents Chemother. 46 (6), pp. 1658 – 
1664. 
96. Noedl, H.; Wongsrichanalai, C.; Miller, R. S.; Myint, K. S.; 
Looareesuwan, S.; Sukthana, Y.; Wongchotigul, V.; Kollaritsch, H.; 
Wiedermann, G.; Wernsdorfer, W. H. (2002): Plasmodium falciparum: 
effect of anti-malarial drugs on the production and secretion 
characteristics of histidine-rich protein II. In: Exp. Parasitol. 102 (3 - 4), 
pp. 157 – 163. 
97. Noedl, H.; Wongsrichanalai, C.; Wernsdorfer, W. H. (2003): 
Malaria drug-sensitivity testing: new assays, new perspectives. In: 
Trends Parasitol. 19 (4), pp. 175 – 181. 
98. Noor, A. M.; Gething P. W.; Alegana V. A.; Patil, A. P.; Hay, S. I.; 
Muchiri, E.; Juma, E.; Snow, R. W. (2009): The risks of malaria infection 
in Kenya in 2009. In: BMC Infect. Dis. 9 (1), p. 180. 
99. Nosten, F.; White, N. J. (2007): Artemisinin-based combination 
treatment of falciparum malaria. In: Am. J. Trop. Med. Hyg. 77 (6 Suppl), 
pp. 181 – 192. 
100. O´Meara, W. P.; Bejon, P.; Mwangi, T. W.; Okiro, E. A.; Peshu, N.; 
Snow, R. W.; Newton, C. R.; Marsh, K. (2008): Effect of a fall in malaria 
transmission on morbidity and mortality in Kilifi, Kenya. In: Lancet 372 
(9649), pp. 1555 – 1562. 
101. Okell, L.; Drakeley, C. J.; Ghani, A. C.; Bousema, T.; Sutherland, 
C. J. (2008): Reduction of transmission from malaria patients by 
artemisinin combination therapies: a pooled analysis of six randomized 
trials. In: Malar. J. 7:125. 
102. Olliaro, P. L.; Nair, N. K.; Sathasivam, K.; Mansor, S. M.; 
Navaratnam, V. (2001): Pharmacokinetics of artesunate after single oral 
administration to rats. In: BMC Pharmacol. 1:12. 
103. Outtara, A.; Kone, A.; Adams, M.; Fofana, B.; Maiga, A. W.; 
Hampton, S.; Coulibaly, D.; Thera, M. A.; Diallo, N.; Dara, A.; Sagara, I.; 
Gil, J. P.; Bjorkman, A.; Tkala-Harrison, S.; Doumbo, O. K.; Plowe, C. V.; 
Djimde, A. A. (2015): Polymorphisms in the K13-Propeller Gene in 
Artemisnin-Susceptible Plasmodium falciparum Parasites from Bougala-
Hameau and Bandiagara, Mali. In: Am. J. Trop. Med. Hyg., 92 (6), pp. 
1202 – 1206. 
  
  
114 
 
104. Pascual, A.; Parola, P.; Benoit-Vical, F.; Simon, F.; Malvy, D.; Picot, 
S.; Delaunay, P.; Basset, D.; Maubon, D.; Faugère, B.; Ménard, G.; 
Bourgeois, N.; Oeuvray, C.; Didillon, E.; Rogier, C.; Pradines, B. (2012): 
Ex vivo activity of the ACT new components pyronaridine and 
piperaquine in comparison with conventional ACT drugs against isolates 
of Plasmodium falciparum. In: Malar. J. 11:45. 
105. Peters, J. M.; Fowler, E. V.; Krause, D. R.; Cheng, Q.; Gatton, M. 
L. (2007): Differential changes in Plasmodium falciparum var 
transcription during adaptation to culture. In: J. Infect. Dis. 195 (5), pp. 
748 – 755. 
106. Phyo, A. P.; Nkhoma, S.; Stepniewska, K.; Ashley, E. A.; Nair, S.; 
McGready, R.; Moo, C. l.; Al-Saai, S.; Dondorp, A. M.; Lwin, K. M.; 
Singhasivanon, P.; Day, P. J.; White, N. J.; Anderson, T. J. C.; Nosten, F. 
(2012): Emergence of artemisinin-resistant malaria on the western 
border of Thailand: a longitudinal study. In: Lancet 379 (9830), pp. 1960 
– 1966. 
107. Piper, R.; Lebras, J.; Wentworth, L.; Hunt-Cooke, A.; Houzé, S.; 
Chiodini, P.; Makler, M. (1999): Immunocapture diagnostic assays for 
malaria using Plasmodium lactate dehydrogenase (pLDH). In: Am. J. 
Trop. Med. Hyg. 60 (1), pp. 109 – 118. 
108. Portugal, S.; Drakesmith, H.; Mota, M. M. (2011): Superinfection in 
malaria: Plasmodium shows its iron will. In: EMBO Rep. 12 (12), pp. 
1233 – 1242. 
109. Price, R. N.; Nosten, F.; Luxemburger, C.; ter Kuile, F. O.; Paiphun, 
L.; Chongsuphajaisiddhi, T.; White, N. J. (1996): Effects of artemisinin 
derivatives on malaria transmissibility. In: Lancet 347, pp. 1654 – 1658. 
110. Price, R. N.; Uhlemann, A. C.; Rockman, A.; McGready, R.; 
Ashley, E.; Phaipun, L.; Patel, R.; Laing, K.; Looreesuwan, S.; White, N. 
J.; Nosten, F.; Krishna, S. (2004): Mefloquine resistance in Plasmodium 
falciparum and increased pfmdr1 gene copy number. In: Lancet 364 
(9432): pp. 438 – 447. 
111. Prugnolle, F.; Durand, P.; Ollomo, B.; Duval, L.; Ariey, F.; Arnathau, 
C.; Gonzalez, J.-P.; Leroy, E.; Renaud, F. (2011): A Fresh Look at the 
Origin of Plasmodium falciparum, the Most Malignant Malaria Agent. In: 
PLoS Pathog 7 (2), e1001283. 
112. Qinghaosu Antimalaria CoordinatiTeg Research Group (1979): 
Antimalaria studies on Qinghaosu (1979). In: Chin. Med. J. 92 (12), pp. 
811 – 816. 
  
115 
 
113. Rational Pharmaceutical Management Plus, Center for 
Pharmaceutical Management (Hg.) (2005): Changing Malaria Treatment 
Policy to Artemisinin- Based Combinations. An Implementation Guide. 
114. Rich, S. M.; Leendertz, F. H.; Xu, G.; LeBreton, M.; Djoko, C. F.; 
Aminake, M. N.; Takang, E. E.; Diffo, J. L. D.; Pike, B. L.; Rosenthal, B. 
M.; Formenty, P; Boesch, C.; Ayala, F. J.; Wolfe, N. D. (2009): The origin 
of malignant malaria. In: Proc. Natl. Acad. Sci. 106 (35), pp. 14902 – 
14907. 
115. Ridley, R. G.; Hofheinz, W.; Matile, H.; Jaquet, C.; Dorn, A.; 
Masciadri, R.; Jolidon, S.; Richter, W. F.; Guenzi; A.; Giromatta, M. A.; 
Urwyler, H.; Huber, W.; Thaithong, S.; Peters, W. (1996): 4-
aminoquinoline analogs of chloroquine with shortened side chains retain 
activity against chloroquine-resistant Plasmodium falciparum. In: 
Antimicrob. Agents Chemother. 40 (8), pp. 1846 – 1854. 
116. Rutvisuttinunt, W.; Chaorattanakawee, S.; Tyner, S. D.; Teja-
Isavadharm, P.; Se, Y.; Yingyuen, K.; Chaichana, P.; Bethell, D.; Walsh, 
D. S.; Lon, C.; Fukuda, M.; Socheat, D.; Noedl, H.; Schaecher, K, 
Saunders, D. L. (2012): Optimizing the HRP-2 in vitro malaria drug 
susceptibility assay using a reference clone to improve comparisons of 
Plasmodium falciparum field isolates. In: Malar. J. 11:325. 
117. Rock, E. P.; Marsh, K.; Saul, A. J.; Wellems, T. E.; Taylor, D. W.; 
Maloy, W. L.; Howard, R. J. (1987): Comparative analysis of the 
Plasmodium falciparum histidine-rich proteins HRP-I, HRP-II and HRP-III 
in malaria parasites of diverse origin. In: Parasitology 95 (Pt 2), pp. 209 – 
227. 
118. Roestenberg, M.; McCall, M.; Hopman, J.; Wiersma, J.; Luty, A.J.; 
van Gemert, G. J.; van de Vegte-Bolmer, M.; van Schaijk, B.; Teelen, K.; 
Arens, T.; Spaarman, L.; de Mast, Q.; Roeffen, W:; Snounou, G.; Rénia, 
L.; van der Ven, A.; Hermsen, C. C.; Sauerwein, R. (2009): Protection 
against a malaria challenge by sporozoite inoculation. In: N. Engl. J. 
Med. 361 (5), pp.  468 – 477. 
119. Sam-Yellowe, T. Y. (1996): Rhoptry organelles of the apicomplexa: 
Their role in host cell invasion and intracellular survival. In: Parasitol. 
Today 12 (8), pp. 308 – 316. 
120. Schlitzer, M. (2007): Malaria Chemotherapeutics Part I: History of 
Antimalarial Drug Development, Currently Used Therapeutics, and Drugs 
in Clinical Development. In: ChemMedChem 2 (7), pp. 944 – 986. 
  
  
116 
 
121. Sidhu, A. B.; Uhlemann, A. C.; Valderramos, S. G.; Valderramos, 
S. G.; Krishna, S.; Fidock, D. A. (2006): Decreasing pfmdr1 copy number 
in plasmodium falciparum malaria heightens susceptibility to mefloquine, 
lumefantrine, halofantrine, quinine, and artemisinin. In: J. Infect. Dis. 194 
(4), pp. 528 – 535. 
122. Seder, R. A.; Chang, L.-J.; Enama, M. E.; Zephir, K. L.; Sarwar, U. 
N.; Gordon, I. J.; Holman, L. A.; James, E. R.; Billingsley, P. F.; 
Gunasekera, A.; Richman, A.; Chakravarty, S.; Manoj, A.; Velmurugan, 
S.; Li, M.; Ruben, A. J.; Li, T.; Eappen, A. G.; Stafford, R. E.; Plummer, S. 
H.; Hendel, C. S.; Novik, L.; Costner, P. J.; Mendoza, F. H.; Saunders, J. 
G.; Nason, M. C.; Richardson, J. H.; Murphy, J.; Davidson, S. A.; Richie, 
T. L.; Sedegah, M.; Sutamihardja, A.; Fahle, G. A.; Lyke, K. E.; Laurens, 
M. B.; Roederer, M.; Tewari, K.; Epstein, J. E.; Sim, B. K.; Ledgerwood, 
J. E.; Graham, B. S.; Hoffman, S. L.; VRC 312 Study Team (2013): 
Protection Against Malaria by Intravenous Immunization with a 
Nonreplicating Sporozoite Vaccine. In: Science 341 (6152), pp. 1359 – 
1365. 
123. Shen, J. X. (1989): Antimalarial drug development in China. In: 
Beijing: National Institute of Pharmaceutical Research and Development. 
http://www.who.int/iris/handle/10665/38624#sthash.5hcklOoL.dpuf (May 
11th, 2014). 
124. Simpson, J. A.; Aarons, L.; Collins, W. E.; Jeffery, G. M.; White, N. 
J. (2002): Population dynamics of untreated Plasmodium falciparum 
malaria within the adult human host during the expansion phase of the 
infection. In: Parasitology 124 (Pt 3), pp. 247 – 263. 
125. Sinclair, D.; Zani, B.; Donegan, S.; Olliaro, P.; Garner, P., The 
Cochrane Library (2009), Issue 4: Artemisinin-based combination therapy 
for treating uncomplicated malaria. 
126. Singh, B.; Kim, S. L.; Matusop, A.; Radhakrishnan, A.; Shamsul, S. 
S.; Cox-Singh, J.; Thomas, A.; Conway, D. J. (2004): A large focus of 
naturally acquired Plasmodium knowlesi infections in human beings. In: 
The Lancet 363 (9414), pp. 1017 – 1024. 
127. Snounou, G.; Beck, H. P. (1998): The use of PCR genotyping in 
the assessment of recrudescence or reinfection after antimalarial drug 
treatment. In: Parasitol. Today (Regul. Ed.) 14 (11), pp. 462 – 467. 
128. Snounou, G.; Zhu, X.; Siripoon, N.; Jarra, W.; Thaithong, S.; 
Brown, K. N.; Viriyakosol, S. (1999): Biased distribution of msp1 and 
msp2 allelic variants in Plasmodium falciparum populations in Thailand. 
In: Trans. R. Soc. Trop. Med. Hyg. 93 (4), pp. 369 – 374. 
  
117 
 
129. Snow, R. W.; Guerra C. A.; Noor A. M.; Myint, H. Y.; Hay, S. I. 
(2005): The global distribution of clinical episodes of Plasmodium 
falciparum malaria. In: Nature 434 (7030), pp. 214 – 217. 
130. Straimer, J.; Gnädig, N.; Witkowski, B.; Amaratunga, C.; Duru, V.; 
Ramadani, A. P.; Dacheux, M.; Khim, N.; Zhang, L.; Lam, S.; Gregory, P. 
D.; Urnov, F. D.; Mercereau-Puijalon, O.; Benoit-Vical, F.; Fairhurst, R. 
M.; Ménard, D.; Fidock, D. A. (2015): K13-propeller mutations confer 
artemisinin resistance in Plasmodium falciparum clinical isolates. In: 
Science 347 (6220), pp. 428 – 431. 
131. Sturm, A.; Amino, R.; van de Sand, C.; Regen, T.; Retzlaff, S.; 
Rennenberg, A.; Krueger, A.; Pollok, J. M.; Menard, R.; Heussler, V. T. 
(2006): Manipulation of Host Hepatocytes by the Malaria Parasite for 
Delivery into Liver Sinusoids. In: Science 313 (5791), pp. 1287 – 1290. 
132. Sudoi, R. K.; Githinji, S.; Nyandigisi, A.; Muturi, A.; Snow, R. W.; 
Zurovac, D. (2012): The magnitude and trend of artemether-lumefantrine 
stock-outs at public health facilities in Kenya. In: Malar. J. 11:37. 
133. Sullivan, D. J.; Gluzman, I. Y.; Goldberg, D. E. (1996): 
Plasmodium hemozoin formation mediated by histidine-rich proteins. In: 
Science 271 (5246), pp. 219 – 222. 
134. Sullivan, D. J.; Gluzman, I. Y.; Russell, D. G.; Goldberg, D. E. 
(1996): On the molecular mechanism of chloroquine's antimalarial action. 
In: Proc. Natl. Acad. Sci. 93 (21), pp. 11865 – 11870. 
135. Teja-Isavadharm, P.; Nosten, F.; Kyle, D. E.; Luxemburger, C.; Ter 
Kuile, F.; Peggins, J. O.; Brewer, T. G.; White, N. J. (1996): Comparative 
bioavailability of oral, rectal, and intramuscular artemether in healthy 
subjects: use of simultaneous measurement by high performance liquid 
chromatography and bioassay. In: Br. J. Clin. Pharmacol. 42 (5), pp. 599 
– 604. 
136. The RTS, S. Clinical Trials Partnership (2012): A Phase 3 Trial of 
RTS, S/AS01 Malaria Vaccine in African Infants. In: N. England J. Med. 
367 (24), pp. 2284 – 2295. 
137. The RTS, S Clinical Trials Partnership (2015): Efficacy and safety 
of RTS, S/AS01 malaria vaccine with or without a booster dose in infants 
and children in Africa: final results of a phase 3, individually randomised, 
controlld trial. In: Lancet 386 (9988), pp. 31 – 45. 
138. Tritten, L.; Matile, H.; Brun, R.; Wittlin, S. (2009): A new double-
antibody sandwich ELISA targeting Plasmodium falciparum aldolase to 
evaluate anti-malarial drug sensitivity. In: Malar. J. 8:226. 
  
  
118 
 
139. Valecha, N.; Phyo, A. P.; Mayxay, M.; Newton, P. N.; Krudsood, S.; 
Keomany, S.; Khanthvong, M.; Pongvongsa, T.; Ruangveerayuth, R.; 
Uthaisil, C.; Ubben, D.; Duparc, S.; Bacchieri, A.; Corsi, M.; Rao, B. H. 
K.; Bhattacharya, P.C.; Dubhashi, N.; Ghosh, S.K.; Dev, V.; Kumar, A.; 
Pukittayakamee, S. (2010): An Open-Label, Randomised Study of 
Dihydroartemisinin-Piperaquine Versus Artesunate-Mefloquine for 
Falciparum Malaria in Asia. In: PLoS ONE 5 (7), e11880. 
140. van Vugt, M.; Looareesuwan, S.; Wilairatana, P.; McGready, R.; 
Villegas, L.; Gathmann, I.; Mull, R.; Brockman, A.; White, N. J.; Nosten, 
F. (2000): Artemether-lumefantrine for the treatment of multidrug-
resistant falciparum malaria. In: Trans. R. Soc. Trop. Med. Hyg. 94 (5), 
pp. 545 – 548. 
141. Verhage, D .F.; Telgt, D. S.; Bousema, J. T.; Hermsen, C. C.; van 
Gemert, G. J.; van der Meer, J. W.; Sauerwein, R. W. (2005): Clinical 
outcome of experimental human malaria induced by Plasmodium 
falciparum- infected mosquitoes. In: Neth. J. Med. 63 (2), pp.52 – 58. 
142. Vossen, M. G.; Pferschy, S.; Chiba, P.; Noedl, H. (2010): The 
SYBR Green I malaria drug sensitivity assay: performance in low 
parasitemia samples. In: Am. J. Trop. Med. Hyg. 82 (3), pp. 398 – 401. 
143. Warhurst, D. C.; Craig, J. C.; Adagu, I. S.; Guy, R. K.; Madrid, P. 
B.; Fivelman, Q. L. (2007): Activity of piperaquine and other 4- 
aminoquinoline antiplasmodial drugs against chloroquine- sensitive and 
resistant blood- stages of Plasmodium Falciparum. Role of beta-
heamatin inhibition and drug concentration in vacuolar water- and lipid-
phases. In: Biochem. Pharmacol. 73 (12), pp. 1910 – 1926. 
144. Waters, A. P.; Higgins, D. G.; McCutchan, T. F (1991): Plasmodium 
falciparum appears to have arisen as a result of lateral transfer between 
avian and human hosts. In: Proc. Natl. Acad. Sci. 88, pp. 3140 – 3144. 
145. Werk, R. (1985): How does Toxoplasma gondii enter host cells? 
In: Rev. Infect. Dis. 7 (4), pp. 449 – 457. 
146. White, N. J.: Manson´s Tropical Diseases, 21st edition (2003). 
Section 10, Chapter 71: Malaria. In: Cook G. C.; Zumla, A., pp. 1226 – 
1229. 
147. White, N. J. (2011): The parasite clearance curve. In: Malar. J. 10 : 
278.  
148. White, N. J. (1997): Assessment of the Pharmacodynamic 
Properties of Antimalarial Drugs in vivo. In: Antimicrob. Agents 
Chemother. 41 (7), pp. 1413 – 1422. 
  
119 
 
149. White, N. J. (1999): Delaying antimalarial drug resistance with 
combination chemotherapy. In: Parassitologia 41 (1 – 3), pp. 301 – 308. 
150. White, N.J (2004): Antimalarial drug resistance. In: J. Clin. Invest. 
113 (8), pp. 1084 – 1092. 
151. Wilson, D. W.; Langer, C.; Goodman, C. G., McFadden, G. I.; 
Beeson, J. G (2013): Defining the Timing of Action on Antimalarial Drugs 
against Plasmodium falciparum. In: Antimicrob. Agents Chemother. 57 
(3), pp. 1455 – 1467. 
152. Wilson, R. J. M.; Williamson, D. H (1997): Extrachromosomal DNA 
in the Apicomplexa. In: Microbiol. Mol. Biol. Rev. 61 (1), pp. 1 – 16. 
153. Witkowski, B.; Amaratunga, C.; Khim, N.; Sreng, S.; Chim, P.; Kim, 
S.; Lim, P.; Mao, S.; Sopha, C.; Sam, B.; Anderson, J. M., Duong, S.; 
Chuor, C. M.; Taylor, W. A. J.; Suon, S.; Mercerau-Puijalon, O.; Fairhurst, 
R. M.; Menard, D. (2013a): Novel phenotypic assays for the detection of 
artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-
vitro and ex vivo drug-response studies. In: Lancet Infect. Dis., 13, pp. 
1043 – 1049. 
154. Witkowski, B.; Khim, N.; Chim, P.; Kim, S.; Ke, S.; Kloeung, N.; 
Chy, S.; Duong, S.; Leang, R.; Ringwald, P.; Dondorp, A. M.; Tripura, R.; 
Benoit-Vical, F.; Berry, A.; Gorgette, O., Ariey, F.; Barale, J.-C., Mercerau-
Puijalon, O.; Menard, D. (2013b): Reduced Artemisinin Susceptibility of 
Plasmodium falciparum Ring Stages in Western Cambodia. In: 
Antimicrob. Agents Chemother. 57 (2), pp. 914 – 923. 
155. Woerdenbag, H. J.; Pras, N.; van Uden, W.; Wallart, T. E.; 
Beekmann, A. C.; Lugt, C. B. (1994): Progress in the research of 
artemisinin-related antimalarials: An update. In: Pharm World Sci 16, 
pp.169 – 180. 
156. Woodrow, C. J.; Haynes, R. K.; Krishna, S. (2005): Artemisinins. 
In: Postgrad. Med. J. 81 (952), pp. 71 – 78. 
157. World Health Organization (2015): Guidelines for the treatment of 
malaria. Third edition. Switzerland, p. 32 and pp. 112 – 113. 
158. World Health Organization (2016): World Malaria Report 2016, 
Switzerland, pp. xii - xvii and p. 3. 
159. Wrongsrichanalai, C.; Pickard, A. L.; Wernsdorfer, W. H.; 
Meshnick, S.R. (2002): Epidemiolog of drug-resistant malaria. In: Lancet 
Infect. Dis. 2: pp. 209 – 218. 
  
  
120 
 
160. Yang, H.; Liu, D.; Huang, K.; Yang, Y.; Yang, P.; Liao, M.; Zhang, 
C. (1999): [Assay of sensitivity of Plasmodium falciparum to chloroquine, 
amodiaquine, piperaquine, mefloquine and quinine in Yunnan province]. 
In: Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 17 
(1), pp. 43 – 45. 
161. Yavo, W.; Faye, B.; Kuete, T.; Djohan, V.; Oga, S. A.; Kassi, R.R.; 
Diatta, M.; Ama, M. V.; Tine, R.; Ndiaye, J. L.; Evi, J.-B.; Same-Ekobo, A.; 
Faye, O.; Koné, M. (2011): Multicentric assessment of the efficacy and 
tolerability of dihydroartemisinin-piperaquine compared to artemether-
lumefantrine in the treatment of uncomplicated Plasmodium falciparum 
malaria in sub-Saharan Africa. In: Malar. J. 10:198. 
162. Yeka, A.; Dorsey, G.; Kamya, M.R.; Talisuna, A.; Lugemwa, M.; 
Rwakimari, J. B.; Staedtke, S. G.; Rosenthal, P. J.; Wabwire-Mangen, F.; 
Bukirwa, H. (2008): Artemether-Lumefantrine versus Dihydroartemisinin-
Piperaquine for Treating Uncomplicated Malaria: A Randomized Trial to 
Guide Policy in Uganda. In: PLoS ONE 3 (6), e2390. 
163. Zhang, Q.; Zhang, Y.; Huang, Y.; Xue, X.; Yan, H.; Sun, X.; Wang, 
J.; McCutchan, T. F.; Pan, W. (2011): From In vivo to In Vitro: Dynamic 
Analysis of Plasmodium falciparum var Gene Expression Patterns of 
Patient Isolates during Adaptation to Culture. In: PLoS ONE 6 (6), 
e20591. 
 
Website: 
Nobel Media AB 2016, The 2015 Nobel Prize in Physiology or Medicine- 
Press Release, available from 
https://www.nobelprize.org/nobel_prizes/medicine/laureates/2015/press.h
tml, accessed June 21st, 2016. 
 
  
121 
 
9. Ehrenerklärung 
Ich erkläre, dass ich die der Medizinischen Fakultät der Eberhard Karls 
Universität Tübingen zur Promotion eingereichte Dissertation mit dem Titel 
“Surveillance of artemisinin and partner drug efficacy in uncomplicated 
Plasmodium falciparum malaria in Coastal Kenya” im Kenya Medical Research 
Institute (KEMRI, Kilifi) mit Unterstützung der Arbeitsgemeinschaft um  
Prof. Dr. med. Steffen Borrmann (damals  Universität Heidelberg) ohne sonstige 
Hilfe durchgeführt und bei der Abfassung der Dissertation keine anderen als die 
aufgeführten Hilfsmittel benutzt habe. 
Die Studie wurde durch Herrn Prof. Dr. med. Steffen Borrmann konzipiert, 
welcher ebenso die Betreuung der Versuche und der gesamten Arbeit 
übernommen hat. Die HRP2 Versuche wurden durch mich, Maria Rebekka 
Marschallek, durchgeführt und teilweise durch einen weiteren Doktoranden der 
Universität Heidelberg, Paul Wettzel, ergänzt. Die PCR Genotypisierungen 
wurden einmal durch mich in Kenia durchgeführt und im Anschluss 
vervollständigt und verifiziert durch die Arbeitsgemeinschaft Borrmann an der 
Universität Heidelberg. Die klinischen Daten der CATMAP Studie wurden durch 
das Studienteam in Kenia gesammelt. Die hier aufgeführte Recherche erfolgte 
ausschließlich durch mich, ebenso die statistische Analyse. 
Bei der Abfassung der Dissertation sind Rechte Dritter nicht verletzt worden. 
Ich habe diese Dissertation bisher an keiner in– oder ausländischen 
Hochschule zur Promotion eingereicht. 
 
 
Neubrandenburg, den 19. Januar 2017 
 
Maria Rebekka Marschallek 
  
  
122 
 
10. Danksagung 
Ein großes Dankeschön gilt den kleinen Patienten, ohne die diese Studie nicht 
hätte durchgeführt werden können. Zudem gilt mein Dank meinem Betreuer, 
Prof. Dr. med. Steffen Borrmann, der es mir ermöglicht hat an diesem Projekt 
mitzuarbeiten. Außerdem den Mitgliedern seiner Arbeitsgruppe in Heidelberg, 
die mich tatkräftig unterstützt haben. Ebenso Herrn apl. Prof. Dr. Jude 
Przyborski und seinen Mitarbeitern in Marburg für die Starthilfe bei der 
Laborarbeit. Und natürlich allen Mitarbeitern in KEMRI, die immer ein offenes 
Ohr für meine Anliegen hatten. 
Ich danke jedem einzelnen meiner Geschwister für die gezeigte Geduld und 
meinen Eltern, die mir immer wieder die Welt zu Füßen legen, damit ich sie 
erobern kann. 
  
  
123 
 
11. Appendices 1 – 4 
Appendix 119 
Criteria for inclusion: 
 Age between 6 months to 10 years, inclusive 
 Mono-infection with P. falciparum detected by microscopy 
 Parasitaemia of 10,000 – 300,000 / µl asexual forms 
 Presence of axillary temperature ≥ 37.5 °C or history of fever during the 
past 24 hrs 
 Ability to swallow oral medication 
 Ability and willingness to comply with the study protocol for the duration 
of the study and to comply with the study visit schedule 
 Informed consent from a parent or guardian 
 
 
Criteria for exclusion: 
 Presence of clinical danger signs: not able to drink or breast-feed, 
vomiting (> twice in 24 hrs), recent history of convulsions (> 1 in 24 hrs), 
unconscious state, unable to sit or stand 
 Mixed or mono-infection with another Plasmodium species detected by 
microscopy 
 Presence of severe acute malnutrition defined as weight for height  
< 70 % of the median National Center for Health Statistics / WHO 
 Presence of febrile conditions due to diseases other than malaria (e.g. 
measles, acute lower respiratory tract infection, severe diarrhoea with 
dehydration) or other known underlying chronic or severe diseases (e.g. 
cardiac, renal and hepatic diseases, Human Immunodeficiency Virus / 
Aquired Immune Deficiency Syndrome) 
 Regular medication, which may interfere with antimalarial 
pharmacokinetics or pharmacodynamic assessments (e.g., antibiotics 
with known antimalarial activity) 
 History of hypersensitivity reactions or contraindications to any of the 
medicine(s) being tested or used as alternative treatment(s) 
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Appendix 2 
The absorbance read during the performance oft he HRP2 ELISA resulted in 
OD values which were transferred into the HN-NonLin V1.1 sheet to calculate 
IC50 values (ng / ml). The IC50 values were transferred into nM by using an 
excel sheet containing the needed formula for each drug. 
AS 
nM = 
(ng / ml)*1000 / 284.3 
CQ 
nM = 
(ng / ml)*1000 / 515.87  
DHA 
nM = 
(ng / ml)*1000 / 284.3 
LUM 
nM = 
(ng / ml)*1000 / 528.939 
MFQ 
nM = 
(ng / ml)*1000 / 414.77 
PPQ 
nM = 
(ng / ml)*1000 / 927.5 
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Appendix 3 
Correlations artesunate and dihydroartemisinin 
AS and DHA are both derivatives of artemisinin, whereas DHA is the main 
active metabolite in vivo. One expects a highly significant positive correlation 
between these two drugs, also in favor of the reliability of the assay. Here in all 
drug solutions a significant positive correlation was shown. 
  
  
  
  
126 
 
  
 
 
 
  
  
127 
 
Correlations dihydroartemisinin and piperaquine 
In the analysis including all drug solutions a positive significant correlation 
between DHA and PPQ was found. When analyzing drug solutions separately, 
two out of the seven solutions did show a significant positive correlation 
between those two drugs. 
  
Correlations artesunate and piperaquine 
Between AS and PPQ there were two working solutions that showed significant 
positive correlations [(rho=0.6821, p=0.0064, r2=0.4919), (rho= 0.8162, 
p=0.0001, r2=0.5017)]. Those were the same two drug solutions that also 
showed a significant correlation between DHA and PPQ, the coefficient of 
determination was much higher though. 
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Correlations dihydroartemisinin and lumefantrine 
The analysis among all drug solutions showed a significant positive correlation 
between DHA and LUM. When analyzing this again for each single drug 
solution the correlation was found in three drug solutions. 
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Correlations artesunate and lumefantrine 
Also AS did show a significant positive correlation with LUM in four drug 
solutions. 
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Correlations artemisinins and chloroquine and mefloquine 
There were several different significant positive correlations between the 
artemisinin derivatives and CQ as well as MFQ when analyzing each working 
solutions individually. 
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Correlations piperaquine and chloroquine, mefloquine and lumefantrine 
PPQ did not show any correlation with CQ in the analysis including all drug 
solutions. Analyzing single drug solutions twice a correlation seen was seen. 
  
The correlation seen in the analysis including all drug solutions showed a 
correlation between PPQ and MFQ. This could not be confirmed when 
analyzing drug solutions individually. The same applied for PPQ and LUM.  
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Correlations lumefantrine and chloroquine and mefloquine 
LUM showed a significant negative correlation with CQ in the analysis among 
all drug solutions. Analyzing single drug solutions, once a significant negative 
correlation between LUM and CQ was seen. 
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Four drug solutions did show a significant positive correlation between LUM and 
MFQ. 
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Appendix 4 
 
CQ_rec II III IV V VI VII 
Number of values 3 5 5 5 10 7 
Minimum 7.70 9.63 8.41 6.56 4.93 6.67 
25 % Percentile 7.70 14.68 8..63 8.08 8.42 7.93 
Median 8.35 23.99 14.55 10.22 14.34 12.12 
75% Percentile 70.94 164.40 19.56 91.07 24.35 18.62 
Maximum 70.94 301.60 24.31 167.60 218.30 21.02 
Geometric mean 16.59 32.71 13.13 17.35 16.56 11.83 
Lower 95 % CI of 
geometric mean 
0.73 6.47 7.65 3.46 7.73 7.80 
Upper 95 % CI of 
geometric mean 
378.70 165.40 22.54 87.01 35.49 17.92 
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MFQ_rec II III IV V VI VII 
Number of values 3 5 5 5 10 7 
Minimum 5.68 3.63 2.75 1.19 5.35 1.40 
25 % Percentile 5.68 9.15 5.37 1.73 8.79 4.83 
Median 13.15 14.87 11.79 3.86 16.09 34.99 
75 % Percentile 13.94 31.40 34.31 15.54 25.15 38.99 
Maximum 13.94 47.47 47.99 20.64 34.15 44.22 
Geometric mean 10.13 14.19 12.07 4.68 14.12 17.32 
Lower 95 % CI of geometric 
mean 
2.91 4.57 3.21 1.13 8.91 4.98 
Upper 95 % CI of geometric 
mean 
35.31 44.03 45.38 19.48 22.37 60.28 
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DHA_rec II III IV V VI VII 
Number of values 3 5 5 5 10 7 
Minimum 1.29 1.86 1.31 1.60 1.77 1.38 
25 % Percentile 1.29 2.54 1.52 1.63 2.94 2.47 
Median 1.62 4.15 2.32 1.97 4.82 4.28 
75 % Percentile 1.29 2.54 1.52 1.63 2.94 2.470 
Maximum 2.69 7.46 3.81 2.32 15.14 11.98 
Lower 95 % CI of geometric 
mean 
0.69 2.05 1.33 1.58 3.29 2.06 
Upper 95% CI of geometric 
mean 
4.54 7.35 4.00 2.32 9.27 7.34 
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AS_rec II III IV V VI VII 
Number of values 3 5 5 5 10 7 
Minimum 3.72 2.60 1.04 2.83 1.89 0.47 
25 % Percentile 3.72 3.15 1.66 3.11 3.33 0.57 
Median 5.47 4.74 3.38 3.39 6.94 0.79 
75 % Percentile 6.83 10.49 8.88 5.24 17.20 1.19 
Maximum 6.83 11.81 13.84 6.33 36.83 1.26 
Geometric mean 5.18 5.48 3.37 3.86 7.60 0.80 
Lower 95 % CI of geometric 
mean 
2.41 2.51 1.04 2.63 3.76 0.57 
Upper 95 % CI of geometric 
mean 
11.12 11.97 10.87 5.66 15.33 1.13 
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LUM_rec II III IV V VI VII 
Number of values 3 5 5 5 10 7 
Minimum 6.47 5.17 3.44 1.07 7.94 4.43 
25 % Percentile 6.47 7.02 5.42 1.09 12.38 7.49 
Median 9.59 17.64 11.02 5.57 14.66 14.67 
75 % Percentile 13.38 21.34 21.05 16.72 15.50 52.81 
Maximum 13.38 21.47 25.76 17.11 57.75 89.92 
Geometric mean 9.40 12.98 10.34 4.50 15.08 18.46 
Lower 95 % CI of geometric 
mean 
3.80 5.95 3.98 0.82 10.35 6.91 
Upper 95 % CI of geometric 
mean 
23.21 28.32 26.88 24.69 21.98 49.33 
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PPQ_rec II III IV V VI VII 
Number of values  3 5 5 5 9 7 
Minimum 4.08 4.36 1.90 3.59 2.25 0.67 
25 % Percentile 4.08 4.36 1.90 3.59 2.25 0.67 
Median 5.31 8.38 3.90 5.81 4.84 4.18 
75 % Percentile 7.17 11.37 15.86 8.31 8.64 5.69 
Maximum 7.17 13.38 22.65 10.61 26.81 5.73 
Geometric mean 5.38 8.03 5.19 5.53 5.74 3.09 
Lower 95 % CI of geometric 
mean 
2.67 4.84 1.47 3.24 3.28 1.52 
Upper 95 % CI of geometric 
mean 
10.84 13.33 18.30 9.44 10.03 6.28 
 
